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People with Down syndrome (DS) have elevated neuroinflammation early in life 
and develop neuropathology by the age of twenty. Most individuals with DS go on to 
develop abnormal dementia and Alzheimer’s disease (AD). This dissertation is focused on 
biological pathways involved in DS-AD and includes studies in humans with DS and DS 
mouse models. Locus coeruleus (LC) noradrenergic (NE) neurons decline before other 
transmitter systems on the path to DS-AD, which leads to increased neuropathology and 
accelerated memory loss. To investigate the specific roles of LC-NE in DS-AD, designer 
receptors exclusively activated by designer drugs (DREADDs) were utilized in the Ts65Dn 
mouse model of DS to selectively stimulate or inhibit LC-NE activity. LC-NE activity 
modulated neuroinflammation, memory performance, and AD pathology in this mouse 
model. Altogether these findings implicate the importance of LC-NE function in the 
context of DS-AD. LC-NE dysfunction may also affect resolution response to 
neuroinflammation. Insufficient resolution activity was already known to correlate with 
AD neuropathology in humans and mouse models, but specialized pro-resolving factors 
have not been evaluated as a therapeutics in DS-AD. In the next portion of my thesis, I 
developed a novel therapeutic approach to enhance resolution activity in Ts65Dn mice with 
a pro-resolving mediator, resolvin E1 (RvE1). RvE1 treatment significantly reduced glial 
activation in the brain and pro-inflammatory cytokines in the periphery of Ts65Dn mice. 
RvE1 therapy reversed Ts65Dn deficits in memory and cognitive flexibility, which 
correlated with significant proteomic measures of the inflammatory resolution process. 
Finally, I investigated blood biomarkers that are relevant to AD including neuron-derived 
exosome levels of amyloid-beta peptides and phosphorylated-Tau (P-Tau) and serum 
BDNF levels. These AD biomarkers were already significantly elevated early in childhood 
with unique trajectories associated with dementia in humans with DS. Serum BDNF levels 
correlated with exosome P-Tau levels, suggesting an interaction between these two 
pathways in the development of DS-AD in humans. These data provide novel hope for 
meaningful therapeutics, to be implemented in early childhood in those with DS and inform 
both research and clinical perspectives at the crossroads of DS and AD.  
 






1.1 Aneuploidy: Etiological Consequences for Alzheimer’s disease 
 Identifying the factors that contribute to or reduce healthy aging can lead to 
improved precision medicine that could prevent the onset of aging-related diseases such as 
Alzheimer’s disease (AD). Genetic links to AD have been found in select gene alleles, 
point mutations and also in broader chromosomal abnormalities. In humans, the most 
common survivable chromosomal abnormality is aneuploidy which can occur as 
monosomy of trisomy so chromosomal segments or whole chromosomes. Although 5% of 
all recognized pregnancies have aneuploidy (Hassold and Hunt 2001), this chromosomal 
abnormality is usually not compatible with mammalian embryogenesis, and thus the 
majority of aneuploid pregnancies end during the early stages of embryonic development 
and are responsible for about 35% of spontaneous abortions (Hassold and Sherman 2000). 
The most common human aneuploidies are trisomies, which are characterized by the 
presence of one additional chromosome, which brings the total chromosome number from 
46 to 47. Of all potential human chromosome trisomies that could occur, only a few are 
viable. Trisomy 13, also referred to as Patau syndrome, causes severe intellectual 
disabilities, early medical conditions, and with only 5 to 10 percent living beyond six 
months of age. Trisomy 18, or Edward Syndrome, is the second most common trisomy 
condition and is also characterized by severe intellectual disabilities along with 
microcephaly, so only 1 percent of those with condition survive beyond their first year. 
Given the high mortality rate after birth, Trisomy 13 and 18 are not associable to AD, but 
 




the linkages of aneuploidy to intellectual disability are noteworthy. Finally, the most 
common human trisomy worldwide is Trisomy 21 or Down syndrome (DS). John Langdon 
Down first described the intellectual disability coupled with distinct facial features in 1866 
but the exact causative mechanism was unknown. Nearly a century elapsed before Peter 
Harper and Jerome Lejeune discovered Trisomy 21 in 1959, shortly after chromosome-
staining techniques established the normal human chromosome complement at 46, not 48.  
 
1.2 Down syndrome and Alzheimer’s disease (DS-AD) 
 Since 1929, life expectancy in the DS population has dramtically increased 
(Zigman 2013, Ballard, Mobley et al. 2016) through improvements in health care, social 
inclusion and family support structure. The most significant improvements in longevity 
came after 1970 when average age at death was less than 9 years of age. In only two 
decades, the average age at death dramatically rose to 40 years and today that age has risen 
to above 56 (Figure 1-1, A). It is important to note that longevity saw the greatest increases 
in the White/Caucasian population while the African American /Black population and 
others still lagged behind (Kucik, Shin et al. 2013). This racial disparity for those with DS 
speaks to societal issues in health care accessibility, income wealth divide, and other 
addressable factors. Today, the incidence of DS is approximately one in 800 live births 
with more than 300,000 people affected in the US and 5-8 million people affected 
worldwide (Zigman 2013). Individuals with DS are at high risk of developing early-onset 
AD and this risk increases at very early ages with a prevalence trend abruptly emerging at 
around 35 years of age (Figure 1-1, B). There is a current debate on when Trisomy 21 sets 
 




Figure 1-1. Demographics in the DS population. (A) Life expectancy in the DS 
population over three decades by race. Image was modified from (Kucik et al, 2013) 
(B) Summary of a meta-analysis of prevalence/incidence studies of DS-AD in 
various clinics. Image was modified from (Wiseman et al, 2015).  
 




the stage for eventual DS-AD. DS fetal development anomalies, such as fewer synapses in 
the DS forebrain (Petit, LeBoutillier et al. 1984) and smaller dendritic arborization in the 
cerebral cortex (Becker, Armstrong et al. 1986) predispose babies with DS to have 
impaired brain development. Perturbations in DS brain development also involve impaired 
neuronal differentiation, which leads to abnormally reduced growth in the neocortex, which 
has been found to be most prominent in the temporal and frontal lobes of the brain (Lubec 
and Engidawork 2002). Infants with DS are also at increased risk for conditions in the 1) 
cardiac system, 2) digestive system, 3) respiratory system, 4) musculoskeletal system, and 
5) urinary system (Davidson 2008). Whether these comorbidities affect AD-risk at the 
physiological level is not well established, but it is reasonable to assume that clinical 
studies should account for known comorbidities if possible. These early developmental 
disturbances manifest a unique situation where the early stages of AD can be studied from 
the aging paradigm but also from a developmental perspective in this unique population. 
 
 Genetics has been proposed to account for at least 30% of longevity in animal 
models and, in humans, general stability of gene expression is a primary driver for healthy 
aging (Arking 2001, Arking, Novoseltsev et al. 2004). From a genetic aneuploidy 
perspective, it is important to mention that brain and cognitive development is not only 
disrupted by the overexpression of specific trisomy genes on chromosome 21, but also by 
the deregulation of non-coding genetic elements and abnormal expression of non-
triplicated genes, along with epigenetic alterations at the DNA level. The development of 
new therapies and preventive agents that could halt DS-AD and discovery of reliable 
 




biomarkers to AD is a paramount priority to the highly susceptible DS population. For 
these reasons, the central focus of this dissertation is centered on biological crossroads 
between DS and AD. My investigations using human biosamples and mouse models were 
conducted with the aim of improving life quality specifically for those who have DS.  
 
1.3 Mouse Models Enable Down Syndrome Research 
 There are several mouse models of DS which recapitulate both developmental and 
age-related pathology in DS and in DS-AD. The use of these mouse models to study DS 
enables studies that are not currently possible in Humans including 1) safety and efficacy 
investigations of prevention or intervention strategies, 2) the study of neurological disease 
processes in a controlled environment, 3) validation of imaging and surgical 
methodologies, and 4) studies of gene-gene interactions relevant to DS. A minimum of 166 
protein-coding genes are syntenic between human chromosome 21 (Hsa21) and mouse 
chromosomes (Mmu) within three regions located on (Mmu) 10, 16 and 17 (Sturgeon and 
Gardiner 2011, Busciglio, Capone et al. 2013). Several DS mouse models have been 
developed to investigate the role of different gene segments of Hsa21 developmental and 
age-related impairments observed in DS. A summary of these mouse models is provided 
in (Figure 1-2) and has been extensively reviewed in our recent publication in Current 
Alzheimer Research (Hamlett, Boger et al. 2016). One of the first models of DS to be 
developed had complete trisomy of the Mmu 16 (Ts16), which proved to be lethal (Haydar, 
Blue et al. 1996). In this model, hippocampal neurons are lost at an accelerated rate via 
caspase-mediated apoptosis, which can be abrogated by caspase inhibitors (Bambrick and 
 




Krueger 1999). Due to lethality, this model continues to be used to explore developmental 
effects of Trisomy 21 primarily in vitro. Another mouse model for DS, Ts1Cje, contains 
62 orthologous Hsa21 genes but excludes the gene segment containing the amyloid  
precursor protein (APP) and superoxide dismutase 1 (SOD1). These mice display certain 
neurodegenerative features including oxidative stress (Ishihara, Amano et al. 2009), Tau 
Figure 1-2. Summary of available DS mouse models to date. Hsa = human 
chromosome, Mmu = murine chromosome, gray lines delineate included gene 
segments per mouse, and light gray dotted box represents the so-called Down 
syndrome Critical Region (DSCR). Figure adapted from (Hamlett, et al, 2016). 
 




hyperphosphorylation, mitochondrial dysfunction (Shukkur, Shimohata et al. 2006), along 
with learning and memory deficits (Belichenko, Belichenko et al. 2009). Another DS 
mouse model, Ms1Ts65, is trisomic for a region that contains over 33 orthologs of Hsa21 
genes. These mice display poor performance in water maze tasks but do not exhibit 
hyperactivity. 
 
 The Ts2Cje mouse model of DS has a chromosomal rearrangement caused by a 
translocation to Mmu12 via a Robertsonian chromosome (Villar, Belichenko et al. 2005, 
Levine, Saltzman et al. 2009). Studies of Ts2Cje revealed abnormalities in neuronal 
networks, endosomal changes, and accelerated neurodegeneration in basal forebrain 
cholinergic neurons (BFCN) (Villar, Belichenko et al. 2005). Recently, the DpYey mouse 
models for DS were developed to have orthologous genes that are syntenic to the entire 
Hsa21 region (Yu, Li et al. 2010). These colonies exist as three separate aneuploid mouse 
models: Mmu10:Dp(10)1Yey, Mmu17:Dp(16)1Yey, and Mmu16:Dp(17)1Yey. The triple 
aneuploid mice, Dp(10/17/16)Yey was achieved by conventional breeding of the three 
distinct models (Yu, Li et al. 2010). Interestingly, investigators have found distinct 
phenotypes for each model. Dp(17)Yey mice display abnormal synaptic long-term 
potentiation (LTP)in the hippocampus while the genotype of Dp(16)Yey mice display more 
pronounced impairments in memory, abnormal hippocampal LTP (Yu, Li et al. 2010). This 
evidence suggests that the Mmu16 genes syntenic to Hsa21 represent a crucial element 
related to the cognitive impairments associated with DS-AD. Dp(10)Yey mice display 
alterations in brain morphology which suggests that all three regions are necessary to 
 




completely recapitulate most elements of a DS phenotype. Finally, recent studies revealed 
that the Mmu17 region is also a significant determinant of DS related cognitive deficits 
(Zhang, Meng et al. 2014). These novel mouse models allow stricter studies of the Mmu17, 
Mmu10 and Mmu16 homologous regions in the biology of DS and, when bred together, 
may aid studies that can finally tease out specific genetic contributions to cognitive 
impairments observed in individuals with DS. Currently, Dr. Dian Bianchi, the director of 
NICHD, is assessing several of these DS mouse models for behavior, signaling biases, 
neurodegeneration, and developmental abnormalities to ascertain better how each model 
may best be applied to DS research (Personal communication, T21rs meeting Chicago, 
2017). In this dissertation, I focus exclusively on the Ts65Dn mouse model because it is a 
well-characterized mainstay of the research field and currently has over 372 peer-reviewed 
articles listed by the National Center for Biotechnology Information PubMed database. 
 
1.4 The Ts65Dn Mouse Model of Down syndrome 
 The Ts65Dn mouse model for DS was developed by Muriel Davisson and remains 
the most widely studied mouse model for DS (Davisson, Schmidt et al. 1990). The 
aneuploidy complement of Ts65Dn mice represents 122 orthologs to Hsa21 protein 
encoding genes through a segmental trisomy for Mmu16, and includes the so-called Down 
syndrome critical region (DSCR) (Dierssen, Fillat et al. 2001, Bambrick, Yarowsky et al. 
2003, Gardiner, Fortna et al. 2003, Belichenko, Belichenko et al. 2009). It should be noted 
that the trisomy in this mouse also contains a segment of Mmu17, which has approximately 
60 protein-encoding genes that are not syntenic to Hsa21 genes. Most of these genes have 
 




orthologues on Hsa6 (Duchon, Raveau et al. 2011, Busciglio, Capone et al. 2013). Even 
though Ts65Dn mice lack complete synteny to Hsa21, they exhibit many developmental 
and age-related deficits seen in the DS population, including progressive memory decline 
(Reeves, Irving et al. 1995, Hunter, Bimonte-Nelson et al. 2004), adult-onset degeneration 
of BFCN and LC-NE neurons (Holtzman, Santucci et al. 1996, Granholm, Sanders et al. 
2000, Cooper, Salehi et al. 2001), hippocampal synapse abnormalities (Siarey, Stoll et al. 
1997, Insausti, Megias et al. 1998), and increased APP production (Hunter, Isacson et al. 
2003, Seo and Isacson 2005). Within the DSCR segment lies the APP gene 
(Kleschevnikov, Belichenko et al. 2004) which is responsible for the production of amyloid 
beta (Aβ) peptide monomers and oligomers (Aβ40 and Aβ42), though these oligomers do 
not form plaques in the brain as observed in the Human population.  
 
 Work from multiple groups has demonstrated that Ts65Dn mice have significant 
increases in levels of APP production (Cataldo, Petanceska et al. 2003, Hunter, Bimonte et 
al. 2003, Hunter, Bimonte-Nelson et al. 2004, Choi, Berger et al. 2009, Lomoio, Scherini 
et al. 2009). Even though Ts65Dn mice do not develop plaques, alterations in APP 
processing have been observed in the hippocampus and prefrontal cortex (Hunter 2003b, 
Jason Lockrow 2009, Salehi, Faizi et al. 2009). The overexpression of APP has been 
associated with decreased neurotrophic support, as well as cholinergic and noradrenergic 
neurodegeneration via several mechanisms (Salehi A 2006, Salehi, Ashford et al. 2016). 
Proteolytic processing of APP into Aβ peptides is likely a major driver of neuropathology 
in the Ts65Dn mouse since deletion of one copy of the APP gene from the triplicated DSCR 
 




segments rescues many degenerative phenotypes in the brain (Cataldo, Petanceska et al. 
2003). The Granholm lab has investigated age-related degeneration and memory loss in 
Ts65Dn mice for the past 20 years, and demonstrated significant progressive declines in 
working and spatial memory (Granholm et al., 2000; Bimonte et al., 2003; Hunter et al., 
2004; Lockrow et al., 2011), hyperactivity (Lockrow et al., 2011; 2012; Fortress, Hamlett 
et al., 2015), and LC-NE as well as BFCN and hippocampal degeneration with age 
(Granholm et al., 2001; Hunter et al., 2004; Lockrow et al., 2011, 2012). See Figure 1-3 
and Figure 1-4 for a summary of these previous studies. I focused on this well 
characterized Ts65Dn mouse model to take advantage of the extensive peer-reviewed 
knowledge on neurodegenerative and memory decline hallmarks that aid the studies 
conducted. 
 
1.4.1 Cognitive Impairment in Ts65Dn Mice 
 Several studies have demonstrated that Ts65Dn mice exhibit age-related memory 
loss, starting at least by six months of age (Reeves, Irving et al. 1995, Hyde and Crnic 
2001, Driscoll, Carroll et al. 2004). Behavioral testing revealed that deficits exist 
specifically in spatial and recognition memory (Demas, Nelson et al. 1996, Demas, Nelson 
et al. 1998, Bimonte-Nelson, Hunter et al. 2003). Several different memory tasks have been 
utilized including 1) the 8-arm water radial arm maze (Lockrow, Prakasam et al. 2009), 2) 
novel object recognition tasks (Fernandez and Garner 2008, Belichenko, Belichenko et al. 
2009), and 3) the Morris water maze (Escorihuela, Vallina et al. 1998, Stasko and Costa 
2004, Costa, Stasko et al. 2010). In a meta-analysis of the 3-day water radial arm maze 
 





Figure 1-3. Behavior studies of normosomic and Ts65Dn mice at various ages. (A) 
Analysis of WRAM performance in Ts65Dn mice (gray symbols) and age-matched NS mice 
(black symbols) from several different experiments across age. Note that the Ts65Dn mice 
exhibit no statistical difference in average errors the first four trials, indicating that they are 
capable of performing the task, but have significantly more errors during the last four trials, 
showing a significant reduction in learning. (B) Analysis of total spontaneous activity (in cm) 
in Ts65Dn mice (grey squares) and age-matched normosomic mice (NS, black diamonds) 
across several different experiments. Note that significant hyperactivity is observed at all ages 
examined (6-13 months of age). Plotted dots represent the average of the cohort. (C) Analysis 
of locus coeruleus (LC) phenotypic loss from 4 to 13 months of age. There is a progressive 
loss of LC neurons with age, most notable at 13 months of age. TS= Ts65Dn; NS = 
normosomic. Error bars represent an average ± SEM. Figure was adapted from (Hamlett, et 
al, 2016). 
 




(WRAM) performance at 4, 8, and 10 months of age (Figure 1-3, A), I found significant 
karyotype effects in the last testing day (F=4.708; p = 0.003) in Ts65Dn mice compared to 
Normosomic (NS) littermates. In post hoc analyses using Bonferroni correction, I also 
found that Ts65Dn mice WRAM performance progressively declined (more errors) from 
4 to 10 months of age (p = 0.003), suggesting a similarity to the progressive declines seen 
with DS-AD. Ts65Dn performance on behavioral tasks gets worse from 4 to 12 months of 
age, (Hunter, Bimonte et al. 2003, Stasko and Costa 2004). Ts65Dn mice also exhibit 
significant hyperactivity at a young age (Whitney and Wenger 2013), and a meta-analysis 
of Ts65Dn activity demonstrated that hyperactivity also increases with age until 10 months  
(Figure 1-3, B). As seen in (Figure 1-3, C), Ts65Dn mice had markedly reduced LC 
neuronal counts by the age of 10 months. At 4 months of age, Ts65Dn mice show a broader 
distribution of LC neuronal counts but seem to have a similar overall average. Few studies 
have been conducted on the aging process of other DS mouse models (Sabbagh MN 2015), 
which makes the Ts65Dn mouse model a mainstay in the research field.  
  
1.4.2 Early Neurodegeneration in Ts65Dn Mice 
 Basal forebrain cholinergic neurons (BFCN) provide cholinergic innervation to the 
frontal cortex and the hippocampus, and influence attention and cognition in animal models 
and humans (McGeer 1984, Dunnett, Everitt et al. 1991, Perry, Walker et al. 1999). 
Progressive BFCN neuropathology occurs in Ts65Dn mice at 6-8 months of age 
(Holtzman, Santucci et al. 1996, Granholm, Sanders et al. 2000, Cooper, Salehi et al. 2001, 
Seo and Isacson 2005, Contestabile, Fila et al. 2006, Salehi, Delcroix et al. 2006), with 
 




Figure 1-4. Neuropathology in Ts65Dn mice. Neuron loss in the basal forebrain 
(TrkA staining), hippocampus (Calbindin), and the locus coeruleus (tyrosine 
hydroxylase, TH) in middle-aged Ts65Dn mice compared to age-matched normosomic 
mice (NS). In all these three neuronal populations, there is a progressive loss of 
phenotype with age, starting at six months of age. For BFCNs, this phenotypic loss is 
significant at eight months of age, and for the LC and hippocampal neurons at 10-12 
months of age. Scale bar in (A) represents 150 microns, in (D) 60 microns, and in (F) 
50 microns. Figure was adapted from (Hamlett, et al, 2016). 
 




significant neuronal loss by 10 months of age (Figure 1-4, A-B) as observed by 
immunostaining of choline acetyltransferase (ChAT) and the high-affinity nerve growth 
factor (NGF) receptor, tyrosine receptor kinase A (TrkA). These findings are consistent 
with Ts65Dn deficiencies in hippocampal-dependent spatial memory tasks, such as the 
WRAM, during this age span (Granholm, Sanders et al. 2000) (Hunter, et al. 2004).  
 
 Calbindin-D28K (Cal) is a calcium binding protein, which buffers neuronal 
calcium, and may provide greater resistance to neuronal injury and loss since Cal-positive 
pyramidal cells in the hippocampus do not accumulate heavy intraneuronal neurofibrillary 
tangle (NFT) pathology (Sutherland, Wong et al. 1993). However, Cal-positive neurons 
still degenerate in the human brain with aging and greater loss is associated with AD (Lally, 
Faull et al. 1997). In Ts65Dn mice, I also observed a significant loss of Cal-positive 
neurons in the hippocampal CA1 region (Figure 1-4, C-D) (Hunter, Bimonte-Nelson et al. 
2004). In Chapter 5 studies, I also observed significant reductions of Cal-expressing 
neurons in the hippocampus in Ts65Dn mice at 9 months of age. Cal-positive neuron loss 
specifically observed in Ts65Dn BFCNs may be driven by abnormal reductions in 
neurotrophin expression in the hippocampus (Sutherland, Wong et al. 1993, Pappas and 
Parnavelas 1997). In line with this, the Granholm lab has conducted several studies on 
mature forms of NGF and BDNF and observed significant age-related reductions in levels 
of both factors in the hippocampus and cortex of Ts65Dn mice (Bimonte-Nelson, Hunter 
et al. 2003, Fukuda, Berry et al. 2010). 
 
 




 The LC-NE may be one of the first neuronal transmitter systems to display 
neurodegeneration along with reductions in cortical innervation before the onset of DS-AD 
(Tomlinson, Irving et al. 1981, Mann, Yates et al. 1984, Whitehouse, Struble et al. 1985, 
Chan-Palay 1991, Haglund, Sjobeck et al. 2006). This decline in the LC-NE leads to 
norepinephrine (NE) deficiencies which exert negative effects on neurons, glia, and blood 
vessels throughout the CNS (Feinstein, Heneka et al. 2002, Heneka, Nadrigny et al. 2010). 
A meta-analysis of several different groups of Ts65Dn mice has also confirmed LC 
degeneration with age in this DS mouse model (Lockrow, Boger et al. 2011). LC-NE 
neurons in Ts65Dn mice have normal morphology and cellular density at 4 months of age 
but then progressively degenerate with major neuronal loss evident by 12 months of age 
(Figure 1-4, E-F) (Lockrow, Boger et al. 2011). NE effects on brain function are mediated 
directly, via neurotransmission, and indirectly, via aggravation of Aβ accumulation, 
inflammation, and oxidative stress pathways (Marien, Colpaert et al. 2004, Counts and 
Mufson 2010). LC-NE lesions using the selective NE neurotoxin, N-(2-chloroethyl)-N-
ethyl-2-bromobenzylamine (DSP-4), aggravated amyloid accumulation, oxidative stress, 
and memory loss in transgenic AD models (Kalinin, Gavrilyuk et al. 2007, Jardanhazi-
Kurutz, Kummer et al. 2010). Recent work in the Granholm lab showed that DSP-4 lesions 
in Ts65Dn mice gave rise to accelerated memory loss, elevated inflammation, and more 
robust neurodegeneration (Lockrow, Boger et al. 2011). In previous studies, the Granholm 
lab and others discovered that a long-term administration of the NE prodrug, L-threo-
dihydroxyphenylserine (L-DOPS) recovered memory loss in Ts65Dn mice, which suggests 
that rescue of noradrenergic tone before degeneration is evident may provide lasting 
 




neuroprotective effects (Salehi, Faizi et al. 2009, Lockrow, Boger et al. 2011, Fortress, 
Hamlett et al. 2015). In Chapter 3, I further tested the role of the LCNE on cognition by 
utilizing designer receptors exclusively activated by designer drugs (DREADDs). This new 
approach allowed selective stimulation of declining LC-NE neurons to determine if 
modulation of noradrenergic tone could rescue behavioral deficits in this mouse model 
(Fortress, Hamlett et al. 2015). Altogether, these studies clearly define an obligatory role 
for LC-NE function in cognition and memory performance in mice. 
 
1.5 AD Hallmarks Observed in the Human DS Brain 
 As individuals with DS age, they exhibit a far greater incidence of short-term 
memory impairments compared to their normal baseline performance (Coyle, Oster-
Granite et al. 1986). This age-related change results in significant reductions in 
performance on behavioral indices that measure orientation, object-naming (aphasia), and 
general knowledge (Coyle, Oster-Granite et al. 1986). It is important to note that this 
measurable decrease in cognitive ability is not seen in individuals with other kinds of 
intellectual disabilities, as these people develop AD with an incidence rate that is similar 
to the general population (Dickerson, Sperling et al. 2007). Starting abruptly around the 
age of thirty, individuals with DS experience abnormal declines in executive function, 
language skills, decision making, and cognitive flexibility several years before dementia 
can be clinically diagnosed (Wiseman 2009). Cognitive and neuropathological features of 
AD continue to worsen through the sixth decade in individuals with DS (Lott and Dierssen 
2010, Head, Silverman et al. 2012) which is why this population experience tripled the 
 




incidence rate of AD  shown in Figure 1-1, B when compared to the general population 
(Wiseman, Al-Janabi et al. 2015). Albeit very early, the progression of AD pathology 
suggests that there may be a preclinical phase where therapeutic interventions may be 
effective. In the general population, the delay is at about ten years between the onset of 
some AD pathological biomarkers and dementia diagnosis in the general population 
(Wisniewski and Rabe 1986, Schupf and Sergievsky 2002). The interval between dementia 
AD diagnosis and death is shorter in the DS population, and thus the preclinical phase may 
be entirely different for DS-AD.  
 
1.5.1 Profound Protein Accumulation 
 DS-AD seems to involve a multitude of changes in molecular mechanisms, but two 
molecular hallmarks have been the subject of intense investigations and major hypotheses 
over the last three decades: 1) extracellular amyloid  protein (A) accumulation leading 
to amyloid plaques and 2) significant increases in P-Tau protein leading to NFT deposition. 
Due to its localization on Hsa21, individuals with DS have an overexpression of the APP 
gene. APP can be cleaved into a variety of smaller peptide fragments, with some of them 
being harmful. One of these toxic peptides is A42 peptide, which has a tendency to 
aggregate into fibrils and plaques and is a process that can be exacerbated by changes in 
enzymatic processing that favor the production of toxic amyloid peptides. Amyloid 
deposition is profound in individuals with DS and accumulates in dense plaques that are 
easily visualized by Bielchowsky’s silver stain method after the age of 30 years (Figure 1-
5) (Mann and Esiri 1989, Hirayama, Kobayashi et al. 2004). Early diffuse plaques have 
 




Figure 1-5. Bielschowsky’s silver stain of Human neuropathology. Age-matched 
individuals comparing a control individual without cognitive impairments to a DS 
individual with clinically diagnosed dementia resulting from DS-AD. Under high 
magnification (bottom row), both amyloid plaques NFTs are abundant in brain sections 
from patients with DS-AD while absent from the healthy control. NFTs are labeled 
with white arrows. Black bars represent scale. 
 
 




been described in individuals with DS already in their teens (Lemere, Blusztajn et al. 1996, 
Head 2001), which speak to the etiological consequences of Trisomy 21 on AD pathology, 
especially since accumulation of amyloid in plaques is believed to trigger additional 
pathology in the brain including inflammation and oxidative stress (Butterfield, Griffin et 
al. 2002). 
 
 In addition to the pronounced Aβ deposition in subjects with DS (Lott, Head et al. 
2006, Cardenas, Ardiles et al. 2012), intracellular NFTs also occur abundantly (Hof, 
Bouras et al. 1995, Stoltzner, Grenfell et al. 2000, Mormino, Kluth et al. 2009). NFT 
pathology begins in the entorhinal cortex by the mid‐thirties, and then spreads into the 
hippocampus by mid‐forties, and then into the neocortex by the mid‐fifties, but biological 
variability exists between DS individuals like that seen in the general population (Mann, 
Yates et al. 1984, Mann, Yates et al. 1986, Mann and Esiri 1989, Hof, Bouras et al. 1995). 
However, results from several research studies have reached a consensus that NFTs may 
not appear before the age of 20 in DS (Wisniewski, Dalton et al. 1985, Wisniewski, 
Wisniewski et al. 1985), although a recent manuscript demonstrated abnormal 
phosphorylation of Tau already in the brain of fetuses with DS. This suggests that Tau 
pathology, albeit not accumulating in actual NFTs, is an early event in DS and may 
contribute to later development of other AD pathology (Milenkovic, Jarc et al. 2017). The 
absence of early NFT pathology originally led researchers to hypothesize that APP gene 
dosage and A accumulation are the primary drivers of DS-AD. In Chapter 5, I present 
novel biomarker data in support the amyloid hypothesis and  tauopathy. 
 




1.5.2 Hippocampal Atrophy 
 The hippocampus is essential for working memory function (McGaugh 2000, 
Morris, Moser et al. 2003, Morris, Inglis et al. 2006) and the acquisition, consolidation, 
and retrieval of declarative memories that contain spatial and contextual information 
(Murchison, Zhang et al. 2004). Hippocampal volume is associated with the degree of 
cognitive impairment observed in individuals with DS-AD (Beacher, Daly et al. 2009) and 
with AD (O'Brien, Desmond et al. 1997), suggesting that atrophy resulting from 
neurodegeneration at least partly underlies this decline. Alterations and synaptic integrity 
(Garcia-Cerro, Martinez et al. 2014) and reductions in hippocampal neurogenesis (Lazarov 
and Marr 2010) are also hallmark changes in the hippocampus associated with DS-AD. 
Cal-positive neurons are known to degenerate in the human brain with age, with greater 
loss associated with AD (Lally, Faull et al. 1997). Interestingly, Cal-positive pyramidal 
cells do not accumulate AD pathology with a heavy burden, which suggests that a greater 
ability to buffer calcium correlates with greater resistance to injury and loss (Sutherland, 
Wong et al. 1993). The hippocampus is not the first brain structure to undergo degenerative 
changes but rather may be a secondary consequence of preceding deterioration of afferent 
neuronal populations. The hippocampus is innervated by several important neuronal 
systems including 1) basal forebrain cholinergic neurons (BFCN) (Mesulam, Mufson et al. 
1983, Hunter 2004, Jason Lockrow 2009), 2) serotonergic neurons of the raphe nucleus 
(Levin, Rose et al. 1990) and 3) LC-NE neurons (Mair, Zhang et al. 2005, Salehi, Faizi et 
al. 2009). Primary degeneration of these essential transmitter systems predisposes the 
hippocampus to neurodegeneration and physiological changes associated with AD. 
 




1.5.3 Degeneration of Transmitter Systems in DS-AD 
 The medial septal area, particularly the diagonal band of Broca, provides the 
primary source of the neurotransmitter acetylcholine (Ach) in the hippocampus (Dutar, 
Bassant et al. 1995). Individuals with DS exhibit progressive degeneration of BFCN, which 
correlates with memory loss (Yates, Simpson et al. 1983, Mann, Yates et al. 1985, Isacson, 
Seo et al. 2002, Ikonomovic, Mufson et al. 2003, Schliebs and Arendt 2010). Furthermore, 
decreases in hippocampal ACh due to phenotypic loss of cholinergic neurons are associated 
with cognitive deficits that are typical of AD (Cole and Nicoll 1983, McGeer 1984, 
Dunnett, Everitt et al. 1991, Perry, Walker et al. 1999). BFCNs also provide cholinergic 
innervation to frontal cortical regions, which exert significant influence on information 
processing, attention, and cognition. Although BFCNs are not the focus of this dissertation, 
degeneration of this critical population of neurons may influence other brain-related 
changes observed in my studies.  
 
 LC-NE activity seems to be essential for proper memory function. Noradrenergic 
terminals extensively innervate the central nervous system including the hippocampus 
(Loy R 1980), prefrontal cortex (Stanton PK 1985, Bramham CR 1997, Morris, Moser et 
al. 2003, Vazey EM 2012), and basal forebrain (Espana and Berridge 2006), but also the 
hypothalamus, midbrain, medulla and spinal cord (Marien, Colpaert et al. 2004), with 
minimal innervation of the basal ganglia. For those who suffer AD or DS-AD, LC-NE 
neuron dysfunction and decline occurs very early (Mann, Yates et al. 1984, Marcyniuk, 
Mann et al. 1988, Phillips, Fahimi et al. 2016). LC neuropathology in patients with DS-AD 
 




has been reported to be similar to that observed in AD patients (Wisniewski, Dalton et al. 
1985) albeit more severe, with 60% greater neuronal loss relative to age-matched controls 
(Mann, Yates et al. 1984, German, Manaye et al. 1992). The loss of LC-NE neurons results 
in decreases in NE innervation by as much as 30-50% in both cortical and hippocampal 
brain regions (Yates, Ritchie et al. 1981, Reynolds and Godridge 1985, Godridge, Reynolds 
et al. 1987). For patients with DS-AD, it is important to note that LC-NE neuron loss occurs 
earlier than that observed in the BFCN (Zarow, Lyness et al. 2003) (Mann, Yates et al. 
1982, Chalermpalanupap T 2013). This early vulnerability suggests that these neurons are 
among the most sensitive to the etiological factors of AD, but there may be a more complex 
systems level involvement of different neuronal populations that predispose the LC-NE to 
early declines. A declining or dysfunctional LC would result in reduced noradrenergic tone 
throughout the brain. Reductions in NE would specifically affect BFCNs via ɑ1 adrenergic 
receptor activity (Gibbs and Summers 2002), prefrontal regions via ɑ2 adrenergic receptors 
(Faraone, Biederman et al. 2005, Chamberlain, Del Campo et al. 2007), and the 
hippocampus via β1 adrenergic receptors (Devauges and Sara 1991, Gliebus and Lippa 
2007), although other receptor subtypes are expressed throughout these regions. 
Consequences of LC-NE degeneration on specific memory functions in the Ts65Dn mouse 
model of DS will be discussed in Chapter 3. 
 
1.5.4 Chronic Neuroinflammation 
 Inflammation in the brain is often characterized by the activation of resident 
microglia, which perform immune surveillance and can upregulate the innate immune 
 




response (Gehrmann, Matsumoto et al. 1995) via secretions of cytokines and other 
inflammatory factors (Kong, Ruan et al. 2010). In acute situations, activated microglia 
produce inflammatory mediators that have neuropathic as well as neuroprotective actions, 
which suggests that neuroinflammation participates in defense mechanisms against injury 
and the ensuing cell degeneration and death. In contrast, chronic microglial activation leads 
to significant elevations of multiple neurotoxic factors which drive progressive neuronal 
damage (Cagnin, Brooks et al. 2001, Lull and Block 2010). Chronic inflammation is a well-
established comorbidity with AD (Wyss-Coray and Rogers 2012) and DS-AD (Wilcock 
2012), but for those with DS, this hallmark is exaggerated by trisomy 21 aneuploidy very 
early in life. Previous studies have shown that pro-inflammatory cytokines are elevated in 
fetuses with DS in utero (Hartley, Blumenthal et al. 2015). Dramatic proliferation of 
activated microglia occurs in the brain of children with DS resulting in proinflammatory 
cytokine overexpression (Wilcock and Griffin 2013, Wilcock, Hurban et al. 2015).  
 
 Children with DS also have significant increases in systemic inflammation, 
including more proliferation of cytokine-producing microglia in the brain and elevated 
peripheral immune responses. Similarly, increases in neuroinflammation very early in life 
are assumed to predispose individuals with DS to DS-AD (Wisniewski KE 1985, Webb, 
Collins et al. 1986, D'Eustachio, Jadidi et al. 1987, Swardfager, Lanctot et al. 2010, 
Wilcock and Griffin 2013). Since the 1980s, studies of postmortem brain specimens from 
AD patients revealed significant elevations in neuroinflammatory markers (Eikelenboom 
and Stam 1982, Combs, Bates et al. 2001). Then activated microglia, suggesting chronic 
 




inflammation, were found to be closely associated with AD pathology. Inflammatory 
responses, including immunoglobulin and complement factors, were found to be closely 
associated with abnormal plaque deposits (Eikelenboom and Stam 1982). Inflammatory 
cytokines like interleukin (IL)-1β, IL-6, IL-12, and tumor necrosis factor-ɑ (TNF-ɑ) were 
significantly elevated in the serum from patients with AD (Griffin, Stanley et al. 1989, 
Griffin 2006, Swardfager, Lanctot et al. 2010, Bagyinszky, Giau et al. 2017). Altogether, 
chronic inflammation represents an overall disturbance of innate immunity in the brain, 
which is manifest by alterations in resident microglia cells, the degree of which is 
exacerbated by the genetics of trisomy 21 which worsens with age (Wierzba-Bobrowicz, 
Lewandowska et al. 1999, Head, Lott et al. 2016). In Chapter 4, I utilized a novel anti-
inflammatory therapy in Ts65Dn mice to investigate whether inflammatory resolution 
factors might modulate neuroinflammation. 
 
1.5.5 The Role of LC-NE in Neuroinflammation 
 One important mechanism behind chronic neuroinflammation observed in those 
with DS involves the noradrenergic influence on inflammatory modulation (Cagnin, 
Brooks et al. 2001). In addition to its actions as a neurotransmitter, norepinephrine has 
other roles that help prevent and limit the progression of neuropathology in a variety of 
diseases and conditions. For example, NE reduced lipopolysaccharide (LPS)-induction of 
proinflammatory cytokines, like TNFα, in microglia (Szabo, Hasko et al. 1997), interferon 
γ-induced expression of class II D-related Human Leukocyte antigens (Lull and Block 
2010, Feinstein, Kalinin et al. 2016), and cytokine-dependent induction of type 2 nitric 
 




oxide synthase (NOS2) expression in astrocytes and microglia (Feinstein, Galea et al. 1993, 
Pahan, Namboodiri et al. 1997, Dello Russo, Boullerne et al. 2004). Noradrenergic control 
seems to be conserved in mammals as previous research has demonstrated a strong LC-NE 
influence inflammation-related pathology in transgenic models for Alzheimer's disease. 
Loss of LC-NE innervation with aging or by the selective LC neurotoxin, DSP-4, led to an 
increase in pro-inflammatory cytokine expression and increased activation of microglial 
cells in the limbic system of the brain (Feinstein et al., 2002; Heneka et al., 2002). Previous 
work in our lab has shown that DSP-4 mediated ablation of LC-NE neurons in Ts65Dn 
mice led to activation of microglia in the hippocampus, coupled with increased messenger 
RNA (mRNA) expression of IL-1β (Lockrow et al., 2011). The increased 
neuroinflammation observed in Ts65Dn mice with LC lesion suggests that the LC-NE 
denervation modulates the innate immunity in the brain, but the precision of this control 
remains unknown. However, as mentioned earlier, neuroinflammation is abnormally 
increased even during fetal development in DS. LC-NE degeneration occurs later. This 
suggests that other mechanisms or perhaps an uncharacterized LC-NE dysfunction may 
exist. Studies using designer receptors in Chapter 3 demonstrated significant and rapid 
effects on the immune system of the brain when the activity of LC-NE neurons was 
inhibited, providing further evidence for the strong connection between LC-NE signaling 
and immune control that is temporally precise. If the brain noradrenergic axis fails over 
extended periods of time and neuroinflammation becomes chronic, the LC itself may then 
be subject to the detrimental effects of enhanced inflammatory stress, possibly leading to 
a neuroinflammatory syndrome in the brain.  
 





1.6 Therapeutic Pathways to Resolve Chronic Neuroinflammation 
 The connection between neuroinflammation and DS-AD is a central theme of this 
dissertation and can be explored beyond the LC-NE influence. Neuroinflammation is a 
multifaceted and persistent hallmark of AD neuropathology, and likely contributes to 
neuronal stress, which may manifest disturbances of the proteome, metabolome, and the 
lipidome. Research into inflammation as a major contributor to AD has been spurred by 
several important discoveries. As mentioned earlier, significant elevations in 
neuroinflammation markers and microglial activation is associated with AD pathology. 
Another pivotal discovery was that individuals who regularly consume anti-inflammatory 
therapeutics seemed to be protected from AD. An indirect proof for the role of 
inflammation in AD has been provided by studies utilizing targeted anti-inflammatory 
drugs, such as the tetracycline derivative minocycline (Cuello, Ferretti et al. 2010, 
Lockrow, Boger et al. 2010). The Granholm lab previously demonstrated that minocycline 
treatment in Ts65Dn mice successfully prevents both memory loss and neurodegeneration 
if implemented at 4 months of age (Hunter et al., 2004). Minocycline was also shown to 
reduce neuroinflammation and inhibits amyloid pathology in a transgenic model of AD 
(Ferretti, Allard et al. 2012). Memantine, a glutamatergic N-methyl-D-aspartate (NMDA) 
receptor antagonist, is the only FDA-approved drug for the treatment of AD that is not an 
acetyl cholinesterase inhibitor. However, a meta-analysis of six clinical trials determined 
that Memantine’s protective effect is minimal (Winblad, Jones et al. 2007, Gauthier, Loft 
et al. 2008).  
 





Several epidemiological studies suggested that non-steroidal anti-inflammatory 
drugs (NSAIDs) are neuroprotective against AD pathology (Broe, Grayson et al. 2000, 
Zandi, Breitner et al. 2002). However, early clinical trials studying NSAID treatment 
showed no cure or prevention effects for patients with mild cognitive impairment (MCI) 
or AD (Breitner, Baker et al. 2011, Tabas 2013). Alarmingly, some clinical trials that have 
implemented NSAID therapies (Imbimbo, Solfrizzi et al. 2010, Sonnen, Larson et al. 2010, 
Wu, Rosa-Neto et al. 2011, Sudduth, Schmitt et al. 2013, Amor, Peferoen et al. 2014) have 
observed dangerous long-term outcomes including risks of heart failure, gastrointestinal 
bleeding and kidney failure (Breitner, Baker et al. 2011, Jaturapatporn, Isaac et al. 2012, 
Tabas 2013). Interestingly, individuals with DS demonstrated a significant and chronic 
upregulation of the innate immune system, including elevated cytokines in serum 
(Convertini, Menga et al. 2016, Iulita, Ower et al. 2016) and increased glial activation in 
the CNS (Wilcock, Hurban et al. 2015). NSAIDs and other therapeutic inhibitors like 
aspirin, ibuprofen or rofecoxib had broad and multifaceted impacts on inflammatory 
processes (Ricciotti and FitzGerald 2011, Alhouayek and Muccioli 2014), likely by 
modulating the cyclooxygenase 2 (COX-2) pathway of lipid metabolism. However, 
subsequent clinical trials using NSAID treatment showed minimal effects in patients with 
MCI or AD (Breitner, Baker et al. 2011, Tabas 2013, McGeer, Rogers et al. 2016). 
Altogether, these findings suggest that anti-inflammatory targets other than COX inhibitors 
have to be developed for successful treatment or prevention of neuroinflammation in AD 
or DS-AD. Disease-modifying drugs for neuroinflammation associated with AD are still 
 




under extensive research, and no current clinical trials show significant promise to halt the 
disease (Yiannopoulou and Papageorgiou 2013, Sikazwe, Yendapally et al. 2017).  
 
 Interestingly, lipid metabolism is coupled to noradrenergic influences from the LC-
NE and is mediated by β-adrenoreceptors (AR), since only β-AR agonists (and not α-AR 
agonists) produced similar results (Alhouayek and Muccioli 2014). Modulation of lipid 
metabolism has been described in AD (Hewett, Uliasz et al. 2000, Bazan, Colangelo et al. 
2002) and may correlate with the severity of dementia in AD patients (Ho, Purohit et al. 
2001). The intersection of NE and lipid metabolism reveals yet another noradrenergic 
process that may either promote or inhibit neuroinflammation, depending on the balance 
of signaling mechanisms, bioavailable metabolites and downstream secondary metabolite 
production by other enzymes. These data strongly suggest that anti-inflammatory therapies 
may be successful in slowing or preventing AD pathology in DS if one could find a novel 
approach that does not interfere with LC-NE modulation and does not have significant 
peripheral side effects. In order to prevent, or significantly slow down, neuron loss and AD 
progression for individuals with DS, strategies to inhibit accumulations of Aβ peptide 
products (like Aβ40 and Aβ42), excessive P-Tau, oxidative stress, neurotrophic 
imbalances, and neuroinflammation may extend life by halting AD progression.  
 
 One of the most pressing questions in the field is how do to decrease inflammation 
in the brain to stop AD progression without chronic adverse side effects? Due to mixed or 
poor outcomes of COX-2 inhibitors alternative anti-inflammatory approaches need to be 
 




explored. Disease-modifying drugs for neuroinflammation are still under extensive 
research, and clinical trials have yet to show significant promise for AD therapy 
(Yiannopoulou and Papageorgiou 2013, Sikazwe, Yendapally et al. 2017). The lack of 
efficacious therapies has bolstered new investigations into inflammatory modulation. In 
this dissertation, I explore a novel therapy based on recent knowledge gleaned from poly-
unsaturated fatty acid (FA) biology, lipid metabolism, and potent modulation of 
inflammation that has shown great promise to reduce AD pathology. 
 
1.6.1 Specialized Pro-Resolving Mediators 
Epidemiological and animals studies have suggested that omega-3 (Ω3) FAs might 
have protective properties against AD, but the recent OmegAD study and other Ω3 clinical 
trials found mixed results that suggest few or no benefits of the therapy in multiple 
evaluation indices (Freund-Levi, Eriksdotter-Jönhagen et al. 2006, Freund-Levi, Hjorth et 
al. 2009, Cederholm and Palmblad 2010) even though it was proven that Ω3 crossed the 
blood-brain barrier and elevated levels in the brain (Freund Levi, Vedin et al. 2014). This 
lack of response might have ended studies of Ω3 protective effects if not for 
groundbreaking research, conducted by Dr. Charles Serhan at Harvard University, which 
previously uncovered novel leads connecting Ω3 biology to inflammatory modulation. Ω3 
FAs are converted into a family of specialized pro-resolving mediators (SPMs) (Serhan, 
Chiang et al. 2008) that are capable of counter-balancing inflammation, a unique process 
that is called resolution (Serhan 2007, Buckley, Gilroy et al. 2014). A follow-up 
investigation on the OmegAD study, sought to determine if SPM levels released from 
 




circulating peripheral blood mononuclear cells (PBMCs) from the participants, were 
altered after administration of Ω3. The Ω3 administration did not elevate SPM levels but 
did prevent reductions in SPM levels released from PBMCs of AD patients (Wang, Hjorth 
et al. 2015). It is important to mention that these SPM levels were also correlated with 
cognitive function. Studies in animal models are needed to evaluate how Ω3 biology 
translates to bioactive SPMs in the brain. Methods to enhance Ω3 conversion to SPMs 
remain to be developed. 
  
The resolution mediator process begins with long chain Ω-3 FAs received from a 
diet rich in fish, fish oils, and some plant oils. These long-chain Ω-3 FAs, composed 
primarily of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are converted 
into a large variety of SPMs by a coordination of several enzymatic processes (Figure 1-
6). COX-2 is an important first-step enzyme for the formation of many E-series resolvins 
(RvE). The synthesis of RvE (1-3) from EPA involves cytochrome P450 monooxygenases 
or acetylated COX-2, thus E-series resolvins that can be aspirin-triggered. Further 
enzymatic activities include the formation of 18-hydroxy-eicosapentaenoic acid (18-
HEPE) that is converted by 5-lipoxygenase (5-LOX) to resolvins (Spite and Serhan 2010). 
EPA can also be converted to RvE3 by 15- lipoxygenase (15-LOX) in humans (Isobe, Arita 
et al. 2012). The metabolism of DHA to D-series resolvins (RvD1-6) involves acetylated 
COX-2 or 15-LOX via formation of 17-  hydroperoxy-docosahexaenoic acid (17-HpDHA) 
and 17-hydroxy-docosahexaenoic acid (17-HDHA) (Serhan and Petasis 2011). In the 
absence of 5-LOX, neuroprotectin D1 (NPD1) is formed from 17-HpDHA. In humans, 
 




DHA can be metabolized by 12-LOX to form 14-HDHA and the maresins. It is important 
to mention that SPM-producing enzymes, COX-2 and 5-LOX, are abundantly expressed in 
neurons and glial cells (Zhang L 2006). Chemerin-like receptor-1 (ChemR23) and 
leukotriene B4 receptor (BLT1) are expressed in neurons and microglia of the mouse brain 
(Schwab, Chiang et al. 2007, Serhan 2007) and ChemR23 is also expressed in the human 
brain, both in neurons, astrocytes and microglia (Wang, Zhu et al. 2015). Altogether, the 
ongoing transformation of Ω-3 FAs to SPMs (resolvins, lipoxins, maresins, and 
neuroprotectins) involves several enzymatic steps and metabolite bioavailability that may 
Figure 1-6. Ω-3, SPMs and receptors of the resolution pathway. Enzymatic 
conversion of Ω-3 to SPMs is highly coordinated and mediates precise resolution 
signaling via G-protein coupled receptors. This schematic was created by Eric Hamlett. 
 




each be influenced by disease processes. Perturbations in any of these enzymatic steps 
could have local or systemic consequences on initiation of the resolution process and 
promote inflammation.  
 
1.6.2 Novel Proresolution Therapies 
 In the periphery, SPMs have been shown to down-regulate pro-inflammatory 
cytokines, up-regulate anti-inflammatory cytokines, and promote non-phlogistic 
phagocytosis by macrophages (Ji, Xu et al. 2011). In the heart, lipoxin A4 (LXA4) and 
NPD1 provide enhanced protection upon ischemic stroke in rodent models (Bazan 2009, 
Wu, Wang et al. 2011). RvE1 has been clinically investigated in chronic inflammatory 
conditions in peripheral systems and shows positive results in Phase II clinical trial for dry 
eye inflammation (NCT00799552), for peripheral artery inflammation reduction 
(NCT02719665) and for allergic airway inflammation (NCT01992835). LXA4 has also 
been reported to reduce production of reactive oxygen species (ROS) and to inhibit IL-1β-
induced IL-8 in vitro. RvD1-2 and RvE1 can attenuate inflammation-associated pain in 
mice (Xu ZZ 2010). Interestingly, NPD1 and LXA4 have been reported to protect neuronal 
cells from Aβ-induced cytotoxicity (Bazan 2009, Calandria, Asatryan et al. 2015, Zhu, 
Wang et al. 2015). RvE1 inhibits neutrophil migration into sites of inflammation, which 
reduced cytokine production that can amplify inflammation (Serhan C. 2008, Raouf R 
2010, Xu ZZ 2010). Finally, a recent study by Drs. Schultzberg and Granholm and their 
collaborators identified and quantified SPMs and receptors in the brain of AD patients and 
found several dysfunctions including reduced SPM levels, significant compensatory 
 




elevations of receptors and alterations of enzymes linked to SPM synthesis (Wang X 2015). 
Furthermore, it has been shown in vitro that SPM therapies mediate Aβ clearance and 
improve neuronal survival (Zhu, Wang et al. 2015). Lastly, in vitro studies by Schultzberg's 
group and others show that SPMs reduce neuronal cell death as well as modulate microglial 
phenotype (Hjorth, Zhu et al. 2013, Zhu, Wang et al. 2015, Rey, Nadjar et al. 2016).  
  
1.6.3 Signaling Pathways Involved in Resolution of Inflammation 
 Several studies have revealed a role for SPMs in the nervous system, where they 
initiate a resolution response via a unique class of G-protein coupled receptors (GPCRs) 
(see Figure 1-6). The GPCRs affect cAMP-dependent protein kinase activation and alter 
signaling pathways that are known to be linked to both AD and DS-AD (Perluigi M 2014, 
Burkewitz, Weir et al. 2016, Paschoal, Amano et al. 2017). Specifically, both Mammalian 
target of rapamycin (mTOR) and ERK signaling pathways are effector pathways to some 
resolution receptors and have been shown to be abnormal in individuals diagnosed with 
DS-AD (Iyer, van Scheppingen et al. 2014, Perluigi M 2014) and in mouse models of DS-
AD (Ahmed, Dhanasekaran et al. 2013, Tramutola, Lanzillotta et al. 2016). A recent study 
revealed that specific SPMs are agonists to PPAR-γ and act to modulate cytokine 
production (Muralikumar, Vetrivel et al. 2017). Collectively, these SPM receptors are 
expressed in the neurons and glial cells in the brain (Schwab, Chiang et al. 2007, Serhan 
2007, Wang, Zhu et al. 2015)(Wang et al, 2015). Altogether, the abundance of SPM 
enzymes and receptors in the brain suggests that proresolution processes may influence 
inflammatory homeostasis specifically in the CNS.  
 






Although it is established that ChemR23 and BLT1 respond to RvE1, alternative 
ligands may play a role in resolution processes. ChemR23 can also transduce 
proinflammatory signals upon binding other ligands such as chemerin and Aβ42 (Peng, Yu 
et al. 2015). Interestingly, Aβ42 binding led to internalization of the Aβ42-ChemR23 
complex, suggesting a potential role for Aβ42 clearance or potentially as a signaling 
endosome. Hence, a complex variety of ligands for ChemR23 and for BLT1 may provoke 
biased signaling mechanisms that are dependent upon local conditions that balance pro-
resolution and proinflammatory processes over a chronic time scale. Recently, RvE1 was 
observed to have a profound binding capacity to the ubiquitously expressed peroxisome 
proliferator-activated receptor gamma, PPAR-γ (Arita, Yoshida et al. 2005, Schwab, 
Chiang et al. 2007, Oh, Pillai et al. 2011, Herova, Schmid et al. 2015). PPAR-γ belongs to 
a superfamily of related nuclear receptors (Tyagi, Gupta et al. 2011) that modulate lipid 
homeostasis (Heneka, Reyes-Irisarri et al. 2011). The specific resolution signaling 
pathways include phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt) and 
extracellular-signal-regulated kinase (ERK) (Hoeffer 2010). Signaling via Akt and ERK 
pathways is abnormal in individuals with DS, in comparison to age-matched controls, and 
is also abnormal in the Ts65Dn mouse model of DS-AD (Iyer, van Scheppingen et al. 2014, 
Perluigi, Di Domenico et al. 2015), suggesting that perturbations in this pathway may be 
involved in neurodegeneration. 
 
 




A barrier for studies of resolution processes has been in the development of 
appropriate markers and sensitive methods that allow quantification of the resolving 
cascade in the human brain. SPM serum and tissue concentrations are relatively low, and 
SPM studies necessitate mass spectrometry-based approaches with high sensitivity (Serhan 
2000, Serhan 2002). Studies have also revealed that some if not most SPMs are short-lived 
in the extracellular matrix and serum of mammals (Dangi, Obeng et al. 2010) suggesting 
that ongoing SPM production may be coordinated spatially and temporally to augment 
inflammatory processes as needed. If enzyme coordination is protracted, then 
inflammatory homeostasis may be affected.  Although Bazan and collaborators have 
shown that NPD1 promotes neural cell survival (Stark and Bazan 2011), no studies have 
been performed to date to test whether SPM-based pro-resolving therapies could be 
beneficial in the Ts65Dn mouse model of DS-AD as was done in Chapter 4. Although 
SPMs and their binding receptors are abundantly expressed in the brain (Wang X 2015), 
their role in modulating chronic inflammation remains been clarified in DS-AD. In 
Chapter 4, I observed proteomic modulations in ChemR23, BLT1 and PPAR-γ receptor 
levels in response to a novel RvE1 proresolution therapy along with significant increases 
in ERK phospho-activation. 
 
1.7 Biomarkers of DS-AD  
 After clinical diagnosis of DS-AD, a patient has approximately five to ten years 
before eventual death (Wisniewski and Rabe 1986, Schupf and Sergievsky 2002) which is 
typically less than observed for the general population. For this reason, clinical biomarkers 
 




of AD that offer predictive value for this disease are critically needed. The 
neuropathological biomarkers, Aβ40 and Aβ42, have been detected in brain tissue and 
cerebrospinal fluid (CSF) decades before the onset of dementia in the general population 
(Blennow and Zetterberg 2015), as well as in DS (Englund, Anneren et al. 2007) but present 
challenges in the clinic. Performing lumbar punctures to acquire CSF in those with DS is 
challenging and depends on the functionality of the patient; thus there is a need for the 
development of reliable blood-based biomarkers that are clinically relevant for those with 
intellectual disabilities and pose minimal to no risk to the patient. I envision that a clinical 
test should ideally be able to quantify protein and metabolites specifically from CNS 
neurons glia or microglia to be relevant to AD. A clinically relevant test should utilize 
either serum, plasma, saliva, or urine samples to provide advantages for DS research since 
a consortium of biobanks with blood biosamples representing longitudinal sampling across 
ages already exist worldwide. A reliable clinical test may also prove useful in evaluating 
potential drug targets for early intervention of AD, by enabling reliable measures of 
therapeutic efficacy and provide both diagnosis and prognosis. Finally, an ultimate goal for 
biomarker testing would be to guide and integrate extensively into precision medicine, 
which might enable disease prevention and treatment that is personalized to an individual’s 
specific pattern of genetic variability, environment and lifestyle factors (Reitz 2016). 
 
1.7.1 Exosome Biomarker Potential 
 In the last two decades, a new biomarker target has emerged that involves the 
intercellular transfer of extracellular vesicles (EVs) (Gho and Lee 2017). Most cell types 
 




in the body, including neurons, release small (~100 nm) endosomally-derived vesicles, 
known as cellular exosomes (Figure 1-7) (Coleman and Hill 2015, Fiandaca, Kapogiannis 
et al. 2015). Exosomes contain rich sources of proteins, mRNA, and microRNA (miRNA) 
cargo that reflect their cellular origin and play a prominent role in cellular signaling, 
removal of unwanted proteins, and transfer of pathogens to other cells (Coleman and Hill 
2015). Interestingly, bioactive lipids have also been found in exosomes, (Laulagnier, Motta 
et al. 2004) which reveal that exosomes may also act as vectors of inflammatory 
modulation (Kourembanas 2015). Whether other COX-2-derived lipids, like  SPMs, get 
sorted into exosomes remains unknown. Secreted exosomes are found in most biological 
Figure 1-7. Neuronal exosome isolation. Neuronal exosome get trafficked through 
the blood brain barrier and can be readily isolated clinically by blood draw by immuno-
selection of the L1CAM neuronal marker. L1CAM expression levels are 10-30 times 
the mean observed anywhere else in the mammalian body.  
 




fluids (blood, CSF, and urine) and circulate in interstitial space, both in the brain and the 
periphery (Salido-Guadarrama, Romero-Cordoba et al. 2014). The mechanisms of 
exosome transport into biological fluids is likely driven by endothelial intracellular 
transport, which seems to be governed in part by exosomal surface markers. A recent study 
discovered that removal of exosome surface proteins with proteinase K decreases 
endothelial transport rates of exosomes by 45% while inhibition of endocytosis, with 
cytochalasin D, caused a 50% decrease in transport (Kusuma, Manca et al. 2016). 
Collectively, exosomes are actively transported from interstitial space, regardless of origin, 
through endothelial cells into the blood which makes the cargo of exosomes an extremely 
attractive target for clinical biomarker testing. Neuronal exosomes have unique neuron-
specific surface markers, which enable targeted isolation from circulating biological fluids 
(Fiandaca, Kapogiannis et al. 2015, Goetzl, Boxer et al. 2015, Goetzl, Boxer et al. 2015). 
Specifically, a neural cell adhesion molecule, L1-cell adhesion molecule (L1-CAM, or 
CD171), is highly expressed on the neuron surface in all brain regions and is therefore 
transferred to the surface of exosomes (Figure 1-7). Therefore, L1-CAM is a relatively 
stringent surface protein that allows immuno-enrichment of neuronal exosomes for 
biomarker studies. 
 
 Recent studies have found that neuronal exosomes may act as vectors of several 
important pathological hallmarks of AD. Early endosomes deliver APP to neuronal 
exosomes which possess the ability to process APP into Aβ peptides by self-contained 
proteases (Haass, Lemere et al. 1995, Rajendran, Honsho et al. 2006, Sharples, Vella et al. 
 




2008, Perez-Gonzalez, Gauthier et al. 2012, Yuyama, Sun et al. 2015). Therefore neuronal 
exosomes seem to have the potential to vectorize toxic Aβ peptide products and also P-Tau 
to neighboring cells, other brain regions, and across the blood brain barrier into the 
circulatory system. Since AD biomarkers are exosome cargo, this suggested that neuronal 
exosomes extracted from either plasma or CSF can be used to assess neuropathological 
processes within CNS neurons (Vingtdeux, Sergeant et al. 2012, Jaunmuktane, Mead et al. 
2015, Yuyama, Sun et al. 2015). Recent findings indicate that Aβ, Tau, and other AD 
biomarker cargos found in neuronal exosomes accurately predict the onset of dementia as 
early as ten years before symptom onset in patients with sporadic AD or frontotemporal 
dementia (FTD) (Fiandaca, Kapogiannis et al. 2015, Kapogiannis, Boxer et al. 2015). Since 
these exosomal biomarkers had not been analyzed in individuals with DS, I hypothesized 
that neuronal exosomes obtained from individuals with DS would have elevated levels of 
Aβ peptides and P-Tau that could document a preclinical AD-phase in the DS population. 
Neuronal exosomes analyses were the focus of Chapter 5. 
 
 
1.7.2 BDNF as a Clinical Biomarker of DS-AD 
 Brain-derived neurotrophic factor (BDNF) is necessary for development and 
maintenance of several different neuronal populations in the brain and can be retrogradely 
or anterogradely transported within the neuronal axon (Adachi, Kohara et al. 2005). 
Released BDNF can be measured in cerebral spinal fluid (CSF), but the most attractive 
approach would be to measure BDNF in serum due to ease of acquisition and sample 
 




availability. Serum BDNF levels seem to be strikingly associated with AD and several 
other neurological conditions and thus make it an attractive potential biomarker for AD 
risk. Several studies have been conducted to test this plausibility. For example, reduced 
serum BDNF levels were associated with decreased cognitive performance in patients with 
AD as compared to healthy older subjects (Laske, Stransky et al. 2007, Gunstad, Benitez 
et al. 2008, Lee, Shin et al. 2009, Forlenza, Torres et al. 2011), but did not correlate with 
age or various cognitive test scores (Yasutake, Kuroda et al. 2006). However, a recent study 
revealed a positive correlation between serum BDNF levels with specific working memory 
and decision-making scores in healthy older adults (Hakansson et al., 2017), suggesting 
that BDNF levels may be correlated with specific memory modalities rather than global 
cognition performance. It is important to note that significant reductions in serum BDNF 
have been reported in patients with MCI (Yu, Zhang et al. 2008), a cognitive stage 
preceding AD (Winblad, Palmer et al. 2004, Forlenza, Diniz et al. 2010, Albert, DeKosky 
et al. 2011). In contrast, other studies have reported increased serum BDNF levels in 
patients with MCI and early AD (Laske, Stransky et al. 2007, Angelucci, Spalletta et al. 
2010). These oppositional findings may suggest that BDNF levels reflect an early 
compensatory response that gives way to decreases in latter AD stages or with age.  
 
 In the DS population, circulating BDNF dynamics seem to be markedly different 
to that observed in the general population. Although AD incidence is severe in the DS 
population, several studies have counter-intuitively found significant elevations in serum 
BDNF levels in individuals with DS when compared to age-matched controls (Dogliotti, 
 




Galliera et al. 2010, Tlili, Hoischen et al. 2012). The DS-associated increase in serum 
BDNF at early ages is profound in multiple cross sections of age and up to 500% increases 
(ages 2-14) to 623% increases (ages >60) were observed when compared to age-matched 
controls (Dogliotti, Galliera et al. 2010). This marked increase in serum BDNF for those 
with DS seems to be correlated to regulatory roles of the Dual-specificity tyrosine 
phosphorylation-regulated kinase (DYRK1A), a trisomy 21 gene that is triplicated and 
overexpressed (Tlili, Hoischen et al. 2012). Contrary to these findings in young subjects 
with DS, a recent study by our group has demonstrated significantly reduced levels of 
BDNF in frontal cortex and hippocampus of middle-aged and aged Ts65Dn mice, 
suggesting either that brain levels of BDNF are different from those found peripherally, or 
that BDNF levels are shifted to down-regulation as memory loss and AD pathology sets in 
later in life (Lockrow, Boger et al. 2010). Studies have not been undertaken in the human 
DS population across lifespan, nor have studies been done to correlate BDNF levels with 
AD biomarkers in this population. This was the focus of Chapter 5 in this dissertation.  
 
1.8 Purpose of the Study 
 In this dissertation, I investigated biological mechanisms at the crossroads of DS and 
AD, using both a mouse model for DS and blood samples isolated from individuals with 
DS. Despite the fact that more than 300,000 people in the US are affected by this condition, 
few treatments are available for DS-AD, which is a paramount concern for the DS 
community. I specifically focused on the contribution of LC-NE degeneration to memory 
and neuroinflammation and implemented a novel proresolution therapy to modulate 
 




neuroinflammation. My studies are tied by a common thread between DS-AD related 
pathology including memory loss, inflammatory processes occurring in DS and exacerbated 
by LC-NE degeneration, as well as the contribution of BDNF signaling to AD biomarkers 
and inflammation. As shown in Figure 1-8, there is a balance between LC-NE activity, 
BDNF, and inflammation in the brain, where both BDNF and NE innervation can prevent 
the activation of inflammation to occur. The studies in this dissertation focused on this 
balance from different perspectives. Within this interdependence, this dissertation addresses 
elements that could each aid the future of precision medicine in the DS community. 
 
  In Chapter 3 of this dissertation, I utilized DREADDs, a novel chemical genetic 
approach, to specifically control LC neuronal activity to assess the influence that the LC-
NE system has on various aspects of memory and inflammation in the Ts65Dn mice. I 
employed two study paradigms: 1) LC inhibition at four months when LC morphology 
Figure 1-8. Interplay of LC-NE activity, BDNF and inflammation. Three facets of 
DS-AD that have significant impacts upon each other. Each is modulated by highly 
coordinated processes and upon failure creates failure in the whole. DS-AD reflects an 
emergent spectrum of neuronal disorders that occur subsequently.  
 




appears intact and 2) LC stimulation at 14 months when the LC has suffered 
neurodegeneration. The first series of experiments were designed to assess whether 
stimulation of the LC-NE after degeneration is evident, would rescue memory deficits 
neuroinflammation. The second series of experiments were designed to assess whether 
inhibition of the LC-NE before degeneration is evident, would enhance memory deficits and 
exacerbate the neuroinflammatory phenotype that is observed in Ts65Dn mice. Having 
determined that inflammation may be rapidly modulated by LC-NE activity, Chapter 4 
assessed the efficacy of activating the resolution system via a proresolution mediator SPM 
therapeutic approach. These experiments were designed to test the efficacy of administering 
a purified resolution mediator, RvE1, to rescue memory deficits, chronic neuroinflammation 
and a peripheral component of inflammation in Ts65Dn mice. In Chapter 5, I examined 
three circulating neuronal exosome biomarkers, Aβ42, P-T181-Tau and P-S396-Tau along 
with serum BDNF levels over broad cross sections of age with the hypothesis that exosome 
markers and circulating BDNF levels would define a preclinical period for DS-AD.  
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2. General Methods 
 
2.1 Sample Details 
For animal studies, Ts65Dn mice (B6EiC3Sn a/A-Ts(1716)65Dn/J, stock# 005252) 
and Normosmic mice (B6EiC3SnF1/J, stock# 001875) males were obtained from the 
Jackson Laboratory (Bar Harbor, ME). Ts65Dn mice are partially trisomic for a segment 
of murine chromosomes 16 and 17, (Davisson et al., 1990). Human blood samples were 
obtained from 84 individuals at several sites including 1) The MUSC Down syndrome 
Clinic, 2) Linnaeus University (Sweden), 3) University of California at Irvine (UCI) 
Institute for Clinical and Translational Science (Irvine, CA), 4) Barrow Neurological 
Institute and Banner Sun Health Research Institute (Arizona), 5) Hospital of Sant Pau in 
Barcelona (Spain), and 6) Harvard University. Participants either had a normal 
chromosomal count (control) or were trisomic for chromosome 21 (DS). Blood samples 
were processed at each clinical site according to standard protocols, and aliquots were 
shipped on dry ice to MUSC for banking. Human postmortem brain samples were obtained 
from 1) the MUSC Brain Bank, (Charleston, SC) and 2) The UCI MIND Down Syndrome 
Center. All subjects gave written consent approved by an Institutional Review Board 
(IRB), were approved for organ donation under state regulatory control practices for organ 
donation, and/or at the equivalent regulatory agency at all of the collaborative institutions. 








2.2 Vivarium Practices for Mouse Studies 
All experimental procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) of the Medical University of South Carolina in accordance with 
the guidelines described in the US National Institutes of Health Guide for the Care and Use 
of Laboratory Animals. The U.S. Department of Agriculture (USDA) has approved 
MUSC's license and registration (56-R-0001) for compliance with the Animal Welfare Act 
(accreditation #: A3428-01). The institution’s animal program has maintained accreditation 
with AAALAC International since 1987 (Institution #695) with constant compliance with 
regulatory inspections by the U.S. Department of Agriculture (USDA).  
 
Ts65Dn mice have been used by our laboratory routinely (Bimonte- Nelson et al., 
2003, Hunter et al., 2003a, Hunter et al., 2004a, Lockrow et al., 2009, Lockrow et al., 2010, 
Lockrow et al., 2011 and Hamlett et al., 2016). Animal care was also supplemented by 
trained vivarium staff members in the Division of Laboratory Animal Resources (DLAR) 
at the Medical University of South Carolina who are on call as needed for any health 
problems that may arise. Mice were uniquely identified by two methods: cage cards and 
ear punch. The cage cards detailed species, strain, sex, body weight, date of birth, 
investigator, department, protocol number and special remarks. When the mice arrived 
from Jackson Labs, each animal received a unique ear-punch identification pattern. All 
mice were tracked and frequently monitored with key parameters and observations copied 
in a laboratory notebook and in a secure digital database. All mice were co-housed (4 per 
cage), received food and water ad libitum, and were maintained on a 12 hour light/dark 
 




cycle (light 6:00 a.m. through 6:00 p.m.). If mice exhibited aggressive behavior, they were 
switched to single housing until experimental endpoint. All cages had bedding changes 
once every week, and nesting material was maintained for enrichment.  
 
2.3 General Surgical Practices 
All instruments, mats, sharps, gauze, cotton and other materials used in surgical 
procedures were either pre-sterilized or prepared by autoclave sterilization. The analgesics, 
Buprenorphine [0.05 - 0.1mg/kg body weight], 100-200 microliters per mouse) and a 
subcutaneous injection of a long-acting local anesthetic, Bupivacaine [1 mg/kg body 
weight] were administered at the incision site 30 minutes prior to surgery. For anesthesia, 
all mice received an intraperitoneal injection of Ketamine: Xylazine (120 mg/kg: 6 mg/kg 
body weight) to induce a deep anesthesia plane where direct toe pinch did not result in a 
reflex response. Mice were examined first every hour for 3 hours postoperatively and 
thereafter mice were monitored daily, with records being kept to ensure the health and 
overall well-being of the animals. Animals were allowed a minimum of 21 days to recover 
following surgical procedures before behavioral analyses were conducted. After surgeries, 
all animals were singly housed in sterile cages with fresh bedding to decrease infection 
potential during healing. To ensure repeatability of the experiments, all mouse experiments 
were conducted in two separate waves, which promotes scientific rigor in the design.  
 
2.4 Drug Administration Pathways 
For the DREADD experiments (Chapter 3), I delivered stereotactic injections of 
 




the DREADD construct carried by the adeno-associated-virus (AAV) bilaterally into the 
LC via a Hamilton syringe Dr. Heather Boger performed the majority of the stereotaxic 
injections and provided me with training with the instrument and practical considerations 
with viral particles. Animals were kept isolated for a period of 3 days postoperatively to 
allow for viral shedding and protection of vivarium personnel and then placed in cages 
with fresh bedding. After 21 days, all behavioral experiments were conducted after 
intraperitoneal injections of Clozapine-N-Oxide (CNO; Sigma, St. Louis MO.), or vehicle 
(Saline) in a randomized cross-over design. After initial testing, the injections were 
switched so that each animal received the alternate treatment. This design allowed for each 
animal to also serve as its own control for all behavioral paradigms, except the Water 
Radial Arm Maze which could only be performed once. For the Resolvin E1 (RvE1) 
experiments (Chapter 4) I utilized subcutaneous implantation of mini-osmotic pumps 
(Alzet, Cupertino, CA) because it is rapid, can be done with a very small incision, does not 
require daily injections and collectively minimizes stress, discomfort, and pain to the 
animal. More extensive details of drug administrative procedures are outlined in each 
Chapter. 
 
2.5 Behavioral Testing in Ts65Dn mice (Chapters 3-4) 
Proper and consistent handling reduces any unnecessary stress the animal might 
experience while under laboratory care and during behavior analyses. This is important 
because anxiety would have a negative impact on the accurate measurement of behavior 
and memory outcomes. Therefore, all mice were acclimated to the behavior room for at 
 




least 30-minutes prior to behavior experiments to minimize anxiety. I performed behavioral 
tasks in this sequential order: 1) Locomotor testing, 2) Novel object recognition task 
(NORT), 3) WRAM “win stay,” 4) WRAM reversal, and 5) rotarod. This behavioral 
battery was utilized in all animal experiments with the exception of rotarod which was only 
tested in the Resolvin E1 experiments (Chapter 4). Rotarod measures were discontinued 
since no significant motor deficiencies were observed between NS and Ts65Dn mice. 
 
2.5.1 Spontaneous Locomotion Testing 
In order to monitor changes in overall motor activity in mice, spontaneous activity 
was measured using the Digiscan Animal Activity Monitor system. Mice were placed in 
the darkened plexiglass testing chamber (40cm x 40cm wide and 30 cm tall) and allowed 
to move freely while photobeam breaks in X, Y, and Z axes were recorded (Figure 2-1). 
Measurements for total activity, horizontal activity (movement left or right), and vertical 
activity (rearing or jumping) were collected over a period of one hour with sampling at 12-
minute intervals. The data obtained were represented as movement over time, average 
movement, and total movement as well as center time, which indicates the mouse 
confidence level in moving in an open space. All animals were tested in waves, and all 
tasks were performed on each mouse individually behind black plastic sheeting to avoid 
distraction interference with task activity. This is a common behavioral measurement for 
general activity in rodents and has been utilized for many years by our research group 
(Boger, Middaugh et al. 2006, Boger, Mannangatti et al. 2011, Lockrow, Boger et al. 2011). 
 





2.5.2 Novel Object Recognition Task (NORT)  
The NORT is a 3-day memory task based on familiar object recognition. The 
Granholm lab has extensively utilized the NORT in Ts65Dn mice, showing a significant 
deficit in discrimination of novel versus familiar objects, both after a short and long delay 
interval (Lockrow, Boger et al. 2010, Hamlett 2015). Briefly, mice were individually placed 
in the testing arena for a period of 30 minutes with no objects present for habituation 
purposes (Figure 2-1). This habituation period is necessary to reduce anxiety in the mice so 
that they will interact with the objects in the latter stages of the task. On the next day of 
testing, mice were placed in the chamber with two identical objects in the midline that were 
equidistant from each other and the walls (approx. 12 cm from the side walls and 12 cm 
apart). Interactions with both objects were recorded for 15 minutes with a digital video 
camera mounted overhead. After a 90-minute delay, mice were placed in the chamber with 
two objects: a familiar object from the preceding set and a novel object. Interactions with 
Figure 2-1. Open field and NORT testing sequence. Locomoter and NORT tasks 
were performed sequentially over 3 days to assess hyperactivity and familiarity 
memory. All experiments were conducted at similar times each day cycle after 30 
minutes of habituation. 
 




both objects were recorded for 15 minutes. The spatial location of the objects remained the 
same throughout testing. Videos were scored for the amount of time spent with each object 
by a blind observer. For each study, The data were calculated as two dependent measures: 
the percent time with the novel object and the discrimination index as performed previously 
(Jason Lockrow 2009, Hamlett 2015). The discrimination index (DI) represents the net time 
with the novel object relative to total time spent with both objects. All trails were digitally 
recorded on a webcam coupled to iSPY software, which is freely available online 
https://www.ispyconnect.com/. 
 
2.5.3 Optimization of the NORT  
During my thesis work, I evaluated the impact NORT arena dimensions could have 
on overall object interactions in mice. This placement of objects in this square arena 
presented two open space zones which made slightly different object distance from the 
wall, depending on where the mice traveled. I sought to create homogeneity in this 
parameter and replaced the arena with a rectangular box with optimal dimensions (36cm x 
25 cm wide x 25 cm high), made of durable white plastic, and was light-weight (Target 
Inc., Minneapolis, MN) (Figure 2-2, A). The optimized arena had no extra open spaces 
and the mice explored within a 10 cm radius of an object at all times (roughly double the 
body length of the mouse). The original NORT arena had the same dimensions used in 
locomotor testing (40cm x 40cm wide and 30 cm tall) and typically had interaction times 
around 30 seconds which was not significantly different between NS or TS mice (Figure 
2-2, B). I compared overall object interactions in the new arena to previous measures made 
 




Figure 2-2. Optimization of the NORT task. (A) Old vs Optimized Arena dimensions. 
(B) Total Object time for Novel or Familiar objects was not significantly different. (C) 
Two way ANOVA revealed that the optimized arena significantly increased object 
exploration for both NS and TS mice. (D) Image of the objects used in this task for 
clarity. Error bars represent the average ± SEM. 
 




in the original arena. A two-way ANOVA of these data revealed a significant effect of 
optimizing the arena (p < 0.0001), [F1,67 = 33.82]. Tukey's post hoc analysis revealed the 
optimization effects were significant for both NS (p = 0.0001) and TS mice (p = 0.0004) 
with no differences in overall object interaction time between the two groups (Figure 2-2, 
C). The optimization resulted in an 83% improvement in object interaction time thus 
making the NORT task interface more powerful. With the optimized arena, mice achieved 
an interface with the object over 10% of total time measured, which allowed for more 
reliable discrimination index measures.  
 
While attending the Neuroscience 2014 conference, I surveyed the types of objects 
that researchers utilize in NORT arenas worldwide and discovered alarming differences in 
size, shape, and materials of construction, which altogether could affect the outcome and 
repeatability of the task. Objects should be non-odorant and easy to clean between trials, 
so plastic or metal construction is preferable. Objects should be of comparable size to each 
other so that mice will not have an overtly different surface area for object interface. Also, 
objects should not be larger than the mouse to avoid overwhelming the mouse which might 
decrease interaction time. I utilized plastic or metal objects that were similar in size (3 cm 
wide by 4 cm tall) (Figure 2-2, D). All objects were stabilized to heavy metal washers with 
epoxy resin to resist movement by the mice. To ensure equivalence between the objects, I 
compared interaction times for NS and TS mice. One way ANOVA revealed that 
interaction times for the familiar objects were not significantly different during the 
familiarization phase of the NORT. One way ANOVA also revealed that interaction times 
 




for the unique novel objects were not significantly different during the novelty phases of 
the NORT. This test increased my confidence in the methods used since no exploration 
bias could be observed with any object used in the NORT task. 
 
2.5.4 Water Radial Arm Maze (WRAM): a Spatial Reference Memory Task 
There are two major paradigms utilized to evaluate spatial memory in rodents: (1) 
“win-stay” tasks, such as the Morris water maze, in which a single escape platform remains 
in the same position throughout testing, and the mouse must remember the platform location 
in order to escape, and (2) delayed spatial “win-shift”, tasks, which require the subject to 
alternate, or shift, search strategies in order to find multiple targets. As win-stay tasks 
involve only one target, they specifically measure reference or recognition memory. Win-
shift tasks, such as radial arm mazes, contain multiple targets and assess spatial working 
memory function if the objects are removed as testing progresses within the same day. I 
utilized only the “win stay” version of the WRAM task in Chapter 3 and 4, which was 
slightly modified from previous studies (Shukitt-Hale, McEwen et al. 2004, Alamed, 
Wilcock et al. 2006), and has been used in mouse models for AD to evaluate spatial memory 
function (Wilcock, Alamed et al. 2006) and in our laboratory previously (Bimonte, Hyde et 
al. 2000, Lockrow, Boger et al. 2010). The “win stay” WRAM task is similar in design to 
the land version of the DS, where the escape platform remains fixed while the starting 
position varies. Since the land RAM requires the use of food as a motivator, requiring the 
subjects to be food deprived, this presents confound to studies of Ts65Dn mice because they 
tend have reduced appetite and reduced body weights.  The WRAM water motivation 
 




effectively mitigates the risk of these factors to influence the outcome of spatial memory.  
 
Water motivated RAM tasks are superior to land based behavior tasks since mice 
will attempt escape with near 100% completion (Cravens 1974; Alamed, et al., 2006). The 
WRAM is motivated by the innate tendency of mice to swim immediately to an escape 
platform, which is a consistent motivator across age and karyotype. The task is non-
appetitive and thus allows interpretation regardless of differences in body weight or the 
reward value. The WRAM measures memory function in a manner similar to the Morris 
water maze but with restricted swim vectors. While the Morris water maze utilizes a round 
tub and measures swim speed and distance, spatial memory performance in the WRAM is 
measured by arm entry errors. The maze itself is constructed of galvanized steel and painted 
black and filled with water to a level 1 cm above the escape platforms. The maze consists 
of an eight-arms containing the hidden platform at the end of one arm and is located in a 
room with salient extra-maze cues that remained constant throughout the first days of testing 
(Figure 2-3, A). It is important that the testing individual is also a salient extra-maze cue so 
care must be made in odorants, clothing presentation, and room position to keep task 
performance optimal. I utilized large images directly above the arms including 1) solid 
black, 2) black and white stripes, and 3) white with a red dot. Since mice do not see red 
colors, I assume they see the cue as solid white/light gray. Mice must be monitored during 
the WRAM task, so the testing individual is also an extra maze cue. For all WRAM work 
in this dissertation, the testing individual refrained from odorants, wore the same high-
contrast shirt with the letters “Ba-Zn-Ga,” and held a relatively fixed position during each 
 




Figure 2-3. WRAM task design. (A) WRAM “win stay” arena design with visual cues 
utilized. The platform remained fixed in the same location. On day 3, the platform was 
switched to a new location to evoke a set shift in the task to test cognitive flexibility (B) 
The testing sequence over 3 days followed a strict algorithm. (C) Swimming ability 
between NS and Ts65Dn mice was equivalent in all studies.  
 




trial. The WRAM is favorable to the open Morris water maze testing in this mouse 
population testing for several reasons including 1) it is more rapidly performed, 2) results 
(errors) are quantifiable, and 3) thigmotactic behavior is reduced (swimming in a tighter and 
tighter spiral without using extra-maze cues), which can confound interpretation of the 
outcome and has been documented in Ts65Dn mice (Escorihuela RM 1995, Costa, Walsh 
et al. 1999). As Ts65Dn mice are susceptible to swim-induced hypothermia at lower water 
temperatures (Stasko and Costa 2004), water and ambient temperatures were maintained at 
24oC, and mice were towel dried and placed under warming lamps between trials.  
 
For all experiments in this dissertation, I utilized a 3-day “win-stay” WRAM spatial 
memory task that was optimized to facilitate rapid testing with less fatigue than other water 
maze paradigms. To prevent exhaustion, only 12 trials were run each day as two blocks of 
six trials, with mice run in cohorts of six per block, permitting a short rest (3-5 min) between 
each trial and a longer rest (45 min) while the other cohort of mice were being run. WRAM 
trial frequency and duration facilitates rapid testing with decreased likelihood of fatigue 
during the task. All WRAM experiments performed in this dissertation, I utilized a strict 
sequence of entry arms that randomized the starting position for each trial (Figure 2-3, B) 
to force the mice to utilize extra-maze cues to locate the fixed hidden platform through all 
trials of testing. On day 1, 9 trials of training were performed where the platform was 
alternated between visible (up above the water) and hidden (down under the water) and 
remained hidden in the last 3 trials. On days 2-3, spatial memory testing was performed with 
the platform hidden for all 12 trials. On day 3, after spatial memory testing and a resting 
 




period of 45 min, a final test was performed to measure cognitive flexibility. For this test, 
the fixed hidden platform was moved to a new location while all extra-maze cues remained 
unchanged. Entries to the original platform location (perseverance) and incorrect arm entries 
were counted over 8 trials. Trials were run as two blocks of eight trials, with mice run in 
cohorts of six per block, permitting a short rest (3-5 min) between each trial.  
 
Because swimming deficiency could bias WRAM spatial reference memory testing, 
I examined swim speed and transition times between all arms of the maze. I found that the 
overall means of each group were not significantly different and that all mice, regardless of 
experimental condition, were able to complete 95% of all swim transit arm-to-arm in 
approximately 8 seconds (Figure 2-3, C). These results indicated that all experimental 
groups had equivalent swimming capacity and performed the WRAM spatial memory task 
without swimming or visual deficits that are found in some Ts65Dn mouse colonies. The 
data were recorded as incorrect arm entries with one error added for every 8 seconds of 
failure to make an arm selection. For each mouse, four trials of errors were summed into a 
block to smooth intertrial variance. Data were reported in blocks with 3 blocks per day for 
the WRAM “win stay” trials, and 2 blocks for the subsequent WRAM reversal trials. All 
trails were digitally recorded on a webcam coupled to iSpy software mentioned earlier. 
 
2.5.5 Accelerating Rotarod 
In order to test motor coordination and motor learning, the accelerating rotarod 
(Ugo Basile, Verese, Italy) was utilized to direct mice to walk and balance on a rotating 
 




rod at increasingly higher rates of rotations per minute (r.p.m). On day zero, mice were 
exposed to the slowest rate of 4rpm for 10 minutes to allow them to acclimate to the 
expectations of the task so that there was no learning deficit on day one of testing. On days 
1-3, mice were subjected to the rotating speeds of 4, 8, 16, 24, 32, and 40 r.p.m. for a 
maximum of 5 min per speed. The amount of time the mouse spends on the rotating rod 
was recorded by the instrument and then recorded into a spreadsheet. The data were 
recorded as the latency to fall, with a mouse with perfect motor performance staying on the 
rotarod for 300sec for that speed. It becomes increasingly harder for the mouse to stay on 
the rotating platform with increased speed. All animals were tested in waves to allow a rest 
between each speed and each testing wave had a random sampling of mice from different 
experimental conditions to prevent any chance for testing bias.  
 
2.6 Mouse Euthanasia and Tissue Preparation 
 To prepare biosamples, mice were euthanized by isoflurane exposure and 
subsequent decapitation. All methods were consistent with the recommendations of the 
Panel on Euthanasia of the American Veterinary Medical Association (AVMA). Blood was 
harvested by cardiac puncture and allowed to coagulate for 30 mins at room temperature. 
Coagulated blood was spun at 700 x g, and the resultant serum was decanted into sterile 
tubes for further study. During blood coagulation, brains were carefully removed from the 
cranium and rapidly dissected. Tissues were divided for Western blot and immunostaining 
according to our standard procedures (Boger, Mannangatti et al. 2011, Lockrow, Boger et 
al. 2011, Hamlett 2015). The frontal cortex, left parietal cortex, and left hippocampus were 
 




dissected and placed into pre-weighed tubes, weighed to determine tissue weight, snap 
frozen on dry ice, and stored at -80ºC until further use. Remaining brain tissue was fixed 
in 4% paraformaldehyde for 48 hours, then placed into 30% sucrose in PBS for at least 72 
hours before sectioning at 40µm on a Microm cryostat (Thermo Scientific, Waltham, MA).  
 
2.7 Immunohistochemistry  
Pre-fixed brain specimens including regions with the hippocampus, BFCN, and 
LC-NE and cortex were sectioned at 40µm and processed for immunohistochemical 
analyses as described previously (Lockrow et al., 2011, Fortress and Hamlett, 2015). To 
reduce unspecific background signal, sections were blocked in protein-rich 10% normal 
serum that was matched to the host species that produced the secondary antibody, typically 
normal goat serum (NGS) in TBS-Triton X-100 for 1 hour at room temperature. Primary 
antibodies were first tested at various concentrations within the manufacturer’s 
recommendations on select testing sections. For Diaminobenzidine immunostaining, 
sections were incubated with biotin-conjugated secondary antibodies directed against the 
appropriate species, then ABC solution (Vector, Burlingame, CA) followed by 
development with 3,3′-Diaminobenzidine tetrahydrochloride (DAB, Sigma, St. Louis, 
MO) (see Lockrow et al., 2011). The tissue was mounted onto slides, dehydrated, and 
cover-slipped with Permount (Fisher Scientific, Fair Lawn, NJ). For immunofluorescence, 
sections were incubated for one hour with secondary antibodies directed against the 
appropriate species. Secondary antibodies were conjugated with either TRITC or FITC and 
used at a dilution of 1:200, (Jackson Immunoresearch, West Grove, PA). The tissue was 
 




mounted onto slides, dehydrated, and coverslipped with ProLong Gold Anti-fade Mountant 
(Fisher Scientific, Fair Lawn, NJ). All images were captured using a Nikon Eclipse 80i 
microscope (Nikon Instruments, Melville, NY) equipped with a Q-cam digital camera or 
with an Olympus confocal laser scanning microscope equipped with FlowView FV3000 
software (Olympus, Tokyo, Japan). Primary and secondary antibodies utilized in all 
experiments are listed in each Chapter method section. 
 
2.8 Enzyme-linked Immunosorbent Assay (ELISA) 
 For cytokine detection in serum (Chapter 4), I utilized a novel bead-based- 
cytometry multiplexed ELISA technology to quantify cytokines. The multiplexing 
technology is based on color-coded polystyrene beads built using different concentrations 
of red and infrared fluorophore dyes (over 100 uniquely-colored bead sets exist). The 
unique beads are combined with selective antibodies to individuals cytokines (34 in total) 
and then utilized concurrently within the same assay well. For example, a capture antibody 
for IL-6 is coupled to a population of dark red beads, and a capture antibody for GM-CSF 
is coupled to a population of pink beads. These two antibody-coupled beads can now be 
mixed together forming a 2-plex. Each analyte is distinguished from the other because they 
are bound to differently colored/fluorescent beads. The beads were washed and then 
analyzed by a dual-laser system and a flow cytometry system (Bio-Plex 200, Biorad, 
Hercules, CA). One laser activates the fluorescent dye within the beads which identifies 
the specific analyte. The second laser excites the fluorescent conjugate (streptavidin-
phycoerythrin) that has been bound to the beads during the assay. The amount of the 
 




conjugate detected by the analyzer is in direct proportion to the amount of the target 
analyte. The results were quantified according to a standard curve. Multiplexed ELISA 
analyses were performed with Eve Technologies (Calgary, Canada). 
 
2.9 Western Blots 
Samples for western blot analyses were homogenized in standard 
radioimmunoprecipitation buffer that was supplemented with protease and phosphatase 
inhibitors (Sigma-Aldrich, St. Louis, MO) via handheld pulse grinder followed by 4 x 20 
seconds of sonication with a handheld sonic dismembrator that fragmented DNA and 
thoroughly mixed the sample. Protein rich sample homogenates were quantified using the 
BCA protein assay (Peirce, Rockford, IL). Sample homogenate was combined with 
reducing buffer (4 × solution: 4.5% sodium dodecyl sulfate (SDS), 15% β-mercapto-
ethanol, 0.018% bromophenol blue, and 36% glycerol in 170 mM Tris-HCl pH 6.8) to a 
concentration of 25 μg of protein per 30μl and heated at 90°C for 10 min. Samples were 
then separated by SDS-PAGE (BioRad, Hercules, CA) 10% gradient gels and transferred 
to PVDF membranes by BioRad trans-blotter system. The membranes were blocked with 
Licor blocking buffer (Lincoln, NE) for 1 hour at room temperature, then probed with 
primary antibodies diluted in 0.1% Tween + Licor blocking buffer. The membranes were 
washed twice for 10 min each in 0.1% Tween phosphate buffer solution (PBST) was then 
probed with goat anti-mouse or goat anti-rabbit IR-Dye 670 or 800cw labeled secondary 
antisera in 0.1% Tween, 0.01% SDS + Licor blocking buffer for 1 hour at room 
temperature. Washes were repeated after secondary labeling, washing twice for 10 min in 
 




PBST, then placed in water. Membranes were imaged using a LICOR Odyssey scanner. 
Boxes were manually placed around each band of interest, which returned near-infrared 
fluorescent values of raw intensity with intra-lane background subtracted using Image 
Studio analytical software (LICOR, Lincoln, NE). 
 
2.10 General Statistical Considerations 
I tested all data sets for outliers using Grubbs’ with alpha set at 0.05 and removed 
any outliers found in any data set per cohort. I performed Shapiro-Wilk normality test and 
found that all or most data sets (Chapters 3-5) passed normality and were well suited for 
univariate/parametric tests including analysis of variance (ANOVA) and linear regression. 
Due to specific requirements for each data set, statistical tests for behavioral tasks are 
defined in each Chapter section. For Western blot and immunostaining data, I performed 
ordinary two-way analysis of variance (ANOVA) to test for differences between the four 
groups (karyotype x treatment), and Tukey’s post hoc analyses were used in order to 
examine statistical patterns that were not specified a priori. It is important to have sufficient 
animal numbers in each treatment group to sufficiently power the analyses. Power analyses 
were performed on pilot data from previous work in our group, and the following group 
sizes would be needed to yield 80% power with α set at 0.05: n=8 for behavioral outcome 
measures, morphological and western blot assessments, and for multiplex ELISA tests. All 
post hoc results were reported with an acceptable alpha value of p < 0.05 and graphical 
data are presented as a mean ± standard error of the means (SEM). All statistics were 
performed with GraphPad Prism 7.03 (San Francisco, CA). 
 




Chapter 3. The Locus Coeruleus, Memory, and Neuroinflammation 
  
3. Introduction  
In the Ts65Dn mouse model of DS, depletion of NE levels exacerbates cognitive 
impairment and AD neuropathology. Studies utilizing DSP-4, an irreversible inhibitor of 
the NE transporter that selectively lesions the LC, revealed a significant increase in 
cognitive impairment and AD neuropathology in young Ts65Dn mice (Lockrow, Boger et 
al. 2011) and other mouse models (Kalinin, Gavrilyuk et al. 2007). On the other end of the 
spectrum, restoring deficient NE levels with chronic L-DOPS or Xamoterol 
supplementation significantly enhanced hippocampal-dependent memory (Salehi A 2009) 
and restored cued memory and memory recall of platform location in the Morris Water 
Maze (Murchison, Zhang et al. 2004). Our group has contributed to these findings during 
observations where a chronic L-DOPS treatment was found to protect LC, BFCN, and 
hippocampal neurons from degeneration in the Ts65DN mouse (Fortress et al., 2015). 
Remarkably, the rescuing effect of L-DOPS supplementation can be observed in middle-
aged 10 month old Ts65Dn mouse cohorts that have significant LC degeneration (Fortress, 
Hamlett et al. 2015). We assume that NE must be in decline at this age and that L-DOPS 
rescued this insufficiency. These recent studies suggest that the LC-NE system provides 
substantial neuroprotective effects in Ts65Dn mice, but it has not been shown previously 
whether selective stimulation of LC-NE neuronal firing rates may improve cognitive 
performance in Ts65Dn mice. Furthermore, selective inhibition of LC-NE neuronal firing 
rates would provide a valuable understanding of the connection between LC activity, 
 




hippocampal-dependent behavior, neuroinflammation and neurotrophic support. New 
molecular tools that could directly control LC firing would be valuable to studies especially 
if they limit the inflammatory confounds of chemical lesions and non-target effects of 
pharmacological manipulations 
 
DREADDs are a novel chemical-genetic tool that allows for direct GPCR control 
over a specific neuronal population. DREADDs can be targeted to LC-NE neurons under 
control of the synthetic PRSx8 promoter for dopamine-beta-hydroxylase (DβH, which is 
an enzyme selective for LC-NE neurons (Alexander, Sarah C. Rogan et al. 2009). By 
combining the PRSx8 promoter sequence contained within the genetic DREADD construct 
carried within AAV viral particles with precise stereotaxic injection to the LC pontine 
nucleus, bilateral expression of either hM4D (Gi-coupled, inhibitory) or hM3D (Gq-
coupled, stimulatory) mutated ACh muscarinic receptors were bilaterally targeted to LC-
NE neurons (Vazey EM 2012, Fortress, Hamlett et al. 2015). For the nomenclature in the 
term hM3D, M3 denotes the muscarinic receptor subtype, the prefix “h” refers to the 
Human species, “D” stands for DREADD and “q” for the G protein coupling preference of 
Gq/11 or “i” for the G protein coupling preference of Gi/o. Visualization of viral transfection 
efficiency was enabled by a hemagglutinin tag (HA 1.1), which was engineered as a 









Discreet control of human muscarinic DREADDs is achieved because these 
receptors do not bind and are not activated by the native cognate ligand, ACh, but instead 
bind an exogenous compound, CNO, due to select point mutations in the receptor gene 
coding sequence (Armbruster, Li et al. 2007a,b). Specifically, M3 had two point mutations 
(Y149C, A239G) to become hM3D and M4 had two point mutations (Y113C, A203G) to 
become hM4D. CNO is biologically inert in rodents at physiologically active 
concentrations, is readily soluble, and can be delivered systemically to animal models by 
intra-peritoneal injection. Despite the short half-life of CNO in mice (Guettier, Gautam et 
al. 2009), the biological effects of acute treatment of experimental animals that express 
DREADDs are usually much longer (over 10 hours). Although DREADDs lack high 
temporal resolution, because of the longer-term effects of CNO and also due to temporal 
dynamics of GPCRs, they enable studies of longer-term processes such as LC activity 
during wakeful periods of memory assessment. Further, LC activity manipulation over 
longer periods provides a unique experimental window to explore the role of the LC during 
the neurodegenerative paradigms of AD or DS-AD.  
 
A schematic of DREADD GPCR signaling processes for both hM3D and hM4D 
are depicted in Figure 3-1. The physiological effects of DREADD G protein-coupled 
receptor activation have been shown to be very similar to the wild-type muscarinic 
counterpart (Nawaratne, Leach et al. 2008). When CNO binds the stimulatory, Gq-coupled 
hM3D receptor, it evokes the GPCR signaling cascade, similar to M1, M3, and M5 
muscarinic receptor types, that stimulates PLC-dependent IP3 release of calcium from the 
 




endoplasmic reticulum. The increase in intracellular calcium leads to persistent activation 
of neuronal activity (Vazey and Aston-Jones 2014). When CNO binds the inhibitory hM4D 
receptor, it leads to neuronal silencing along the Gi/o pathway. To date, there has been 
limited focus on using DREADDs to study memory consolidation (Zhu, Pleil et al. 2014, 
Fortress, Hamlett et al. 2015, Varela, Weiss et al. 2016, Whissell, Tohyama et al. 2016). In 
this study, I employed DREADD Gq- and Gi-dependent signaling because of the known 
role that LC activity plays in learning and memory processes (Berridge and Waterhouse 





Figure 3-1. DREADD mechanism. After 1) stereotaxic delivery of AAV viral 
particles, 2) construct integration occurs with high efficiency. LC-NE expression is 
driven by 3) the Prsx8 promoter of the 4) DREADD construct which features the 
HA1.1 tag as a transgene. 4) CNO activates the DREADD receptor which then signals 
through a G-protein to 5) change neuronal probability of firing. 
 




3.1 Chapter 3 Specific Aims 
The objectives of this study were: 1) to examine if cognitive deficits observed in 
middle-aged (11-13 month old) Ts65Dn mice could be reversed by stimulation LC-NE 
neurotransmission and 2) to examine the role of LC-NE neurotransmission in younger (four 
months old) Ts65Dn mice by inhibiting LC-NE neurotransmission. In the first study, AAV 
delivery of hM3D DREADDs specifically into LC-NE neurons in 14 month old Ts65Dn 
mice and age-matched normosomic controls was employed to explore whether stimulation 
of LC-NE neuronal activity would enhance working memory and decrease 
neuroinflammation or AD pathology in the brain. For all hM3D experiments, I employed 
sequential locomotor and memory tasks to evaluate working memory. I hypothesized that 
hM3D-mediated stimulation of LC-NE neurons would have a greater impact on behavioral 
function in Ts65Dn mice than in age-matched normosomic mice since normosomic mice 
already demonstrate maximum task performance. AAV delivery of hM4D DREADDs 
specifically into LC-NE neurons in Ts65Dn mice and age-matched normosomic controls 
was employed to explore whether inhibition of LC-NE neuronal activity would inhibit 
working or spatial reference memory and affect AD pathology in the brain. For all hM4D 
experiments, I employed a sequential locomotor and memory tasks to evaluate working 
memory, spatial reference memory and cognitive flexibility during reversal learning. In the 
second study, I hypothesized that hM4D-mediated inhibition of LC-NE neurons into young 
Ts65Dn mice would lead to earlier memory loss and associated degeneration of neurons 
and inflammation, which would suggest that the loss of LC-NE neurons drives other AD-
related pathology in this mouse model. 
 





3.2 Chapter Specific Methods  
3.2.1 Animal Cohorts 
Ts65Dn mice and normosomic (NS) littermate controls (all male) were obtained 
from Jackson Laboratories (Bar Harbor, ME). For DREADD hM3D studies, all mice were 
aged 11-13 months before treatment. For DREADD hM4D and Green fluorescent protein 
(GFP) control studies, all mice were aged four months before treatment. Cohort size is 
provided in Figure 3-2. 
 
3.2.2 AAV-DREADD Vectors Employed 
In Chapter 3, three different constructs were utilized including 1) DREADD 
hM3D-Gq to stimulatory, DREADD hM4D-Gi inhibitory, or 3) GFP inactive. The 
construct contained the PRSx8 promoter (Hwang et al., 2001) which drove the expression 
of the hM3D and hM4D designer receptors which coexpressed a C-terminal HA tag for 
subsequent identification by microscopy (Armbruster, Li et al. 2007a,b, Alexander, Rogan 
et al. 2009) (developed by Bryan Roth, University of North Carolina). Male Ts65Dn mice 
and littermate normosomic male mice (NS) were anesthetized with Ketamine: Xylazine 
(120 mg/kg: 6 mg/kg i.p.) and given a long-acting local anesthetic in the skin overlying the 
Figure 3-2. Chapter 3 Cohort size. 
 




injection site (Bupivacaine, 1 mg/kg s.c.) prior to surgery. Anesthetized mice were placed 
in a rodent stereotaxic apparatus with a mouse adaptor, and intracranial injections of AAV 
were delivered bilaterally into the LC via a Hamilton syringe at the following stereotaxic 
coordinates: -5.34 AP, -2.5DV, ±1.0ML from Bregma (Paxinos 2004). The AAV vectors 
included either: 1) AAV-PRSx8-hM3D HA, 2) AAV-PRSx8-hM4D or 3) AAV-CMV-
GFP (Vazey EM 2014). Each vector was cloned and packaged with AAV viral particles 
(serotype 2/9) at the University of Pennsylvania Vector Core at a concentration of (2 x 1012 
tu/µl). Both DREADD receptors contained a c-terminal HA tag for identification (provided 
by Bryan Roth, University of North Carolina, Chapel Hill, NC). For sham control 
experiments, Syn-GFP viral vector (addGene, Cambridge, MA) was cloned and packaged 
into AAV viral particles (serotype 2/9) at the University of Pennsylvania Vector Core. 
AAV viral particles were delivered at a rate of approximately 0.1 µl per minute over ten 
minutes for a total volume of 1.0µl per injection site. After microinjection, the syringe was 
left in place for 10 minutes to limit diffusion into the injection track. Animals were then 
sutured, removed from the apparatus, and monitored for a full recovery before returning to 
disposable cages housed in a BSL2 room. Behavioral testing began 20 days after the AAV 
injections. Stimulation of the hM3D receptor with the pharmacologically inert agent, CNO, 
facilitates tonic neuronal stimulation of NE release in target neurons (Armbruster, Li et al. 
2007a,b). The same hM3D construct used in the current study has recently been utilized by 
our lab and others to demonstrate increased firing rates of LC neurons (Vazey EM 2014, 
Fortress, Hamlett et al. 2015). Stimulation of the hM4D receptor with CNO facilitates tonic 
neuronal inhibition of NE release in target neurons (Armbruster, Li et al. 2007a,b). The 
 




same hM4D construct used in the current study has recently been utilized by others to 
demonstrate decreased firing rates of LC neurons (Smith, Bucci et al. 2016).  
 
3.2.3 Stereotactic Surgery and Intracranial Injections 
  We utilized a stereotaxic instrument that uses a Vernier scale to make use of a three-
dimensional map of the skull in order to locate specific anatomical brain regions which can 
be obtained from atlases for various species. Once the subject is placed in the stereotaxic 
frame, an incision was made to expose the skull surface. Once the anatomical location had 
been determined on the skull, marks were placed on the skull, and burr holes were drilled 
to expose the superficial brain tissue. This method provides a level of precision and 
accuracy that allows neurosurgeons and neuroscientists to target manipulations at discrete 
subsets of neuronal populations. Stereotactic injections of AAV were delivered bilaterally 
into the LC via a Hamilton syringe at the following stereotaxic coordinates: -5.34 AP, -
2.5DV, ±1.0ML from Bregma. AAV was delivered at a rate of approximately 0.1 µl per 
minute over ten minutes for a total volume of 1.0µl per injection site. After microinjection, 
the syringe was left in place for 10 minutes to limit diffusion into the injection track. The 
incision was closed using sterile monofilament nylon suture for skin incisions, and topical 
antibiotic ointment was applied. Animals were kept under a heat lamp until normal 
consciousness and mobility were regained. All sutures were removed after complete 
healing of the incision, usually after 7 days. Animals were allowed 21 days to recover 
following surgical procedures. Dr. Heather Boger performed the majority of the stereotaxic 
injections and provided me with training in using the instrument. 
 




3.2.4 Clozapine-N-Oxide Activation of DREADDs  
It has previously been shown that the administration of CNO in rodents leads to 
detectable levels of retroconversion into the bioactive compounds clozapine and N-Des 
which may create experimental bias in behavioral outcomes. In rodents, a [1 mg/kg body 
weight] dose of CNO reduced the acoustic startle reflex, and higher dosages demonstrate 
a dose response curve (MacLaren, Browne et al. 2016). The [0.3mg/kg body weight] 
dosage was chosen for the experiments in this dissertation because it is efficacious in 
creating a biological response in LC neurons by EEG measurements (Vazey and Aston-
Jones 2014). Furthermore, retroconversion of CNO has been shown to be attenuated by 
ascorbic acid in vitro and mice have high endogenous levels of ascorbic acid that are stable 
through 14 months of age in the brain (Iwama, Amano et al. 2012). Finally, we utilized the 
control GFP vector comprising viral infection and delivery of an inert GFP-construct. Upon 
CNO administration in these cohorts, no effects were observed on any behavioral indices 
suggesting that the CNO dosage did not bias the outcomes measured.  
 
All mice were tested 21 days after intracranial surgery to allow healing and receptor 
translation/trafficking. Intraperitoneal injections of Clozapine-N-Oxide (CNO; Sigma, St. 
Louis MO.), can be administered five minutes before the start of behavioral testing, which 
provides ample time for CNO activation of DREADD receptors (Vazey and Aston-Jones 
2014, Fortress, Hamlett et al. 2015). For each behavioral testing day, mice received either 
CNO [0.3 ug/g body weight] or vehicle (Veh) injection in a randomized cross-over design. 
The vehicle used in both conditions consisted of sterile 0.9% saline (Figure 3-3). 
 




Following injections, mice were placed in locomotor activity chambers for 1 hour 
immediately before habituation in the NORT arena. The next two days, all mice were given 
the same injections again and evaluated in the NORT memory task. The mice were then 
rested for one day to ensure CNO clearance. Then the treatments were switched for each 
mouse (i.e., CNO to Veh cross-over) followed by habituation and NORT memory testing. 
WRAM testing was performed on all groups with CNO injections only since task 
performance is positively affected by practice and cannot be carried out under a reversal 
paradigm. After testing, mice were sacrificed and the brains rapidly extracted within one 




Figure 3-3. Chapter 3 Experimental design. 
 




3.2.5 Tissue Preparation 
 Within one week of behavioral testing, all mice were euthanized using an overdose 
of isoflurane, and the brains were rapidly dissected. Tissues were divided for HPLC or 
immunohistochemistry according to our standard procedures (Boger, Mannangatti et al. 
2011, Lockrow, Boger et al. 2011). The right frontal cortex and right hippocampus were 
dissected for catecholamine tissue levels and placed into pre-weighed tubes, weighed for 
tissue weight, snap frozen on dry ice, and stored at -80ºC until use. The remaining brain 
tissue was placed into 4% paraformaldehyde for 48 hours for immersion fixation, then 
placed into 30% sucrose in PBS for at least 72 hours before sectioning at 40µm on a 




 The hippocampus and the pontine region containing the LC were sectioned at 40µm 
and processed for immunohistochemical analyses. For DAB staining (Figure 3-2) sections 
were incubated with biotinylated anti-rabbit secondary antibodies, then ABC solution 
(Vector, Burlingame, CA) followed by development with 3,3′-Diaminobenzidine 
tetrahydrochloride (DAB, Sigma, St. Louis, MO) (Fortress, Hamlett et al. 2015). The tissue 
was mounted onto slides, dehydrated, and cover-slipped with Permount (Fisher Scientific, 
Fair Lawn, NJ). All images were captured using a Nikon Eclipse E-600 microscope 
equipped with a Q-cam digital camera.  
 
 




Series of every sixth section were blocked in 10 % normal goat serum (NGS) in 
TBS-Triton X-100 and incubated with anti-β1 receptor (1:500, Santa Cruz, Dallas, TX), or 
anti-tyrosine hydroxylase (TH, 1:1000, Pel-Freeze, Rogers, AR) and anti-HA antibodies 
(1:1000, Cell Signaling Technologies, Danvers, MA) overnight at room temperature. The 
sections processed for fluorescence microscopy (HA and TH immunohistochemistry) were 
then incubated for one hour with secondary antibodies directed against the appropriate 
species, conjugated with TRITC or FITC, respectively (1:200, Jackson Immunoresearch, 
West Grove, PA). Details about primary antibodies used in Chapter 3 are included next. 
 
 
3.2.7 LC Characterization  
 Confocal laser scanning microscopy (Olympus Fluoview BX61) was utilized to 
generate 3D images of at least 7 randomly distributed sections from the locus coeruleus in 
both normosomic and Ts65Dn mice. NIS-Elements software was used to determine the 
percentage of HA-labeled TH-positive LC neurons based on blind hand-counting. 
Specifically, all TH-positive neurons in the LC were counted in multiple sections from 
each brain. Thereafter, all TH-immunoreactive neurons co-labeled with HA and were 
counted on the same sections. Percent co-expression to total TH was quantified. 
 
 




3.2.8 Statistical Considerations 
For DREADD hM3D studies, one-way ANOVA was performed for comparison 
between the groups, eliminating the need for multiple pairwise hypothesis tests. Tukey’s 
post hoc analysis was used for all post hoc tests in order to examine statistical patterns that 
were not specified a priori, and post hoc results were reported with an acceptable alpha 
value of p < 0.05. For DREADD hM4D studies, I wanted to rule out effects of surgery, 
stereotactic injection of virus into the LC and viral transfection effects. I first performed 
ordinary one-way ANOVA to test for significant differences between control groups (AAV 
GFP) with saline or CNO treatment and the inactive inhibitory DREADD group (AAV 
hM4D) with only saline treatment. In order to examine statistical patterns that were not 
specified a priori, I used Tukey’s post hoc analysis for all for all one-way ANOVAs. Since 
no significant within-group differences were observed in either NS or Ts65Dn mice, for 
any behavioral task I focused subsequent analyses to compare CNO treatment effects 
relative to the viral construct (AAV-GFP control or DREADD hM4D) and karyotype (NS 
or Ts65Dn). I performed ordinary two-way ANOVA to test for differences within AAV 
groups (karyotype x treatment), and Tukey’s post hoc analysis was used in order to 
examine statistical patterns that were not specified a priori. For the 3-day WRAM task, I 
performed a linear regression to test for significant differences in slope and elevation (y-
intercept) over the repeated measures of errors made. All statistics were performed with 









3.3.1 LC Degeneration in Ts65Dn mice  
Immunohistochemical assessment of the LC-NE region using TH antibodies 
revealed a marked loss of both TH-positive cell bodies and neurites in the LC region in 
adult Ts65Dn mice compared to NS mice (Figure 3-4). The loss of TH-immunoreactive 
neurons in the LC was not observed at earlier ages (Ts65Dn and NS mice, four months old, 
(Figure 3-4, A vs. B). TH-stained sections in 12 month old Ts65Dn mice revealed atrophic 
neurons as well as swollen and dystrophic neurites in the LC (Figure 3-4, D), and reduced 
TH staining within neuronal cell bodies. It has been established that the LC begins to 
degenerate as early as six months of age in Ts65Dn mice (Salehi A 2009, Lockrow J 2011), 
with a significant loss of neurons observed in our group at 12 months of age using unbiased 
stereological cell counting. The age of mice chosen for the two studies in Chapter 3 was 
based on the LC-NE cell loss reported previously. Given that LC-NE morphology is 
equivalent between Ts65Dn and Normosomic mice at four months of age, the DREADD 
hM4D-mediated approach targeting this age allowed functional assessment without major 
confounds associated with LC-NE neurodegeneration observed in older Ts65Dn mice. 
 
 In order to determine transduction efficiency of the vector in LC-NE neurons, I 
performed immunostaining of the HA tag included in the viral construct, utilizing double 
labeling with TH and HA antibodies (Figure 3-5). Five weeks post-injection, robust 
expression of the HA tag was observed in the LC region using immunofluorescence, in 
both NS (Figure 3-5, C) and Ts65Dn mice (Figure 3-5, D). Co-labeling of HA and TH 
 




Figure 3-4. LC-NE immunostaining in Ts65Dn and NS mice at various ages. At 
four months of age, there was no difference in terms of TH staining density between 
NS (A) and Ts65Dn (B) mice. However, at 12 months of age, there was a marked 
reduction in TH-immunoreactive fiber density and cell packing density in Ts65Dn 
mice (D), compared to NS mice (C). (E) Average staining density is significantly 
reduced in Ts65Dn mice. Images taken at 10X, scale bar in (D) = 200µm. 
 
 




Figure 3-5. TH and HA immunostaining in the LC. (A) Experimental design for the 
DREADD study. The AAV-HA tag vector was injected via stereotaxic injections into 
Ts65Dn or NS mice. Twenty days after surgery, mice were tested for behavior. After a 
two-day wash-out period, mice were given the opposite treatment in a cross-over design, 
(B-D) TH immunostaining (green), HA staining (red), and overlay (yellow, D) in a 
Normosomic mouse LC. (E-G) TH (green), HA (red), overlay (yellow) in the LC of a 
Ts65Dn mouse. (H): Transduction efficiency table, showing range, mean and st. dev. 
measured in a total of 19 double labeled sections. (H) FITC-labeled HA immunostaining 
in the LC region at a higher magnification, with evidence of axonal transport of the 
DREADD receptors (arrow heads). The scale bar in D and G represents 100 microns, 
and the scale bar in H represents 40 microns. 
 




revealed that average of 98% of TH-positive cells in the LC also co-stained with the HA1.1 
tagged DREADD receptor (sampling was performed in 19 sections in 5 subjects, both NS 
and Ts65Dn mice; range of co-labeling: 86-100 percent, see Figure 3-5, G). Anterograde 
hM3D receptor trafficking in axons adjacent to the LC nucleus was observed, suggesting 
a functional integration of the DREADDs into LC neurons (Figure 3-5, H white arrows). 
The HA-TH double labeling demonstrated that AAV transduction of the DREADD 
receptors in LC-NE neurons was successful, efficient, and specific to the LC neurons, both 
in NS and in Ts65Dn mice. Immunostaining gave us great confidence that our combined 
targeting approach with a stereotactic injection of AAV delivery particles into the LC, with 
expression driven by the PRS x 8 promoter effectively invoke DREADD-mediated control 
of the locus coeruleus. 
 
3.3.2 AAV DREADD hM3D-mediated behavior 
DREADD hM3D Spontaneous Locomotion Behavior  
 Stimulation of the hM3D receptor with the pharmacologically inert agent, CNO, 
facilitates neuronal tonic increases in target neurons. The same hM3D construct used in the 
current study has recently been utilized by others in our group to demonstrate increased 
firing rates of LC neurons. Statistical analysis of the two NS groups (with or without CNO 
injections) revealed that NS mice showed no significant differences in locomotion (p = 
0.673), center time (p = 0.847), or object discrimination in the NORT task after hM3D 
activation with CNO (p = 0.522) as evident from the graphs in Figure 3-6, A-C. Based on 
these findings, the two NS groups have been collapsed for the purpose of examining a 
 




priori the effects of trisomy and CNO + trisomy compared to NS mice.  
 
Because hyperactivity has been observed in the Ts65Dn mouse model and may 
influence other behavioral components, I first examined the effects of LC hM3D 
stimulation on baseline motor activity in Ts65Dn mice (Figure 3-6, A). Both NS and 
Ts65Dn mice without CNO exhibited spontaneous behavior similar to what I have 
previously reported for age-matched mice of both karyotypes (Lockrow, Boger et al. 2011), 
strongly indicating that the AAV injection itself did not give rise to alterations in 
spontaneous activity. An ANOVA analysis revealed overall statistical differences between 
the groups [F2,15 = 5.101; p = 0.0249], and Tukey’s post hoc analysis further revealed that 
vehicle-treated Ts65Dn mice displayed significantly increased spontaneous activity 
relative to NS control mice (p = 0.0231), revealing hyperactivity in TS mice. CNO 
injections in Ts65Dn mice significantly attenuated hyperactivity, with CNO-treated 
Ts65Dn mice exhibiting significantly less total activity than vehicle-treated Ts65Dn mice  
(Tukey’s; p = 0.0111). CNO-treated Ts65Dn mice were not significantly different in 
overall locomotor activity than NS control 
 




Figure 3-6. Stimulatory DREADD hM3D behavioral outcomes. (A) Vehicle-treated 
Ts65Dn mice exhibited a significant increase in total distance traveled (cm) which was 
attenuated with CNO treatment. (B) Vehicle-treated Ts65Dn mice spent less time in the 
center of an open-field compared to NS mice, which was reversed with CNO. (C) 
Vehicle-treated Ts65Dn mice spent significantly less time with the novel object than 
NS mice, and this deficiency was normalized after treatment with CNO, with a 
significant difference between Ts65Dn mice with our without CNO. (D) NS mice were 
significantly more likely to recognize the novel object than vehicle-treated Ts65Dn 
mice, which was normalized after CNO treatment. There was no significant difference 
between the NS VEH and CNO groups for any of these measures. Error bars represent 
mean ±SEM. 
 




mice (p =0.4508), suggesting that stimulating hM3D receptors restored spontaneous 
activity to levels observed in NS mice. Next, the time spent in the center of the activity 
arena was evaluated, and an overall ANOVA revealed significant group differences also 
for this measure [F2,15 = 5.315; p = 0.0243], (Figure 3-6, B). Interestingly, although 
vehicle-treated Ts65Dn mice were significantly more active than NS mice, they spent 
significantly less time in the center of the open field arena relative to NS mice, as revealed 
using post hoc analysis (Figure 3-6, B, p = 0.0088). However, Ts65Dn mice treated with 
CNO spent significantly more time in the center of the open field arena compared to non-
treated Ts65Dn mice (p = 0.0291), with center times that were comparable to those 
observed in NS mice, suggesting that hM3D-mediated stimulation of LC activity reduced 
anxiety-like behavior and hyperactivity in Ts65Dn mice. The spontaneous locomotion data 
are the first to demonstrate that hM3D/CNO stimulation of LC-NE can acutely reduce 
hyperactivity in the Ts65Dn mouse model, without exerting any effects on either total 
activity or on center time in NS mice transfected with the DREADDs. 
 
DREADD hM3D NORT Performance  
 I first evaluated whether or not hM3D-mediated stimulation of the LC could 
alleviate memory deficits in Ts65Dn mice at an age when LC degeneration and cognitive 
impairment are both apparent (Figure 3-6, C vs. D). Twenty days post AAV injection, I 
tested NS and Ts65Dn in the novel object recognition task. All mice received an i.p. 
injection of either CNO or vehicle each day of the task, 5 min prior to testing. To determine 
if mice had a preference for the novel object, I first calculated the percent time spent with 
 




the novel object. A Student’s t-test between the two NS groups revealed that there was no 
significant difference between CNO or vehicle treated NS mice in terms of Discrimination 
Index in NORT (p = 0.6470, Figure 3-6, D), therefore the two NS groups were collapsed 
for further comparison with the Ts65Dn groups. An overall ANOVA between NS mice vs. 
the two Ts65Dn groups revealed group differences for time spent on the novel object 
between Ts65Dn mice with or without CNO treatment and NS mice [F2,21= 4.623; p = 
0.0231]. Tukey’s post hoc analysis revealed that mean time spent with the novel object was 
significantly less in vehicle-treated Ts65Dn mice when compared to all NS mice, 
regardless of treatment (Figure 3-6, C, p = 0.048).  
 
 
3.3.3 AAV DREADD hM4D-mediated behavior 
DREADD hM4D Cohorts were Equivalent to all GFP Control Groups  
 To ensure that injection of the control viral construct with green fluorescent protein 
(GFP) did not elicit behavioral effects, I performed one-way ANOVAs to test for 
significant differences between non-inhibited LC-NE groups (GFP saline-treated, GFP 
CNO-treated and hM4D saline-treated) for each dependent variable (Spontaneous 
locomotion, percent center time, NORT discrimination index) separately. I found no 
significant differences between these groups (data not shown) for any outcome measure of 
behavior, which suggested that the inactive state of hM4D is equivalent to any GFP control 
group regardless of treatment. Since all measures were equivalent, I next focused on within 
group (GFP or hM4D) analyses.  
 





DREADD hM4D Spontaneous Locomotion Behavior 
Because hyperactivity in the Ts65Dn mice may influence other behavioral 
components, I examined the effects of hM4D stimulation on baseline motor activity in an 
open field chamber for all groups (Figure 3-7, A-B). I performed two-way ANOVA to test 
for differences within AAV groups (karyotype x treatment). For AAV-GFP (Figure 3-7, 
A-left), the main effect was attributable to karyotype alone which accounted for 60% of all 
variation (F1,16 = 24.9, p = 0.0001). Tukey’s post hoc analyses revealed that Ts65Dn mice 
displayed significantly increased hyperactivity relative to NS mice (p = 0.01). CNO 
treatment did not affect this significant difference (p = 0.015) which supports that CNO is 
biologically inert. For AAV hM4D (Figure 3-7, A-right) karyotype alone accounted for 
43% of all variation (F1,32 = 25.2, p < 0.0001). Tukey’s post hoc analyses revealed that 
Ts65Dn mice displayed significantly increased hyperactivity relative to NS mice (p = 
0.01). CNO treatment did not affect this significant difference (p = 0.001) indicating that 
inhibition of the LC has no effect on hyperactivity or spontaneous locomotion in mice, at 
least not in the current paradigm and age examined. Further, no significant effect was 
observed on mean velocity in the open field between NS and Ts65Dn mice, regardless of 
experimental condition (data not shown), indicating that LC manipulations do not 
adversely affect motor ability. Since changes in stress or anxiety can affect LC-NE 
modulation of arousal required to sustain attention for behavioral tasks, I next examined 
the effects of hM4D-mediated LC inhibition on center activity (Figure 3-7, B) for all 
groups. I performed two-way ANOVA to test for differences within AAV groups 
 





Figure 3-7. Inhibitory DREADD hM4D open field behavioral outcomes. (A) 
Vehicle-treated Ts65Dn mice exhibited a significant increase in total distance traveled 
(cm) and this affect was not lost by CNO treatment. (B) There was no significant 
difference between the NS VEH and CNO groups regardless of viral vector. Error bars 
represent mean ± SEM. 
 




(karyotype x treatment). For both AAV-GFP and AAV hM4D, Tukey’s post hoc analyses 
revealed no significant effects on center time in any of the groups. These results indicated 
that karyotype or AAV groups and suggested that measures of discrimination index in 
novel object recognition tasks were unbiased. 
 
DREADD hM4D NORT Performance 
 I next evaluated if hM4D-mediated inhibition of LC-NE neurons could exacerbate 
NORT recognition memory deficits in NS or Ts65Dn mice. I performed two-way ANOVA 
to test for differences within AAV groups (karyotype x treatment). The analysis was 
performed independently for 90 minutes (short-term memory) and 24 hr (long-term 
memory) when novel objects were introduced. For AAV-GFP at 90 minutes (Figure 3-8, 
A-left), the main effect was attributable to karyotype which accounted for 67% of all 
variation (F1,14 = 29.49, p < 0.0001). Tukey’s post hoc analysis revealed that the mean 
discrimination index was significantly less in vehicle-treated Ts65Dn GFP mice compared 
to NS GFP mice (p = 0.01). Since CNO is biologically inert, CNO treatment did not affect 
this significant difference (p = 0.008). Importantly, the AAV injection per se did not appear 
to exert any behavioral effects, since non-AAV injected NS and Ts65Dn control mice in 
previously published experiments exhibited close to identical NORT performance as AAV-
injected NS and Ts65Dn mice in these experiments. 
 
For AAV-hM4D at 90 minutes (Figure 3-8, A-right), the significant effects were 
observed by karyotype and treatment. Karyotype accounted for 28% of all observed 
 




Figure 3-8. Inhibitory DREADD hM4D NORT behavioral outcomes. (A) Vehicle-
treated Ts65Dn mice spent significantly less time with the novel object than NS mice, 
and this deficiency affected by treatment with CNO. CNO treatment of NS mice 
significantly decreases time spent with the novel object. (B) NS mice were significantly 
more likely to recognize the novel object than vehicle-treated Ts65Dn mice, and this 
effect was exacerbated after CNO treatment. CNO treatment of NS mice significantly 
decreases time spent with the novel object. Error bars represent mean ± SEM.  
 




variation (F1,34 = 18.25, p = 0.0001), treatment for 14% of all variation (F1,34 = 9.46, p = 
0.004). Tukey’s post hoc analysis revealed that mean DI was significantly less in vehicle-
treated Ts65Dn hM4D mice compared to saline-treated NS hM4D mice (p = 0.003). 
Notably, CNO activation of hM4D receptors significantly decreased DI in NS mice (p = 
0.005) and TS mice (p < 0.0001) compared to inactive saline-treated NS mice with hM4D. 
For AAV-GFP at 24 hours (Figure 3-8, B-left), the main effect was attributable to 
karyotype which accounted for 62% of all variation (F1,14 = 22.45, p = 0.0003). Tukey’s 
post hoc analysis revealed that mean discrimination index was significantly less in saline-
treated Ts65Dn GFP mice compared to NS GFP mice (p = 0.02). Since CNO is biologically 
inert, CNO treatment did not affect this significant difference (p = 0.03). For AAV-hM4D 
at 24 hours (Figure 3-8, B-right), the significant effects were observed by karyotype and 
treatment. Karyotype accounted for 16% of all variation (F1,33 = 11.01, p = 0.002), 
treatment for 36% of all variation (F1,33 = 24.36, p < 0.0001) with no significant interaction. 
Tukey’s post hoc analysis revealed that mean DI was significantly less in saline-treated 
Ts65Dn hM4D mice compared to vehicle-treated NS hM4D mice (p = 0.04). Similar to the 
90 minute interval, CNO activation of hM4D receptors significantly decreased DI in NS 
mice (p = 0.003) and TS mice (p < 0.0001) compared to inactive saline-treated NS mice 
with hM4D. Notably, CNO activation of hM4D receptors significantly decreased DI in 
Ts65Dn mice (p < 0.0001) compared to saline-treated Ts65Dn mice. 
 
Importantly, the AAV injection per se did not appear to exert any behavioral effects, 
since AAV-GFP injected NS and Ts65Dn control mice exhibited close to identical 
 




performance in both locomotor activity (Figure 3-7) and in the NORT Discrimination 
Index (Figure 3-8) as the AAV injected NS and Ts65Dn mice with vehicle in this 
DREADD experiment. Collectively, these findings suggest that CNO-mediated hM4D 
inhibition of LC-NE neurons reduces performance in a working memory task, both at 
shorter and longer inter-trial intervals, in 4 month old Ts65Dn and NS male mice. Age-
matched Ts65Dn and NS control mice without AAV injection exhibited close to identical 
behavioral performance compared to Ts65Dn, and NS mice injected with AAV-GFP, 
strongly suggesting that surgery, AAV injections, and viral transfection did not give rise to 
behavioral alterations. Thus, these data demonstrated that LC-NE inhibition via hM4D-
CNO administration affected working memory performance in both karyotypes (TS and 
NS mice) at 4 months of age.  
 
DREADD hM4D WRAM Performance 
Before subjecting the mice to spatial reference memory testing, I examined swim 
speed and transition times between the arms in the maze. I found that the overall means of 
each group were not significantly different and that all mice, regardless of experimental 
condition, were able to complete 95% of all swim transit arm-to-arm in under 8 seconds 
(refer to Chapter 2, Figure 2-4, C). These results indicate that all experimental groups 
have equivalent swimming capacity and can perform the WRAM spatial memory task 
without visual deficits that are found in some Ts65Dn mouse colonies (Scott-McKean, 
Chang et al. 2010).  
 
 




As seen in Figure 3-9, A Ts65Dn mice exhibited more errors than NS groups on 
all three days, regardless of treatment with hM4D-CNO or with the vehicle. In addition, 
the Ts65Dn group with hM4D-CNO treatment showed a marginal increase in errors on day 
3 of the trial when compared to GFP-CNO treatment, although this difference was not 
statistically significant from within the day. I performed a linear regression to test whether 
the slopes and overall elevations were different between the four cohorts. Although the 
slopes for each mouse cohort were not significantly different from each other, only the 
Ts65Dn hM4D-CNO treated group had a slope which was not significantly different from 
zero (p = 0.07). The elevations (y-intercepts) were significantly different (F3,19 = 14.40, p 
< 0.0001) and were primarily driven by karyotype with Ts65Dn mice having an overall 
trend of 63% increase in errors over NS mice. 
 
The WRAM task can be evaluated from the initial start trial block (maximum errors 
made) to the final finish trial block (minimum errors made) in order to focus statistical 
analyses on the overall performance of the task. I performed two-way ANOVA to test for 
differences within AAV groups (karyotype x trail learning) in order to assess learning 
aspects relative to the groups when the LC-NE is inhibited. Both karyotype (F3,44 = 21.3, p 
< 0.0001) and trail learning (F1,44 = 68.6, p < 0.0001) had significant effects and together 
accounted for 73% of all variation. Tukey’s post hoc analyses revealed that both NS GFP, 
NS hM4D groups displayed significantly fewer errors at the final trial (p < 0.0001) 
compared to the start trail (Figure 3-9, B). The Ts65Dn GFP group also displayed 
significantly fewer errors at the final trial compared to the start trail although considerably 
 




Figure 3-9. Inhibitory DREADD hM4D WRAM behavioral outcomes. (A) 
Longitudinal comparison. Ts65Dn mice make significantly more errors than NS mice, 
and this was not affected by LC inhibition (hM4D) until the very last trails in Day 3. 
(B) Start-to-Finish comparison. NS mice were significantly more likely to enhance 
WRAM performance than Ts65Dn mice. LC inhibition (hM4D) in Ts65Dn mice did 
not significantly enhance performance. Error bars represent mean ± SEM.  
 




less robust (p = 0.001) than any NS group. Interestingly, the Ts65Dn hM4D group did not 
show a strong trend of fewer errors in this task comparison, but this was not significant 
suggesting that LC-NE inhibition did have some impact on spatial learning. To ensure there 
was no bias in summing errors of four trails into one block, I evaluated longitudinal 
differences in this WRAM task with the highest fidelity on a per trial basis without binning. 
I performed a paired, longitudinal two-way ANOVA to compare mean differences between 
experimental groups which resulted in a similar overall result (data not shown). 
Collectively, LC-NE inhibition can subtly impact WRAM performance in later WRAM 
trials if sufficient learning deficits exist as in Ts65Dn mice. 
 
DREADD hM4D WRAM Reversal Learning  
After 3 days of spatial learning, mice were subjected to a new platform location to 
test perseverance and error rate, each collectively assessing reversal learning and cognitive 
flexibility. After platform switching, all groups demonstrated perseverance to the original 
platform in the initial trial block. I performed a two-way ANOVA to test for differences 
within AAV groups (karyotype x trial learning) in order to assess reversal learning aspects 
when the LC-NE is inhibited (Figure 3-10, A). Trial learning had the greatest overall effect 
(F1,44 = 22.9, p < 0.0001) and accounted for 32% of all variation. However, Tukey’s post 
hoc analyses revealed that only the NS GFP group had a significant decrease in 









Figure 3-10. Inhibitory DREADD hM4D WRAM reversal learning. (A) 
Perseverance to original platform location. Only NS mice significantly decreased 
perseverance errors. (B) Ts65Dn mice make significantly more errors than NS mice 
and LC inhibition (hM4D) exacerbates this effect in Ts65Dn mice. Error bars 
represent mean ± SEM.  
 




Since the WRAM task has been practiced over three days, normal mice with strong 
cognitive flexibility should rapidly learn the new target cue after platform switching. All 
mice demonstrated high error rates when finding the new hidden platform in the first trial 
block due to the platform reversal. Within four trials, however, mice with normal cognitive 
flexibility quickly learn the new platform locations and then make minimal errors. I 
performed a two-way ANOVA to test for differences within AAV groups (karyotype x trail 
learning) in order to assess if LC-NE inhibition affected error rate (Figure 3-10, B). I found 
that with practice, mice make significantly fewer errors in the final trial block (F1,44 = 32.9, 
p < 0.0001). However, karyotype significantly affected the overall performance outcome  
(F3,44 = 12.3, p < 0.0001) upon LC inhibition and accounts for 30% of total variance. 
Tukey’s post hoc analyses revealed that only the NS GFP and NS hM4D groups made 
significantly fewer errors from start to finish (NS GFP, p = 0.0009 and NS hM4D, p = 
0.02). After reversal learning, the NS GFP group made significantly fewer errors than the 
TS GFP group (p = 0.04) and the Ts65Dn hM4D group (p < 0.0001). LC inhibition in 
Ts65Dn resulted in significantly more errors than the Ts65Dn GFP group (p = 0.02). 
Overall, hM4D-mediated inhibition of the LC caused mice to make more average errors in 
the second trial block with the greatest effect seen in Ts65Dn mice.  
 
3.3.4 β1-Adrenoreceptor Immunostaining 
We have previously shown that Ts65Dn mice have significant elevations in β1-AR 
expression at 11-13 months (Fortress, Hamlett et al. 2015). Since treatment with the NE 
precursor, L-DOPS, normalizes this phenotype we originally presumed β1-AR expression 
 




is partly driven by a feedback regulation response to declining NE levels caused by 
degeneration of the of the pontine LC-NE nucleus in Ts65Dn mice at that age. In this study, 
LC morphology seems intact in Ts65Dn mice at 4 months of age so I presumed no β1-AR 
expression differences would be detected in LC terminal projection fields. Further, I 
hypothesized that hM4D inhibition of the LC would cause β1-AR expression levels to 
increase. After immunostaining of β1-AR, I observed significant changes in overall 
expression (Figure 3-11). I quantified β1-AR intensity and performed a two-way ANOVA 
to test for differences within AAV groups (karyotype x treatment) in order to assess if LC-
NE inhibition would cause compensatory effects on β1-AR expression levels at 4 months 
of age. For all measures, I observed that β1-AR intensity was predominantly affected by 
karyotype (F1,35 = 29.9, p < 0.0001) but also by treatment (F3,35 = 3.365, p = 0.029). Factor 
interaction was significant (F3,35 = 4.82, p = 0.0065) since LC inhibition only significantly 
affected Ts65Dn mice.  
 
In the hippocampus (Figure 3-11, A), Tukey’s post hoc analyses revealed that 
DREADD inhibition of the LC had no effect on β1-AR intensity in the NS GFP and NS 
hM4D groups. As expected both NS groups had significantly lower β1-AR staining 
intensity than the Ts65Dn GFP group (p = 0.0003 and p = 0.0001 respectively). 
Surprisingly, DREADD inhibition of the LC normalized expression in the Ts65Dn hM4D 
group to equivalent levels observed in either NS group, which is significantly lower than 
the Ts65Dn GFP group  (p = 0.006). β1-AR immunostaining (Figure 3-11, C-F), revealed 
dense punctate fibers with clear elevations in the Ts65Dn GFP group. In the perirhinal 
 




Figure 3-11. Inhibitory DREADD hM4D β1-AR immunostaining. (A) 
Hippocampus. Ts65Dn mice have significantly elevated expression when compared to 
NS mice. LC inhibition (hM4D) in Ts65Dn mice normalized expression. (B) Parietal 
Cortex. Ts65Dn mice have significantly elevated expression when compared to NS 
mice. LC inhibition (hM4D) in Ts65Dn mice normalized expression. (C-F) 
Hippocampus immunostaining featuring LCNE fiber staining. (G-J) parietal cortex 
immunostaining featuring LCNE fiber staining. Error bars represent mean ±SEM.  
 




cortex (Figure 3-11, B), Tukey’s post hoc analyses revealed that DREADD inhibition of 
the LC again had no effect in the NS GFP and NS hM4D groups. Both NS groups had 
significantly lower β1-AR intensity than the Ts65Dn GFP group (p = 0.006 and p = 
0.004repectively). DREADD inhibition of the LC normalized β1-AR expression in the 
Ts65Dn hM4D group to equivalent levels observed in either NS group, which is 
significantly lower than the Ts65Dn GFP group (p = 0.05). β1-AR immunostaining (Figure 
3-11, G-J), again revealed dense punctate fibers with elevations only in the Ts65Dn GFP 
group. Altogether, the findings suggest that DREADD inhibition of LC-NE normalized 
aberrant β1-AR expression at afferent innervation fields in Ts65Dn mice. It is possible that 
chronic suppression of LC-NE release in the target regions can lead to degeneration of NE 
neurites, and thus also a reduction in β1-AR.  
 
3.3.5 Microglial CD45 Immunostaining 
The Granholm Lab has previously shown that Ts65Dn mice have significant 
elevations in microglial activation at 8 months of age relative to NS mice (Lockrow, Boger 
et al. 2010). In Ts65Dn mice, this was observed as higher CD45 expression concurrent 
with a greater frequency of heavily ramified or amoeboid cellular phenotypes in the 
hippocampus and various cortex fields (Lockrow, Boger et al. 2011). Since treatment with 
the selective DSP-4 NE neurotoxin selectively ablates NE innervation in afferent 
innervation fields and exacerbates microglial activation, I presumed that DREADD 
mediated inhibition of the LC might also elevate the neuroinflammatory phenotype in our 
hM4D groups. Therefore, I immunostained CD45 and assessed microglial activation as 
 




seen in Figure 3-12. Inhibition of LC-NE neurons via hM4D DREADDs gave rise to a 
significant increase in CD45 immunostaining, and increased morphological signs of 
microglial activation, both in the hippocampus and the frontal cortex. To confirm the 
observed effects, I quantified CD45 intensity and performed a two-way ANOVA to test for 
differences within AAV groups (karyotype x treatment) in order to assess if LC-NE 
inhibition had effects on CD45 expression patterns at 4 months of age. For all measures, I 
observed that CD45 intensity was predominantly affected by karyotype (F11,126 = 3.92, p < 
0.0001) and also by treatment (F1,126 = 4.32, p = 0.039). Factor interaction was significant 
(F3,35 = 4.82, p = 0.0065) since LC inhibition affected expression levels in NS and TS mice. 
 
In the frontal cortex (Figure 3-12, A), Tukey’s post hoc analyses revealed that 
Ts65Dn GFP mice had significantly greater CD45 intensity than NS GFP mice (p = 0.014). 
DREADD inhibition of the LC significantly elevated CD45 intensity in the NS hM4D 
group relative to the NS GFP group (p = 0.003) and in the Ts65Dn hM4D group relative 
to the TS GFP group (p = 0.04). DREADD inhibition of the LC creates a hyper-activated 
microglial phenotype in Ts65Dn that was almost three-fold higher than that observed in 
the NS GFP mice. CD45 immunostaining (Figure 3-12, C-F), revealed more frequency of 
activated microglia (white arrows) in the Ts65Dn, and in the hM4D group where LC 
inhibition occurred. In the parietal cortex (Figure 3-12, B), Tukey’s post hoc analyses 
revealed that Ts65Dn GFP mice exhibited significantly greater CD45 intensity that NS 
GFP mice (p = 0.007). DREADD inhibition of the LC significantly elevated CD45 signal 
intensity in the Ts65Dn hM4D group relative to the Ts65Dn GFP group (p = 0.04). CD45 
 




Figure 3-12. Inhibitory DREADD hM4D microglial CD45 staining. (A) Frontal 
Cortex. Ts65Dn mice have significantly elevated expression when compared to NS 
mice. LC inhibition (hM4D) causes significant elevations in expression in both NS and 
Ts65Dn mice. (B) Parietal Cortex. Ts65Dn mice have significantly elevated expression 
when compared to NS mice. LC inhibition (hM4D) causes significant elevations in 
expression in both NS and Ts65Dn mice. (C-F) Frontal Cortex immunostaining 
featuring activated microglia (white arrows). (G-J) Parietal Cortex immunostaining 
featuring activated microglia (white arrows). Error bars represent mean ± SEM.  
 




immunostaining (Figure 3-12, G-J), revealed frequency denser pattern of activated 
microglia (white arrows) in the Ts65Dn, and in the hM4D group of both karyotypes. As 
seen in two brain regions, hM4D inhibition of the LC caused a shift towards a more 
activated microglial phenotype in Ts65Dn that was at least 2.5 times higher than observed 
in NS GFP mice. Altogether, the findings suggest that hM4D inhibition of LC-NE 
exacerbates neuroinflammation as observed by increased CD45 expression and higher 
frequency of activated cellular phenotypes in both NS and  Ts65Dn mice. 
 
Collectively, these results show significant DREADD-mediated effects on LC 
function, both in young and in middle-aged Ts65Dn mice. hM3D mediated stimulation of 
LC-NE activity in residual LC neurons of middle-aged (14 months old) Ts65Dn mice 
exerted significant beneficial effects on hyperactivity, center activity, and performance in 
the NORT. hM4D mediated inhibition of LC-NE activity in young (4 month old) Ts65Dn 
mice exerted a significant reduction in performance of the behavioral tasks, coupled with 
alterations in beta adrenoreceptors and activation of microglial cells in the frontal cortex 
and hippocampus. Finally, the AAV-GFP experiment revealed that AAV injections per se 
did not alter behavioral performance in the NORT, either in NS or Ts65Dn mice.  
 
3.4 Discussion 
The findings presented here are the first to demonstrate that hM3D/CNO-mediated 
LC activation can restore memory function in adult Ts65Dn mice. We observed that 
artificially stimulating LC-NE function acutely via selective hM3D/CNO-mediated LC 
 




activation and systemically via the NE pro-drug, L-DOPS, enhanced cognition in Ts65Dn 
mice in hippocampal-dependent behavioral tasks, including the NORT and the 
spontaneous alternation task. Further, when comparing the behavioral performance in the 
two experiments, it was evident from group to group comparison (Figures 3-7 and 3-8), 
that the AAV injections themselves did not produce any behavioral alterations in either 
Ts65Dn or NS mice. Previous work by us and others has shown that Ts65Dn mice undergo 
a progressive loss of LC-NE neurons, beginning at six months of age (Salehi A 2009, 
Lockrow, Boger et al. 2011), and the current work extended and confirmed these findings. 
Stimulation of the DREADD receptors via i.p. injection of CNO also reduced hyperactivity 
in Ts65Dn mice, and increased center time in the spontaneous locomotion box, suggesting 
that hyperactivity and anxiety may have been corrected with DREADD stimulation of the 
LC-NE transmitter system. Further, double labeling using HA and TH antibodies 
confirmed efficient and selective transduction of DREADD receptors into LC-NE neurons, 
with an average of 98% co-expression of TH and the HA tag. Similarly, Vazey and Aston-
Jones also found a close to 100% transduction efficiency by the same construct in LC 
neurons, corroborating transduction efficiency observed in this study (Vazey EM 2014). 
 
Several pharmacological and genetic manipulations in rodents have linked NE 
production in the LC to hippocampal function. DβH-knockout mice that are deficient in 
DβH exhibit memory retention deficits which can be reversed by treatment with the β1 
agonist Xamoterol (Murchison, Zhang et al. 2004). In humans with DS, the LC undergoes 
an accelerated and significant degeneration by as much as 60% compared to age-matched 
 




non-DS brains (German, Manaye et al. 1992). The LC-hippocampal NE circuit is important 
for blood-brain barrier integrity, regulating neuroinflammatory processes, and has direct 
effects on learning and memory (for review, see O’Donnell et al., 2012). It has been shown 
that development of AD pathology is aggravated by LC-NE neurodegeneration 
(Chalermpalanupap T 2013), and we have reported similar findings regarding DS-AD 
neuropathology in the Ts65Dn mouse (Lockrow, Boger et al. 2011). In a recent study, 
crossed DβH knockout mice with APP/PS1 mice overexpressing mutant APP and PS1. 
They found that LC-NE loss in the AD mouse leads to greater deficits in hippocampal-
dependent memory tasks and that L-DOPS administration alleviated these effects, 
providing additional evidence for the important role of LC-NE neurons for neuropathology 
and memory deficits occurring both in idiopathic AD and in DS-AD (Hammerschmidt T 
2013). The current data extend the knowledge in this area by demonstrating that stimulation 
of remaining LC-NE neurons exerts powerful effects on behavior related to hippocampal 
function.  
 
 The findings presented here are the first to demonstrate that hM3D/CNO-mediated 
LC activation can regulate cognition in the Ts65Dn mouse model of DS. Previously, our 
laboratory has shown that the loss of LC-NE can exacerbate cognitive impairment and 
neuropathology in Ts65Dn mice (Lockrow, Boger et al. 2011), suggesting a role for NE 
dysfunction in the accelerated neuropathology observed in Ts65Dn mice. As seen with L-
DOPS administration, artificially restoring LC-NE function via selective hM3D/CNO-
mediated LC activation enhanced hippocampal-dependent memory in Ts65Dn mice, and 
 




corroborates the findings of others demonstrating a role for NE in facilitating cognition 
(Salehi, Faizi et al. 2009, Dang, Medina et al. 2014, Salehi, Ashford et al. 2016). Our group 
has recently shown that stimulation of hM3D DREADD receptors in the LC-NE neurons 
by systemic injection of the inert DREADD ligand CNO doubles the firing frequency of 
LC-NE neurons and facilitates cortical EEG changes (Vazey and Aston-Jones 2014), 
suggesting that activation of hM3D receptors following CNO administration can drive LC 
neuronal firing rates. Our results presented herein expand upon these studies by 
demonstrating that LC-NE activity driven by CNO-mediated hM3D stimulation affects 
both consolidation and retrieval of hippocampal-dependent memory in the Ts65Dn DS 
mouse model. The findings also demonstrate that AAV-DREADD intracranial injections 
resulted in a near complete transduction of TH-positive LC neurons, suggesting that the 
PRSx8-hM3D-HA vector represents an effective method for assessing behavioral 
consequences of selectively stimulating or inhibiting LC neurons using the newly 
developed DREADD systems.  
 
These DREADD/CNO experiments further demonstrate that acute activation of a 
residual, albeit degenerating, LC-NE pathway, is sufficient to normalize deficits in 
hippocampal-dependent memory in Ts65Dn mice. This is supported by evidence that 
pharmacologically restoring NE levels in Ts65Dn mice and in DβH-deficient mice enhance 
hippocampal-dependent memory (Salehi, Faizi et al. 2009, Murchison, Schutsky et al. 
2011, Dang V 2014). In addition to enhanced performance in the NORT, hM3D stimulation 
of the LC-NE in Ts65Dn mice gave rise to increased center time and reduced hyperactivity 
 




in the spontaneous locomotion chamber. Reduced center time may be a reflection of 
anxiety as well as hyperactivity, which may lead to reduced attention and/or performance 
in memory tasks (Warner G 2014). Specifically, impaired executive function is closely 
connected to LC-NE degeneration (Vazey EM 2012), and individuals with DS exhibit 
deficits in this cognitive domain (Krinsky-McHale, Devenny et al. 2008, Lanfranchi, 
Jerman et al. 2010). 
 
As a first to the field, I employed novel inhibitory hM4D DREADDs, to explore 
the role of LC-NE inhibition on the performance of behavioral tasks and development of 
AD pathology in a mouse model for DS, Ts65Dn mice. I found significant hyperactivity in 
Ts65Dn groups, regardless of hM4D stimulation, and significantly reduced novel object 
discrimination profiles in the NORT. For Ts65Dn and NS mice that received AAV-hM4D 
and CNO treatment, I observed reduced discrimination in the NORT, both in the short- and 
long-term interval. Even though LC morphology seems intact between the cohorts (Figure 
3-4), whether this intact structure functions normally is doubtful based on memory 
performance results. This is supported by evidence that pharmacological restoration of NE 
levels of LC function in older Ts65Dn mice and in DβH-deficient mice enhances working 
memory and novelty discrimination performance (Salehi, Faizi et al. 2009, Dang V 2014). 
On the other hand, hM4D stimulation in 4 months old Ts65Dn and NS mice did not give 
rise to reduced performance in the WRAM except in the last day, demonstrating that spatial 
reference memory was not overtly affected by inhibiting LC-NE firing rates in young (4 
months old) mice. As mice work longitudinally through the WRAM task, they typically 
 




demonstrate steady improvements in performance, seen as 10-30% improvements in error 
rate over each preceding trial. LC inhibition did reveal spatial memory task effect in final 
trials of the WRAM, but this was observed only in the Ts65Dn mice, which suffer 
deficiencies throughout task duration. Thus hM4D-mediated effects may not necessarily 
exacerbate spatial memory deficits but may influence the ability to perfect the task with 
practice. 
 
DREADD hM4D inhibition of the LC-NE revealed unanticipated effects in β1-
adrenoreceptor expression in terminal afferent fields. We have previously shown that 
Ts65Dn mice have significant elevations in β1-AR expression at 11-13 months (Fortress, 
Hamlett et al. 2015) and that treatment with the NE precursor, L-DOPS, normalized β1-
AR expression. In this study, we originally hypothesized that hM4D inhibition of the LC 
would cause β1-AR expression to increase with the assumption that β1-AR expression is 
mainly driven by a feedback regulation response to declining NE levels caused by LC 
degeneration. Surprisingly, LC inhibition normalized β1-AR expression specifically in 
Ts65Dn mice. This finding indicates that NE alone may not be the primary driver of  
abnormal elevations of β1-AR phenotype in Ts65Dn mice and that other possibilities must 
be considered. DREADD hM4D receptors signaling results in G protein-coupled inwardly-
rectifying potassium channel (GIRK) channel-mediated neuronal inhibition, so perhaps 
aberrations of LC influence on this channel in Ts65Dn mice causes elevations in β1-AR, 
which could underly a molecular mechanism driving the observed compensatory response. 
Since β1 receptor knockout mice exhibit impaired memory retrieval, an optimal expression 
 




level of these receptors seems to be necessary for many aspects of memory performance 
and has major implications for hippocampal-dependent behavioral tasks (Murchison, 
Schutsky et al. 2011), perhaps by facilitating excitatory transmission, as suggested by 
others (Zhang L 2013). Understanding the cellular mechanisms downstream of β1 receptor 
activation is necessary for facilitating hippocampal memory in aging Ts65Dn mice may 
enhance the discovery of novel drug targets for both the AD and DS-AD populations. 
Further studies are needed to better understand the mechanisms that drive significant 
elevations in β1-AR expression in Ts65Dn mice. 
 
It was previously shown that Ts65Dn mice have significant elevations in microglial 
activation at 8 months of age relative to NS mice. In Ts65Dn mice, this was observed as 
higher CD45 expression concurrent with a greater frequency of heavily ramified or 
amoeboid cellular phenotypes in the hippocampus and various cortex fields (Lockrow J 
2011). Treatment with DSP-4, a select neurotoxin of LC neurons would be expected to 
significantly decrease NE tone in afferent innervation fields and has been observed to 
exacerbate microglial activation. I hypothesized that DREADD mediated inhibition of the 
LC might also elevate the neuroinflammatory phenotype in all hM4D groups that receive 
CNO. As seen in Figure 3-12, hM4D-mediated LC inhibition significantly elevates the 
neuroinflammatory phenotype in our hM4D groups as observed by CD45 intensity and 
increases in cellular phenotypes that are prototypical of activated microglia. Here I report 
that enhanced microglial activation is already present at 4 months of age in Ts65Dn mice. 
At such a young age, I contemplate the importance of the LC in preventing microglial 
 




activation and chronic neuroinflammation. In this study, all animals received 9 days of 
daily LC inhibition, which was sufficient to manifest a neuroinflammatory phenotype. 
With clinical DS-AD, such microglial activation occurs years before the certain appearance 
of Aβ plaques in DS by the age of 20. These findings add further support the theory that 
LC dysfunction underpins early neuroinflammation in the DS population. 
 
Neurotrophins exert significant influence on neuron survival, synaptic plasticity, 
learning and memory (Chao 2003). The neurotrophin, BDNF, is highly expressed 
throughout the central nervous system, especially in the hippocampus and cerebral cortex 
(Phillips, Hains et al. 1990, Wetmore, Ernfors et al. 1990). BDNF is critical to the survival 
and function of hippocampal, cortical, cholinergic, noradrenergic and dopaminergic 
neurons (Alderson, Alterman et al. 1990, Hyman, Hofer et al. 1991, Ghosh, Carnahan et 
al. 1994, Holm, Rodriguez et al. 2003) and for synaptic plasticity and memory processing 
in the adult brain (Alonso, Vianna et al. 2002, Bekinschtein, Cammarota et al. 2008). 
Recent studies revealed a link between NE and enhanced BDNF synthesis. Stimulation of 
hippocampal astrocytes with NE resulted in increased release of BDNF (Zafra, Lindholm 
et al. 1992). Stimulation of embryonic hippocampal neurons with NE activates the 
Phosphoinositide-3-kinase and MAPK signaling cascades and induces BDNF (Chen, 
Nguyen et al. 2007). Furthermore, BDNF mRNA transcription was significantly elevated 
by ~200% specifically in response to NE stimulation (Vaghi, Polacchini et al. 2014). BDNF 
has also been explored regarding dementia risk because expression levels are correlated 
with lifestyle factors such as reduced caloric intake (Lee, Seroogy et al. 2002) and increased 
 




physical activity (Neeper, Gomez-Pinilla et al. 1995, Vaynman, Ying et al. 2003). Reduced 
levels of BDNF in the brain is thought to be associated with in Alzheimer’s disease 
(Sutherland, Wong et al. 1993, Pappas and Parnavelas 1997, Nagahara, Merrill et al. 2009, 
Iulita, Do Carmo et al. 2014). Since BDNF is a key regulator of neuronal plasticity and 
survivability, it is considered a major pharmaceutical target to prevent neurodegeneration. 
Degeneration of the LC-NE would have widespread repercussions on early cognitive 
impairment, chronic inflammation and neurotrophic support, it has emerged as a central 
therapeutic target to prevent DS-AD. The work accomplished thus far will provide a sound 
basis for BDNF studies in the near future. 
 
Collectively, our results came from artificially stimulating LC-NE function acutely 
via hM3D/CNO-mediated LC activation or via inhibiting LC-NE function via hM4D/CNO 
mediated LC silencing. Utilizing DREADD technology enables the discrimination of 
neuronal contributions to complex behavior without actions on neighboring cells or 
peripheral systems. Our study provides direct evidence for the feasibility of DREADD 
receptor technology to explore the role of discrete neuronal populations in 
neurodegenerative disorders at physiological active CNO concentrations that are not likely 
to retroconvert to appreciable levels of Clozapine, a known psychoactive drug. Our 
findings expand upon previous findings by us and others (Murchison, Zhang et al. 2004, 
Salehi A 2009, Murchison, Schutsky et al. 2011) suggesting that the LC-NE pathway is a 
plausible target for new therapeutics in treating DS-AD and idiopathic AD. The increase 
in the number of aging adults with DS will provide a significant opportunity and challenge 
 




to improve their quality of life in the very near future. AD-related neuropathology is an 
unfortunate fact for aging adults with DS and the findings here further implicate the 
important role the LC-NE will have for each individual. Therefore, employing NE-
enhancing drugs for individuals with DS-AD may lead to significant improvement not only 
in memory but also in anxiety and attention-related behaviors. This is especially important 
since classical AD medications may be less effective in DS-AD compared to idiopathic 
AD (Iulita, Do Carmo et al. 2014), and there are currently no effective medications 
available to mediate cognition in DS patients (Warren B. Zigman 2004, Nelson, Johnson 
et al. 2005). It is imperative to test and verify the efficacy of pharmacological drugs that 
can modulate noradrenergic functions in this population, to decrease neuroinflammation 




The work described in Chapter 3 involved an ongoing project funded by the 
Alzheimer’s Foundation and would not have been possible without significant 
contributions from Dr. Ashley Fortress (a former graduate student), Dr. Heather Boger, 
and Dr. Ann Charlotte Granholm. Acknowledgment is owed to Dr. Ashley Fortress, who 
initiated the first DREADD hM3D study, which I subsequently completed. Dr. Boger was 
a critical advisor and also performed a majority of the stereotactic injections of the AAV 
virus into the locus coeruleus which I assisted with. I was the primary contributor in all 
aspects of these projects including DREADD injections, vivarium roles, animal behavior, 
 




immunostaining, western blots, statistical evaluations and original authorship of all 
publications. I considerably reorganized and revised previous work to lead to a published 
paper with both Fortress and myself as equal first authors (Fortress, Hamlett et al., 2015) 
and a review article (Hamlett 2015) for which I was the first author. Boger, Paredes and 








Chapter 4. A Specialized Pro-Resolving Mediator Approach in Ts65Dn  
 
4. Introduction 
 Chronic neuroinflammation may represent an overall disturbance of innate 
immunity in the brain, which is manifested by alterations in resident microglia cells, the 
degree of which is highly affected by aging, genetics, diet and daily activity (McGeer and 
McGeer 2004). In Chapter 1, I introduced how Ω3 fatty acids can be transformed into 
potent SPMs that are highly efficacious in modulating inflammatory responses. Several 
studies have revealed an important role for SPMs in the nervous system, but the 
experiments conducted in this Chapter specifically focus on RvE1. RvE1 initiates a well-
characterized resolution response via a conserved class GPCRs (see Figure 4-1). RvE1 is 
known to bind to ChemR23 and BLT1 receptors, which mediated release of intracellular 
Ca2+, prevent of cAMP accumulation, and alter signaling pathways that are known players 
in AD and DS-AD  (Ohira T 2010, Oh, Pillai et al. 2011, Perluigi M 2014, Burkewitz, Weir 
et al. 2016, Paschoal, Amano et al. 2017). mTOR and ERK proteins are effectors of these 
signaling pathways and both have been shown to be abnormal in individuals diagnosed 
with DS-AD (Mattson 2007, Williams B 2007 , Iyer, van Scheppingen et al. 2014, Perluigi 
M 2014) and in mouse models of DS-AD (Ahmed, Dhanasekaran et al. 2013, Tramutola, 
Lanzillotta et al. 2016). RvE1 was also observed to have a profound binding capacity to 
PPAR-γ (Arita, Yoshida et al. 2005, Schwab, Chiang et al. 2007, Oh, Pillai et al. 2011, 
Herova, Schmid et al. 2015), which makes its therapeutic value comparable to 
rosiglitazone, a proven PPAR-γ agonist that also has therapeutic potential for AD 
 




(Muralikumar, Vetrivel et al. 2017). As mentioned in the Introduction, the ChemR23 and 
BLT1 receptors along with PPAR-γ are highly expressed in both neurons and microglia in 
the brain and thus are assumed to be major contributors to proresolution outcomes that 
would be relevant to neuronal systems.  
 
 One of the most pressing questions in the field is how do to decrease inflammation 
in the brain to stop AD progression without chronic adverse side effects? In recent studies, 
Schultzberg, Granholm and co-investigators identified and quantified SPMs and their 
receptors in the brain of AD patients and found several dysfunctions including reduced 
SPMS, significant elevations of receptors and alterations of enzymes linked to SPM 
synthesis (Wang, Zhu et al. 2015). In the OmegAD study, Ω3 administration did not cause 
significant elevations in a specific SPM measures for patients with AD despite being given 
over 6  months (Wang, Hjorth et al. 2015).  Altogether, this research suggested that an 
intervention that could bypass the normal Ω3-to-SPM enzymatic process by direct delivery 
of SPMs at an effective dose could possibly be a viable way to resolve neuroinflammation 
and potentially prevent AD pathology.   
 
4.1 Chapter 4 Specific Aims 
I constructed and implemented an ideal first-of-kind methodological approach to 
administer purified resolution agonists chronically in Tc65Dn mouse model, which mimics 
major hallmarks of early neurodegeneration and persistent neuroinflammation seen in the 
DS population. My approach has strengths because it effectively bypasses the complexity 
 




of all enzyme mechanisms that are needed to create SPMs naturally, with the expectation 
this kind of treatment would directly activate the resolution pathway. The central 
hypothesis in this Chapter was that resolution agonists could activate brain resolution, 
reduce neuroinflammation and prevent memory loss in a mouse model of DS. I tested this 
hypothesis with the potent EPA-derived SPM, RvE1, which was given as a chronic 
therapeutic for one month followed by measures of peripheral cytokines, microglial 
activation, and several behavioral indices.  
 
4.2 Chapter Specific Methods  
 
4.2.1 Animal Cohorts 
Ts65Dn mice and normosomic (NS) littermate controls (all male) were obtained 
from Jackson Laboratories (Bar Harbor, ME). All mice were aged 8 months before 
treatment. Cohort size is provided in Figure 4-1. 
 
 
4.2.2 Pharmacological Treatments 
RvE1 crosses the blood-brain barrier, like its parent EPA compound, suggesting an 
effective treatment outcome could be achieved in the brain (Freund-Levi Y 2014). At 8 
Figure 4-1. Chapter 4 Cohort size 
 




months of age, mice received a subcutaneous mini-osmotic pump (Alzet, Cupertino, CA) 
delivering one of two sterile solutions: Vehicle (5% EtOH, 95% saline) or Resolvin E1, 
[10 ng/g body weight/day] dissolved in the vehicle. The pump was calibrated to deliver 
approximately 2.3 microliters per day for a maximum of 35 days to deliver a daily dose of 
300 ng to a 30 gram mouse per day. After implantation, the minor incision was closed using 
sterile monofilament nylon suture, and topical antibiotic ointment was applied. Animals 
were kept warm until normal consciousness and mobility were regained, and sutures were 
removed after complete healing of the incision, which was usually after 7 days.  
 
4.2.3 Behavioral Tests 
After 25 days of continuous chronic treatment, four behavioral experiments 
occurred sequentially: spontaneous locomotion, NORT, the 3-day WRAM, WRAM 
reversal and rotarod. These behavior tasks are commonly used throughout this dissertation 
and are fully described in the General Methods (see Chapter 2). 
 
Figure 4-2. Experimental Design. All mice were aged 8 months and then received the 
mini-osmotic pump filled with select treatment. This resulted in four experimental 
groups NS (Veh or RvE1) and Ts65Dn (Veh or RvE1) that were continuously dosed 
for 35 days. Behavior task were initiated only 25 days after dosing began and were 
completed before dosing was finished. 
 




4.2.4 Tissue Preparation 
 Within one week of behavioral testing, all mice were euthanized using an overdose 
of isoflurane, and the brains were rapidly dissected. Tissues were prepared for 
immunohistochemistry and western blot as described in General Methods (Chapter 2).  
 
4.2.5 Immunostaining    
Details about primary antibodies used in Chapter 4 are included below. 
 
4.2.6 Statistical Considerations 
I tested all data sets for outliers using Grubbs’ with alpha set at 0.05 and found no 
outliers. I performed Shapiro-Wilk normality test and found that all data sets passed 
normality and were well suited for univariate/parametric tests including analysis of 
variance (ANOVA) and linear regression. For behavior data, I performed ordinary two-
way ANOVA to test for differences between the four groups (karyotype x treatment), and 
Tukey’s post hoc analysis was used to examine statistical patterns that were not specified 
 




a priori. For the 3-day WRAM task, I performed a linear regression to test for significant 
differences in slope and elevation (y-intercept) over the repeated measures. For western 
blot and immunostaining data, I performed ordinary two-way ANOVA to test for 
differences between the four groups (karyotype x treatment), with Tukey’s post hoc 
analysis to examine statistical patterns that were not specified a priori. All data were 
graphically represented as mean ± SEM. 
 
4.3 Results 
4.3.1 RvE1-mediated Behavior  
RvE1-mediated Spontaneous Locomotion Behavior  
Because hyperactivity has been observed in the Ts65Dn mouse model and may 
influence other behavioral components (Lockrow J 2011), I first examined the effects of 
RvE1 treatment on baseline motor activity in Ts65Dn mice (Figure 4-3). I then tested  
overall motor ability in a rotarod task (Figure 4-3, A) and found no significant difference 
in either NS or Ts65Dn mice regardless of treatment. In the open field task, I observed no 
significant effects of treatment on center time for any group Figure 4-3, B), suggesting that 
anxiety was not a confounding factor and that RvE1 treatments did not enhance anxiety. 
For total distance traveled in the open field task (Figure 4-3, C), Veh–treated Ts65Dn mice 
exhibited significant elevations in spontaneous behavior relative to the Veh-treated NS 
mice (p < 0.0001). RvE1 treatment significantly decreased overall locomotion in the 
Ts65Dn (p = 0.009) suggesting that of the hyperactivity observed in Ts65Dn mice can be 
at least partially corrected by this SPM therapy.  
 





Figure 4-3. Locomotor Behavior. (A) Rotorod movements were equivalent between 
all cohorts. (B) RvE1 treatment had no effect on center time for NS or Ts65Dn mice. 
(C) Ts65Dn mice show significant elevations in hyperactivity, which was normalized 
by RvE1 treatment. Error bars represent average ± SEM.  
 




RvE1-mediated NORT Performance  
I next evaluated if chronic RvE1 therapy could impact NORT performance in NS 
or Ts65Dn mice (Figure 4-4). Each analysis was performed independently at 90 minutes 
(short-term memory) and at 24 hr (long-term memory) when novel objects were 
introduced. I observed no significant differences in total exploration time at either interval 
(Figure 4-4, A) for any group, suggesting that the treatment did not affect their natural 
exploratory drive. For all comparisons, I performed two-way ANOVAs to test for 
differences between groups (karyotype x treatment). At the 90 minute interval (Figure 4-
4, B-left), the main statistical effect was attributable to karyotype 18% of all variation (F1,28 
= 16.27, p = 0.0004), to treatment with 26% of all variation (F1,28 = 23.44, p < 0.0001) with 
an interaction effect equaling 24% of all variation (F1,28 = 21.24, p < 0.0001) since RvE1 
treatment only affected Ts65Dn performance. Tukey’s post hoc analysis revealed that the 
mean discrimination index was significantly less in vehicle-treated Ts65Dn mice compared 
to NS mice (p < 0.0001). Importantly, the RvE1 treatment per se did not appear to exert 
any behavioral effects on NS mice. Finally, RvE1 treatment significantly increased 
performance for the Ts65Dn mice (p < 0.001) to novel object discrimination levels 
observed in age-matched NS mice 
 
At the 24 hour interval (Figure 4-4, B-right), the main effect was attributable to 
karyotype equaling 27% of all variation (F1,27 = 26.93, p < 0.0001), to treatment with 28% 
of all variation (F1,27 = 28.20, p < 0.0001) with an interaction effect equaling 14% of all 
variation (F1,27 = 13.84, p = 0.0009) since RvE1 treatment only exerted effects on Ts65Dn 
 




Figure 4-4. NORT Behavior. (A) Mice explored objects robustly in all trials. RvE1 
treatment had no significant effect on amount of time Ns and Ts65Dn mice spent 
exploring the objects at both the 90 minute and 24 hour interval. (B) RvE1 treatment 
had no effect on NS mice in the NORT task. Ts65Dn mice display sever deficits 
which are normalized by RvE1 treatment at both intervals. Error bars represent 
average ± SEM.  
 




mice. Tukey’s post hoc analysis revealed that the mean discrimination index was 
significantly less in vehicle-treated Ts65Dn mice compared to NS mice (p < 0.0001). 
Again, RvE1 treatment significantly increased performance for the Ts65Dn mice (p < 
0.001) equivalent to NS ability at this time interval in the NORT. Collectively, these 
findings suggest that RvE1-treatment significantly improves performance in this working 
memory task, both at shorter and longer inter-trial intervals, specifically in 8 month old 
Ts65Dn male mice. Age-matched NS control mice with RvE1 treatment exhibited close to 
identical behavioral performance compared to Vehicle-treated NS mice, strongly 
suggesting that optimal performance cannot be further improved under this paradigm. The 
main conclusion from this task is that the chronic RvE1 treatment profoundly enhanced 
familiarity memory in the Ts65Dn mice by an unknown mechanism. 
 
RvE1-mediated WRAM Performance 
To assess spatial reference memory, I performed a three day WRAM (see Chapter 
2) and recorded errors to find the hidden platform (Figure 4-5). Since normal mice steadily 
improve performance in this task over three days, I expected significant effects in task 
perfection. I performed a repeated measures two-way ANOVA (Treatment x Trail Day) on 
total errors as the dependent variable. I found that the main effect was shared between task 
perfection which equaled 30% of all variation (F2,58 = 68.71, p < 0.0001), and treatment 
which contributed 31% of all variation (F3,29= 11.7, p < 0.0001). Altogether, the perfection 
of the task over days was impacted by RvE1 treatment in the Ts65Dn group only. Tukey’s 
post hoc analysis revealed that Ts65Dn mice made significantly more errors than NS 
 




groups on all three days (Day1, p = 0.006; Day 2, p = 0.004; Day 3, p = 0.001). RvE1-
treated Ts65Dn mice showed a significant decrease in errors on the last two days (Day 2, 
p = 0.008; Day 3, p = 0.001). Collectively, these findings suggest that RvE1-treatment 
significantly improves performance in this spatial reference memory task, specifically in 8 
month old Ts65Dn male mice. Age-matched NS control mice with RvE1 treatment 
exhibited close to identical behavioral performance compared to vehicle-treated NS mice, 
suggesting that optimal performance in this task cannot be further improved under this 
experimental paradigm.  
 
 
Figure 4-5. WRAM Behavior. NS mice perfected performance over the 3-day task. 
RvE1 treatment had no significant effect on amount of errors NS made each day. 
Ts65Dn mice display significantly more errors and less task perfection. Chronic RvE1 
treatment normalized Ts65Dn performance that that observed in NS mice. Error bars 
represent average ± SEM.  
 




RvE1-mediated WRAM Reversal Learning  
After 3 days of spatial learning, mice were subjected to a new platform location to 
test perseverance to the original platform location (more perseverance equals less cognitive 
flexibility) and errors (a test of flexible ability to switch to a new platform. I expected NS 
mice to display low perseverance and few errors upon finishing this new task due to rapid 
perfection of the task after practice. After platform switching, all groups demonstrated 
perseverance to the original platform in the initial trial block. I performed a two-way 
ANOVA to test for differences between the groups (Treatment x Practice) in order to assess 
reversal learning aspects when the LC-NE is inhibited (Figure 4-6, A). As expected, 
practice had the greatest overall effect in this test (F1,20 = 55.1, p < 0.0001). Tukey’s post 
hoc analyses revealed that both NS groups had a significant decrease in perseverance (p < 
0.0001) and the RvE1 treated Ts65Dn mice displayed a significant decrease in 
perseverance (p < 0.0001) relevant to Veh-treated Ts65Dn mice. The Veh-treated Ts65Dn 
group persevered to the original platform location significantly more than the Veh-treated 
NS group (p = 0.002) and the RvE1-treated Ts65Dn group (p = 0.013). Altogether, Ts65Dn 
mice have deficits in reversal learning as assessed by this task. 
 
Since the WRAM task has been practiced over three days, normal mice with strong 
cognitive flexibility should rapidly learn the new target cue after platform switching. All 
mice demonstrated high error rates in finding the new hidden platform in the first trial block 
due to the platform reversal. I performed a two-way ANOVA to test for differences 
between the groups (Treatment x Practice) in order to assess if RvE1-treatment affected 
 




Figure 4-6. WRAM Cognitive Flexibility. (A) After platform switching, all mice 
displayed perseverance choice to the old platform location. NS mice quickly learned 
the new platform location while Veh-treated Ts65Dn mice displayed deficits. RvE1 
nullified this deficit in Ts65Dn mice. (B) All mice made many errors at the start of this 
cognitive flexibility task. At finish, NS made few errors regardless of treatment while 
Veh-treated Ts65Dn mice made significantly more errors. Chronic RvE1 treatment 
normalized Ts65Dn performance to that observed in NS mice. Error bars represent 
average ± SEM.  
 




error rate (Figure 4-6, B). As seen before, practice contributed the largest effect in mice 
making significantly fewer errors at the end of this task (F1,20 = 79.53, p < 0.0001). Since 
RvE1 treatment had a strong effect on the Ts65Dn group only, an interaction effect of 11% 
of total variation was observed (F3,20 = 7.74, p = 0.0013). Tukey’s post hoc analyses 
revealed that both NS groups made significantly fewer errors (p = 0.0002) and the RvE1 
treated Ts65Dn group also had a significant decrease in perseverance (p < 0.0001). By trail 
finish, the vehicle-treated T365Dn group made significantly more errors than the vehicle-
treated NS group (p < 0.0001) and the RvE1-treated Ts65Dn group (p < 0.0001). 
Collectively, these findings suggest that RvE1-treatment significantly improves cognitive 
flexibility, specifically in 8 month old Ts65Dn male mice. Age-matched NS control mice 
with RvE1 treatment exhibited close to identical behavioral performance compared to 
vehicle-treated NS mice, suggesting that optimal performance in this task cannot be further 
improved under this paradigm. A combined comparison of the NOR and WRAM memory 
tasks reveals that the RvE1-treated Ts65Dn mice are much more like the NS groups 
(Figure 4-7). In both performance and in overall standard error, the vehicle-treated Ts65Dn 
group demonstrated greater variance. 
 
4.3.2 RvE1-mediated Responses in the Resolution Proteome 
RvE1 treatment mediates profound improvements in memory and hyperactivity in 
the Ts65Dn mice. I was interested if these effects might be mediated by overall changes or 
response in SPM enzymes, GPCRs that bind RvE1, PPAR-y, and the ERK signaling 
pathway. I performed western blot analysis of all groups with n=8 for each study. For each 
 




Figure 4-7. Compensation in RvE1-Binding GPCRs. (A) ChemR23 was equivalent 
in the Veh-treated NS and Ts65Dn brain. Reduced levels suggested a compensatory 
response to RvE1-treatment in both cohorts (B) BLT was equivalent in the Veh-treated 
NS and Ts65Dn brain. Reduced levels suggested a compensatory response to RvE1-
treatment in both cohorts. Error bars represent average ± SEM.  
 




protein marker, I performed a two-way ANOVA to test for differences between the groups 
(karyotype x treatment). I first assessed overall effect in the brain, and then parsed the 
analyses into three different brain regions (frontal cortex, hippocampus, and parietal 
cortex) in order to ascertain how the treatment affected different regions that have distinct 
importance to memory performance For ChemR23 (Figure 4-7, A), I found that the major 
effect was with Treatment alone which accounted for 33% of total variation (F1,91 = 45.5, 
p < 0.0001). Tukey’s post hoc analyses revealed that RvE1-treatment significantly 
decreased ChemR23 abundance in both NS mice (p = 0.0001) and Ts65Dn mice (p < 
0.0001). RvE1 treatment decreased ChemR23 in all brain regions with p-values reported 
(Figure 4-7, A-lower panels). For BLT1 (Figure 4-7, B), I found that the major effect was 
with Treatment alone equaling 33% of total variation (F1,90 = 32.18, p < 0.0001). Tukey’s 
post hoc analyses revealed that RvE1-treatment significantly decreased BLT1 abundance 
in both NS mice (p = 0.0002) and Ts65Dn mice (p = 0.0028). RvE1 treatment decreased 
ChemR23 in all brain regions with significant p-values reported for frontal cortex and 
hippocampus only (Figure 4-7, B-lower panels).  
 
For PPAR-y (Figure 4-8, A), I found that the major effect was with Treatment 
alone equaling 24% of total variation (F1,89 = 28.16, p < 0.0001). Tukey’s post hoc analyses 
revealed that RvE1-treatment significantly decreased ChemR23 abundance in both NS 
mice (p = 0.0007) and Ts65Dn mice (p = 0.0042). RvE1 treatment decreased PPAR-y in 
all brain regions but were significant only in the hippocampus as seen by the p-values 
reported (Figure 4-8, A-lower panels). Since RvE1 is known to increase phosphorylation 
 




of ERK in vitro, I were interested in testing whether our in vivo therapy might recapitulate 
these findings. I quantified total ERK and phospho (p44/42) ERK and normalized each 
signal the average of the Veh-treated NS group and then took the ratio in order to compare 
relative ERK activation. For this ratio (Figure 4-8, B), I found that the Ts65Dn mice have 
higher levels ERK activation. The major effect was with karyotype equaling 13% of total 
variation (F1,88 = 14.76, p = 0.0002) and with treatment effect equaling 10% of total 
variation (F1,88 = 11.34, p = 0.0011). Tukey’s post hoc analyses revealed that RvE1-
treatment significantly increased ERK activation in both NS and Ts65Dn mice but the 
overall effect was only significant in the latter (p = 0.0039). RvE1 treatment had little effect 
in the parietal cortex while increasing the ratio in frontal cortex and hippocampus. ERK 
activation was significantly increased for RvE1-treated NS and Ts65Dn groups only in the 
frontal cortex when compared to the Vehicle-treated groups as seen by the p-values 
reported (Figure 4-8, B-lower panels). 
 
Ts65Dn mice have been previously observed to have significant loss of Calbindin-
D28 positive neurons in the hippocampus (Lockrow, Boger et al. 2011). I was interested in 
testing whether this 30 day treatment might halt or reverse this hallmark of Ts65Dn 
neurodegeneration. For Calbindin-D28 (Figure 4-8, C), I found that the major effect was 
only with Karyotype alone equaling 23% of total variation (F1,91 = 25.99, p < 0.0001). 
Tukey’s post hoc analyses revealed that Ts65dn mice have significantly less Calbindin-
D28 levels only in hippocampus (p = 0.061) (Figure 4-8, C-lower panels). Over this 
treatment window, RvE1-treatment had no observable effect on the decreased Calbindin-
 




Figure 4-8. Compensation in RvE1-Binding GPCRs. (A) ChemR23 was equivalent 
in the Veh-treated NS and Ts65Dn brain. Reduced levels suggested a compensatory 
response to RvE1-treatment in both cohorts (B) BLT was equivalent in the Veh-treated 
NS and Ts65Dn brain. Reduced levels suggested a compensatory response to RvE1-
treatment in both cohorts. Error bars represent average ± SEM.  
 




Figure 4-9. RvE1 nonresponsive markers. Chronic RvE1 treat had no significant 
effects on (A) Enzymes that convert Ω3 to SPMs (B) A resolution GPCR that does not 
bind RvE1, or in (C) Two different early intermediate synaptic plasticity markers. Error 
bars represent average ± SEM.  
 




D28 relative abundance in Ts65Dn mice.  I next quantified protein levels of two SPM 
enzymes, phospho-5-LOX and 15-LOX (Figure 4-9, A), and found that NS and Ts65Dn 
mice were equivalent for both enzymes and that RvE1 treatment had no overall effects. For 
ALX-FPL2, a GPCR that does not bind RvE1, (Figure 4-10, B), I found that NS and 
Ts65Dn mice were equivalent and that RvE1 treatment had no overall effects. For the 
synaptic plasticity markers, Arc and Synapsin (Figure 4-9, C), I found that NS and Ts65Dn 
mice were equivalent for both markers and that RvE1 treatment had no overall effects. 
Collectively, these findings suggest that RvE1-treatment significantly reduced relevant G-
coupled receptors while having no effect on non-relevant receptors. RvE1-treatment 
significantly reduced PPAR-y and increased the ratio of p-ERK to total ERK. Interestingly, 
different brain regions were affected distinctly for the protein markers that were analyzed. 
This chronic RvE1-treatment was unable to halt or rescue Calbindin-D28 deficits in the 
hippocampi of the 8 month old Ts65Dn male mice.  
 
4.3.3 Immunohistochemistry 
Sustained inflammation in the brain together with microglia activation can lead to 
neuronal damage. A recent study revealed that RvE1 treatment could reduce microglial 
activation in vitro (Rey, Nadjar et al. 2016). I was interested whether this chronic RvE1 
therapy might recapitulate this finding especially in the Ts65Dn mice which have been 
shown to have increased microglial activation in various brain regions (Hunter, Bachman 
et al. 2004). I assessed gross morphology at 100x magnification and found that the overall 
distribution of Iba1+ microglial is equivalent between NS and Ts65Dn mice (Figure 4-10, 
 




Figure 4-10. Iba1 responsive to RvE1 therapy. Veh-treated Ts65Dn mice show 
elevated Iba1 staining with more rounded punctate microglial relative to NS cohorts. 
Chronic RvE1 treatment reversed this aberrant microglial phenotype. 
 




A and C) at 8 months of age. A closer inspection at 600X magnification did reveal sporadic 
swollen, ameboid microglial phenotype with higher Iba1 expression in the hippocampus of 
Ts65Dn mice (Figure 4-10, C white arrows) compared to NS mice. Interestingly, RvE1-
treatment over 30 days reduced the overall occurrence of this microglial phenotype in the 
Ts65Dn mice suggesting that microglial activation may be reduced (Figure 4-10, D).  
 
4.3.4 RvE1-mediated Changes in Many Peripheral Cytokines 
Sustained chronic inflammation is a hallmark feature of Ts65Dn mice in both the 
brain and in the serum (Lockrow, Boger et al. 2011, Lorenzo, Chen et al. 2011, Roberson, 
Kuddo et al. 2012, Hamlett, Boger et al. 2016). Studies have revealed that RvE1 imparts a 
significant decrease in inflammatory cytokines in various model systems (Ishida, Yoshida 
et al. 2010, Flesher, Herbert et al. 2014). Given this support along with the significant 
effects seen with PPAR-y, I sought to test whether this 30-day systemic RvE1 treatment 
might affect overall inflammation in the Ts65Dn mice. I performed a multiplex cytokine 
analysis in all groups. For each cytokine assessed, I performed a two-way ANOVA to test 
for differences between the groups (karyotype x treatment). Overall, I observed significant 
increases in Veh-treated Ts65Dn mice compared to Veh-treated NS mice for many 
cytokines. In all reported cases, RvE1-treatment significantly reduce cytokine abundance 
in the Ts65Dn mice with no observable effect seen in NS mice. Overall effects of cytokines 
are reported as a table in Figure 4-11. Tukey’s post hoc analyses revealed that Ts65dn 
mice have significantly higher cytokine levels for all cytokines listed and these elevations 
were normalized to NS levels with RvE1 treatment, with p-values reported in Figure 4-12. 
 




Figure 4-11. Peripheral Cytokines Overall Effects. Two-way ANOVA analyses for 
nine cytokines that displayed significant effects to chronic RvE1- treatment. 
 




Interestingly, this cytokine panel represents innate immunity (IL-1ɑ, IL-1β, IL-6, IL-12, 
IL-9, TNF-ɑ), adaptive immunity (IL-4, IL 5) and IL10, an anti-inflammatory cytokine.  
 
Figure 4-12. Peripheral cytokine quantification. Two-way ANOVA analyses for 
nine cytokines that displayed significant effects to chronic RvE1- treatment. (A-I) All 
cytokines listed were significantly reduce upon RvE1-treatment in Ts65Dn mice. 
Tukey’s post hoc p-values are reported. Errors bars represent an average ± SEM. 
 





An exacerbated inflammatory response is a feature of DS-AD and also seen in the 
Ts65Dn mouse model (Wilcock and Griffin 2013, Wilcock, Hurban et al. 2015, Head, Lott 
et al. 2016, Iulita, Ower et al. 2016). Chronic neuroinflammation may trigger loss of 
function in cells of the central nervous system and increase the likelihood of 
neurodegeneration and the classical hallmarks of DS-AD (Solana, Pawelec et al. 2006, 
Perry 2010, McGeer and McGeer 2013). Targeted blockade of inflammatory responses 
aggravate the progression of AD and thus raise the question about how to best manipulate 
the immune response to succeed in the management of neurodegenerative disorders (Wyss-
Coray and Mucke 2002, Lucin and Wyss-Coray 2009). The recent realization that 
resolution of inflammation is a highly coordinated and active process controlled by 
endogenous pro-resolving mediators, and that inflammatory cells undergo classical and 
alternative activation, highlight new potential molecular targets to modulate 
neuroinflammation in the brain and elsewhere (Serhan 2007, Serhan, Chiang et al. 2008, 
Gordon and Martinez 2010). Furthermore, the resolution processes are altered in AD 
(Wang X 2015) in that many SPMs are reduced in CSF, and several resolution receptors 
seem to show compensatory elevations.  
 
The Omega-3 FAs, EPA and DHA, seem to have distinct roles in the brain 
particularly as membrane components where DHA is critical. COX-2, 5-LOX, and other 
conversion enzymes act as gateway control points to various SPMs and likely coordinate 
the conversion process with high temporal and spatial precision. In this study, I sought to 
 




bypass this gate by utilizing readily available SPMs to drive the resolution process without 
the confoundings of enzymatic conversion efficiency. The findings presented here were 
the first to demonstrate that chronic administration of the SPM, RvE1, significantly 
reduced hallmark peripheral inflammation, and microglial activation in the Ts65Dn mouse 
model to levels that were equivalent to NS mice. Regarding elevated cytokine expression 
in the blood of Ts65Dn mice, RvE1 significantly reduced these cytokines that are typically 
associated with innate immunity and adaptive immunity and also decreased one anti-
inflammatory cytokine. The exact nature of this effect is presumed to relate to ERK1/2 
signaling or by PPAR-y mechanisms.  
 
RvE1 significantly increased the ratio of p-ERK to total ERK, which recapitulates 
findings in a cardiac model where RvE1 increased Akt, ERK1/2, and endothelial nitric 
oxide synthase phosphorylation (Keyes KT 2010). Similarly, the SPM, LXA4, promotes 
cell survival in murine and human macrophages via activation of the ERK1/2 pathway 
(Prieto, Cuenca et al. 2010). Interestingly, I observed the ERK activation increase to be 
strongest in the frontal cortex followed by hippocampus with little change in the parietal 
cortex. The ERK1/2 proteins are members of the mitogen-activated protein kinase 
superfamily that can mediate cell proliferation (Meloche and Pouyssegur 2007), survival 
or apoptosis (Cagnol and Chambard 2010). In neurons, ERK1/2 phosphorylation mediates 
the effects of BDNF on synaptic plasticity, nuclear signaling, and memory formation 
(Finkbeiner, Tavazoie et al. 1997, Blanquet 2000, Pizzorusso, Ratto et al. 2000), and spine 
growth in CA1 pyramidal neurons of the hippocampus (Alonso, Medina et al. 2004). The 
 




effect is relevant to DS-AD where Aβ is highly produced because sub-chronic injections 
of oligomeric forms of Aβ1-4 into the dorsal hippocampus produces cognitive impairments 
via long-lasting reductions in ERK1/2 phosphorylation. RvE1 acts as an agonist of 
ChemR23 and a partial agonist to BLT1, both proven GPCRs that affect ERK1/2 signaling. 
This interesting balance of GPCR signaling may affect synaptic plasticity. The profound 
improvements in Ts65Dn performance in memory tasks, particularly in cognitive 
flexibility, and the decreases in hyperactivity suggested this, but other factors may also be 
at play. Particularly, PPAR-y also binds RvE1 and upon doing so likely activates and 
translocates to the nucleus to decrease cytokine production. I observed a significant 
decrease in all RvE1 binding receptors and proteins (ChemR23, BLT1, and PPAR-y) upon 
treatment, but with no effect on ALX-FPL2, which does not bind RvE1. Whether PPAR-y 
nuclear translocation was affected by RvE1 treatment remains to be explored. 
 
In order to prevent, or significantly slow down, neuron loss and AD progression for 
individuals with DS, it seems a therapy has to inhibit a plethora of biological dysfunctions 
including; accumulations of Aβ peptide products, especially Aβ42, excessive P-Tau, 
oxidative stress, neurotrophic losses, and neuroinflammation concurrently. The primary 
target of NSAIDs and other therapeutic inhibitors like aspirin, ibuprofen or rofecoxib is 
COX-2, an important enzyme that has broad and multifaceted impacts on inflammatory 
processes. COX-2 is responsible for the generation of inflammatory prostaglandins and 
other prostanoids from arachidonic acid or from endocannabinoids (Ricciotti and 
FitzGerald 2011, Alhouayek and Muccioli 2014). COX-2 metabolites can be further 
 




modified to secondary metabolites that act as ligands to distinct receptors that drive potent 
anti-inflammatory properties. The COX-2 enzyme is coupled to noradrenergic influences 
from the LC. Specifically, COX-2 mRNA expression is highly influenced regulated by NE, 
which provides yet another facet of the LC noradrenergic systems role in regulating 
inflammation. The NE effect was mediated by β-ARs, since only β-AR agonists (and not 
α-AR agonists) produced similar results (Alhouayek and Muccioli 2014). Elevated COX-
2 expression has been described in AD (Hewett, Uliasz et al. 2000, Bazan, Colangelo et al. 
2002) and COX-2 protein levels in the hippocampus of AD patients may correlate with the 
severity of dementia (Ho, Purohit et al. 2001). The intersection of NE and COX-2 reveals 
yet another noradrenergic process that may either promote or inhibit neuroinflammation, 
depending on the balance of signaling mechanisms, bioavailable metabolites and 
downstream secondary metabolite production by other enzymes.  
 
I have observed critical behavioral and molecular evidence pointing to the 
endogenous pro-resolution RvE1 pathway as a potential candidate to reduce 
neuroinflammation in DS-AD and other age-related inflammatory disorders. The present 
study supports further inquiry into SPM supplementation in the DS population especially 
since ChemR23 was recently found also to bind Aβ42. Interestingly, Aβ42 binding led to 
internalization of the Aβ42-ChemR23 complex, suggesting a potential role for Aβ42 
clearance or potentially as a signaling endosome (Peng, Yu et al. 2015). I conclude that 
enhancing RvE1 in the brain may reduce the severity of AD-like neuropathology, decrease 
amyloid plaques, Tau phosphorylation and inflammation, as well as possibly improve 
 




cognitive performance. However, the reductions in ChemR23, BLT1, and PPAR- y protein 
levels in response to chronic RvE1 therapy are hard to ignore. Whether this reduction could 
pose harm to an animal over longer periods needs to be investigated further. 
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Chapter 5. Novel AD Biomarkers in Individuals with Down syndrome 
 
5. Introduction 
Neuropathological biomarkers of AD, including Aβ40 and Aβ42, have been detected 
in brain tissue and cerebrospinal fluid (CSF) decades before the onset of dementia in the 
general population (Blennow and Zetterberg 2015), and in DS (Englund, Anneren et al. 
2007). Performing lumbar punctures (LPs) in those with DS is challenging; thus there is a 
need for the development of reliable blood-based biomarkers for AD in this population. 
Most cell types in the body, including neurons, release small endosomally-derived vesicles, 
known as exosomes (Coleman and Hill 2015, Fiandaca, Kapogiannis et al. 2015). 
Exosomes contain proteins, mRNA and miRNA that reflect their cellular origin and play a 
prominent role in cellular signaling, removal of unwanted proteins, and transfer of cellular 
pathogens to other cells (Coleman and Hill 2015). Because of their small size, secreted 
exosomes diffuse into biological fluids (blood, CSF, and urine) and circulate in interstitial 
space, both in the brain and the periphery (Salido-Guadarrama, Romero-Cordoba et al. 
2014). Neuronal exosomes have unique neuron-specific surface markers, which enable 
targeted examination from circulating biological fluids (Fiandaca, Kapogiannis et al. 2015, 
Goetzl, Boxer et al. 2015, Goetzl, Boxer et al. 2015). 
 
Neuronal exosomes are involved in processing of APP, one of the genes involved in 
AD neuropathology (Haass, Lemere et al. 1995, Rajendran, Honsho et al. 2006, Sharples, 
Vella et al. 2008, Perez-Gonzalez, Gauthier et al. 2012), and they play a crucial role in Aβ 
 




clearance (Yuyama, Sun et al. 2015). Exosomes receive APP from early endosomes after 
cleavage into Aβ peptides, which are then secreted from the cells in exosomes (Yuyama, 
Sun et al. 2015). Neuronal exosomes contain toxic Aβ peptide and P-Tau entities, and 
transmit these to neighboring cells, other brain regions and the circulatory system, 
suggesting that neuronal exosomes can vectorize pathology. Neuronal exosomes that are 
extracted from either plasma or CSF can therefore specifically assess relevant 
neuropathological processes within CNS neurons (Vingtdeux, Sergeant et al. 2012, 
Jaunmuktane, Mead et al. 2015). Other findings indicate that AD biomarkers found in 
neuronal exosomes accurately predict the onset of dementia as early as ten years before 
symptom onset in patients with sporadic AD or FTD (Fiandaca, Kapogiannis et al. 2015, 
Kapogiannis, Boxer et al. 2015). Exosomal biomarkers have not been analyzed in 
individuals with DS. In this part of the study, I originally hypothesized that neuronal 
exosomes obtained from blood in DS would have elevated levels of amyloid-beta (Aβ) 
peptides and P-Tau that could document a preclinical AD phase in the DS population.  
 
Despite intensive investigation in recent years, there is still an incomplete 
understanding of the etiology and pathophysiology of AD and DS-AD. Therefore, the best 
strategies for prevention and treatment are still elusive. Brain-derived neurotrophic factor 
(BDNF) has been explored in dementia risk, and because it is correlated with lifestyle 
factors such as reduced caloric intake (Lee, Seroogy et al. 2002) and increased physical 
activity (Neeper, Gomez-Pinilla et al. 1995, Vaynman, Ying et al. 2003) and is thought to 
be associated with healthy lifestyle and successful aging. BDNF is highly expressed 
 




throughout the central nervous system especially in the hippocampus and cerebral cortex 
(Phillips, Hains et al. 1990, Wetmore, Ernfors et al. 1990), and is important in the survival 
and function of hippocampal and cortical, as well as cholinergic , noradrenergic and 
dopaminergic, neurons (Alderson, Alterman et al. 1990, Ghosh, Carnahan et al. 1994, 
Holm, Rodriguez et al. 2003). In addition, BDNF is critical for synaptic plasticity and 
memory processing in the adult brain (Alonso, Vianna et al. 2002, Bekinschtein, 
Cammarota et al. 2008). In the second portion of Chapter 5, I hypothesized that serum 
BDNF levels would be altered in those with DS relative to controls without DS and that 
exosomal levels of AD biomarkers would be correlated with serum BDNF levels. 
 
5.1 Chapter 5 Specific Aims 
The results presented here are from an international collaboration, including 
investigators from Hospital of Sant Pau in Barcelona (Spain), UCI (Irvine, CA), Barrow 
Neurological Institute and Banner Sun Health Research Institute (Sun City, AZ), the 
Linnaeus University in Sweden, and Medical University of South Carolina (MUSC, 
Charleston, SC). The overall aims were to examine alterations in levels of neuronal 
exosome AD biomarkers in children, young adults, and older adults with DS in comparison 
to age-matched non-DS controls, and also whether AD biomarkers were altered in 
individuals with DS that display dementia. The objectives of this study were: 1) to examine 
if the AD biomarkers, Aβ42, P-T181-Tau, and P-S396-Tau, were altered in neuronal 
exosomes in children, young adults, and older adults with DS in comparison to age-
matched non-DS controls, 2) to determine whether these AD biomarkers were altered in 
 




individuals with DS that display dementia 3) to establish a serum BDNF profile in children, 
young adults, and older adults with DS, 4) to determine whether these AD biomarkers were 
altered in individuals with DS that display dementia and finally 5) to determine if any 
correlations exist between all biomarkers. 
 
5.2 Chapter Specific Methods  
 
5.2.1 Participant Demographics 
All participants gave written consent approved by an IRB or equivalent regulatory 
agency at all of the collaborative institutions. Demographics for exosome and serum BDNF 
analyses are shown in Figure 5-1. 
  
Figure 5-1. Chapter 5 demographics. 
 




5.2.2 Diagnosis of DS Cognitive Status  
The two groups of young controls and young individuals with DS (age 8-35) showed 
no evidence of cognitive decline by caretaker reports (No Cognitive Impairment; NCI, 
Table 1). The adult controls (>35 years) were participants in a healthy aging study at the 
Linnaeus University (Drs. Mohammed and Granholm, Co-PIs) or part of a healthy blood 
donor study at the UCI Institute for Clinical and Translational Science (Dr. Ira Lott). Age-
matched control samples for the young group (<35 years) were obtained from the National 
Institutes of Health (NIH). All control donors were free from chronic medical conditions 
including dementia based on the established neuropsychological assessments (Aprahamian 
I 2011, Lees, Selvarajah et al. 2014).  
 
The participants in the adult DS group (>35 years) were subjected to cognitive testing 
batteries adjusted to DS criteria. A consensus diagnosis of non-cognitively impaired (NCI), 
early symptomatic dementia or fully-symptomatic dementia of Alzheimer’s-type (DS-AD) 
was established based on a neurological and neuropsychological assessment that included 
an adapted neuropsychological battery with multiple cognitive domains. Dementia was 
defined by DSM-IV criteria. The “early symptomatic group” refers to individuals with DS 
that display only mild signs of dementia since MCI has not been formally defined for the 
DS population. Approximately half of the participants who were adults with DS were 
obtained from the Barcelona cohort, and about half were obtained from the UCI cohort, 
with a minority of the samples obtained from the Arizona cohort. Although there is some 
overlap between the cognitive tasks performed at these two sites (see below), the cognitive 
 




batteries used were slightly different. Since the readout of the results of the current study 
was not dependent on cognitive measurements, and not used for correlations or other 
statistical analyses, details of the different batteries are not thoroughly discussed. 
 
In the Barcelona cohort, participants were given a neurological evaluation and 
assessed by a neuropsychologist and performed the following cognitive tests: 1) Kaufman 
Brief Intelligence Test (K-BIT) to assess general intelligence, 2) Down syndrome–Brief 
cognitive exam (MEC-SD) which is a brief cognitive assessment to estimate progression 
of cognitive impairment in people with DS, 3) Neuropsychiatric Inventory (NPI 12 item 
version) to assess dementia-related behavior symptoms, and 4) CAMDEX-DS structured 
informant interview to assess changes in daily living activities, cognition, and behavior 
related to the onset of dementia. During a follow-up neuropsychological assessment visit, 
the following cognitive tasks were administered: 1) CAMCOG-DS, which is a structured 
cognitive assessment which includes neuropsychological domains: orientation, language, 
memory, attention, praxis, abstract thinking and perception, 2) Picture Cancellation task to 
assess attentional processes, 3) Digit Span (forward and backward), to assess attention and 
working memory, 4) Modified Cued Recall Test, to assess episodic memory (short and 
long term memory), adapted for use in people with mild and moderate intellectual 
disability, 5) Cats and Dogs test, to assess executive functioning (inhibition/mental 
flexibility), 6) Ideomotor praxis from the Barcelona Neuropsychological Test Battery, and 
7) Dementia Questionnaire for People with Learning Disabilities (DMR), a screening tool 
which measures cognitive and functional deterioration as a result of dementia.  
 




In the cohort from the University of California at Irvine, participants with DS 
participating at the UCI site completed a neuropsychological test battery annually. The 
battery included both direct and indirect (informant) based measure that assessed several 
cognitive, behavioral and adaptive behavior domains and has been shown to be sensitive 
to dementia-related change in adults with DS. The informant based DMR was in common 
across all sites. At each visit, a study neurologist performed a dementia evaluation 
according to DSM-IV criteria using information gathered directly from the participants as 
well as their informants. The study neurologist performing the examination was blinded to 
the results of the neuropsychological testing. Dementia status of nondemented, possible or 
probable AD dementia was established by the evaluating professionals based on a 
consensus of their expert opinions. 
 
5.2.3 Isolation of Neuronal Exosomes  
Isolation and analysis of neuronal exosome AD biomarkers were performed 
according to Dr. Ed Goetzl’s protocol at the NIH. I had the opportunity to spend time at 
Dr. Goetzl’s laboratory at NIH, where I learned to perform the exosome studies and could 
transfer these techniques to Dr. Granholm’s laboratory (Fiandaca, Kapogiannis et al. 2015). 
(Fiandaca et al., 2015). Briefly, 0.25 mL of plasma was incubated with 0.15 mL 
thromboplastin-D (Fisher Scientific, Inc., Hanover Park, IL) at room temperature for 1 
hour, followed by addition of 0.15 mL Dulbecco’s balanced salt solution (magnesium and 
calcium free, Sigma) containing triple concentration of protease and phosphatase inhibitor 
cocktails (protease inhibitor cocktail, Roche Applied Sciences. Inc., Indianapolis, IN; 
 




phosphatase inhibitor cocktail, Pierce Halt, Thermo Scientific, Inc.). After centrifugation 
(1,500 g, 20 min), the supernates were mixed with 0.126 mL of ExoQuick exosome 
precipitation solution (System Bioscience, Mountainview, CA) and incubated at 4o C for 
one hour to precipitate exosomes. The exosome suspensions were again centrifuged at 
1,500 g for 30 minutes (4o C) and resuspended in 0.25 mL ddH2O with triple concentration 
inhibitor cocktail, as described for immune cell exosomes (Kapiogannis et al., 2014). Each 
sample received 0.05 mL of 3% bovine serum albumin (BSA, 1:3.33 dilution of Blocker 
BSA 10% solution in DBS (Thermo Scientific Inc.). To isolate neuronal exosomes, the 
samples were then incubated for 1 hour with 1 microgram mouse anti-human CD171 (clone 
5G3, L1CAM, eBioscience, San Diego, CA). Then 0.01 mL of Streptavidin-Plus Ultralink 
agarose resin (Thermo Scientific, Inc.) biotinylated with the EZ-Link sulfo-NHS-biotin 
system (Thermo Scientific Inc.) plus 0.04 mL of 3% BSA was added to the exosome 
suspension and incubated at room temperature for 1 hour. The immuno-absorbed samples 
were then centrifuged at 200 g at 4o C for 10 min followed by removal of supernates and 
each resin pellet was suspended in 0.1 mL of 0.05M glycine-HCl (pH 3.0) by vortexing 
(10 sec), incubated at room temperature for 5 min and then centrifuged at 4,000 g at 4o C 
for 10 min. The resultant supernates were transferred to a clean tube and then received 0.01 
mL of 1M Tris-HCl (pH 8.0), 0.025 mL of 3% BSA and 0.365 mL M-PER mammalian 
protein extraction reagent (Thermo-Fisher, Inc.) with triple concentration inhibitor 
cocktails followed by vortex-mixing. Samples were stored at -80o C prior to enzyme-linked 
immunosorbent assays (ELISAs) for AD biomarkers. The yield of neuronal exosome from 
blood samples has been demonstrated previously (Kapiogannis et al., 2014). 
 




Neuronal exosomes have unique neuron-specific surface markers, which enable 
targeted examination from circulating biological fluids (Fiandaca, Kapogiannis et al. 2015, 
Goetzl, Boxer et al. 2015, Goetzl, Boxer et al. 2015). Specifically, L1-CAM (also called 
CD171), is highly expressed on the neuron surface in all brain regions allowing for 
enrichment neuron-derived exosomes. L1-CAM is also expressed in renal collecting ducts, 
vascular endothelial cells, and dendritic reticulum cells (Allory, Audard et al. 2008, Vella, 
Hill et al. 2016) but overall protein abundance is comparatively low when compared to the 
brain. In comparison, scaling L1-CAM expression by organ volume and expression levels 
reveals that the brain has at least 20 fold higher total expression compared to other tissues 
analyzed (Soria, Pampliega et al. 2017). It is important to note that many carcinomas have 
an abnormally high expression of L1-CAM. Thus neuronal targeting may be limited in 
patients with cancer (Inaguma, Wang et al. 2016). Taken together, L1-CAM is a relatively 
stringent, surface protein that allows predominant immuno-enrichment of neuronal 
exosomes for biomarker studies. 
 
After L1-CAM immuno-extraction of neuronal exosomes, size parameters were 
quantified by nanoparticle tracking analysis (NTA) (Malvern, Salsbury, UK), and revealed 
an average vesicle size distribution. NTA is a method for visualizing and analyzing 
particles in liquids that determines particle size to the rate of Brownian motion. The rate of 
movement is related only to the viscosity and temperature of the liquid and is not influenced 
by particle density or refractive index. The technique is used in conjunction with a 
microscope and a specialized illumination unit that together allow small particles, 
 




approximately 10-1000 nanometers, in liquid suspension to be visualized. Computer 
software captures the rate of particle movement and then calculates a sphere hydrodynamic 
radius based on the Stokes–Einstein equation. The technique calculates particle size on a 
particle-by particle basis, overcoming inherent weaknesses in ensemble techniques such as 
dynamic light scattering (Filipe, Hawe et al. 2010). NTA was conducted for a selection of 
neuron exosome isolations to ensure repeatability of technique. 
 
5.2.4 ELISA Analyses of Neuronal Exosome Biomarkers 
Neuronal exosome proteins were quantified using standard ELISA kits for Aβ42, 
human P-S396-Tau (Life Technologies/Invitrogen, Camarillo, CA), human P-T181-Tau 
(Innogenetics Division of Fujirebio US, Inc., Alpharetta, GA), and the tetra-spanning 
exosomal marker, human CD81 (American Research Products-Cusabio, Waltham, MA). 
The CD81 antigen standard curve was validated using human purified recombinant CD81 
antigen (Origene Technologies, Inc., Rockville, MD). The mean value of all CD81 levels 
for each 96-well plate was set at 1.00, and a normalization value for each sample was 
calculated from the ratio of its CD81 level to that of the mean for the plate. ELISA values 
for Aβ42, P-T181-Tau, and P-S396-Tau were then adjusted proportionally to CD81. Mean 
levels of one sample set yields levels of that analyte for the same unit mass of exosomes, 
assuming that the CD81 amount per unit mass of exosomes is the same for all subjects. For 
this study, the Granholm lab received 38 samples in the form of serum aliquots and 46 in 
the form of plasma aliquots, evenly divided between the different groups examined herein.  
 
 




5.2.5 ELISA Analyses of Serum BDNF Biomarkers 
Serum total BDNF protein was quantified using standard the Quantikine ELISA kit 
for total BDNF (R&D Systems, Minneapolis, MN). Microtiter plate wells were coated with 
100 µl of the primary antibody, at a concentration of 1-10 µg/ml in coating buffer. The 
plate and incubate overnight at 4°C and then washed 3 times with wash buffer. Blocking 
solution was added to each well and incubated for 60 minutes at 37°C following by washing 
4 times with wash buffer. Blood samples were diluted, and 100 µl of diluted samples and 
standards were added to individual wells in triplicate. Samples were incubated for 90 
minutes at 37°C and then washed 3 times with wash buffer. Diluted enzyme-conjugated 
detection antibody was added to each well and incubate for 1 hour at 37°C followed by 
washing 3 times with wash buffer. The reactive substrate solution was added to each well 
and incubated at room temperature in the dark for 30 minutes, followed by addition of stop 
solution. Absorbance was read on a 96-well plate reader after thorough mixing. Details 
about ELISA quantification kits used in this study are included below. 
  
5.2.6 Statistical Analyses 
For exosome population tests, I first examined population differences in AD 
markers between the control non-DS group and cases with DS. Grubb’s method was used 
 




to check for outliers in each neuronal exosome biomarker which resulted in 2 out of 84 
values excluded from the Aβ42 and P-S396-Tau data sets. D’Agostino-Pearson normality 
tests were performed on control non-DS and DS groups for each neuronal exosome 
biomarker to test suitability for subsequent parametric analyses. Linear regression analyses 
were performed for each neuronal exosome biomarker over age to assess potential age 
effects. Pearson correlation analyses were performed to determine whether age affected 
group differences in terms of the neuronal exosome AD biomarkers. 
 
The incidence of AD is known to be higher in individuals with DS after the age of 
35 (Hartley, Blumenthal et al. 2014). For exosome grouped tests, the total population was 
subdivided at the age of 35 in order to determine differences between age (younger: < 35 
years, older: >35 years), DS (control-DS) and for interaction effects. A two-way ANOVA 
examined the interaction between dependent variables, age x DS, for each biomarker, 
followed by Tukey’s post hoc test for multiple comparisons. Student’s t-tests were used to 
test for significant differences between genders within each group for each neuronal 
exosome biomarker. The older adult DS group (>35 years) consisted of all individuals with 
DS, independent of dementia status. This group was subdivided into two groups 1) NCI , 
and 2) those with early or with fully symptomatic dementia. Student’s t-tests were used to 
test for significant differences between these groups for each neuronal exosome biomarker. 
All statistical analyses were performed with GraphPad Prism 6 (GraphPad Software, Inc., 
La Jolla, CA) with alpha set at 0.05. 
 
 




For Serum BDNF studies, I observed a bimodal relationship in BDNF levels over 
cross-sections of age. I subdivided the data into two groups from ages 4-19 and ages >20. 
I performed linear regression analyses over these age groups to assess the intersection and 
slope differences. In adults over 40 years of age, I performed one-way ANOVA to test for 
significant differences in BDNF levels between Controls, those with DS without cognitive 




5.3.1 Neuronal Exosome Secretion is Elevated in DS 
Several studies have shown that classical markers of exosomes, such as CD63 and 
CD81, are tetraspanning membrane proteins that are enriched in exosomes (Booth, Fang et 
al. 2006, Raposo and Stoorvogel 2013) and thus provide an effective marker of total 
exosome isolation that can also use in normalization of subsequent analyses of other 
biomarkers. As mentioned earlier, the expulsion of toxic proteins may be one function of 
exosomes. In the context of DS, where toxic Aβ peptides and aberrant P-Tau proteins are 
significantly elevated in neurons, one would postulate that exosomes may be recruited to 
enhance expulsion.  In our recent study, which was a collaboration between several DS 
clinics both in the US and abroad, we hypothesized that neuron-derived exosomes might 
be more abundantly represented in those with DS relative to an age-match control 
population without DS. To test this hypothesis, we isolated neuron-derived exosomes as 
previously described (Hamlett, Goetzl et al. 2016) and quantified CD81 by enzyme-linked 
 




immunosorbent assay (ELISA) (Cusabio, Waltham, MA) against a standard curve of 
recombinant CD81 (Origene Technologies, Rockville, MD) (Figure 5-2). The cohorts 
included a population of participants with DS (8-62 years old) compared to levels found in 
neuron-derived exosomes obtained from plasma of control participants (8-77 years old), 
and both populations were age and gender matched.  
 
 We quantified the size of neuron-derived exosomes by nanoparticle tracking 
analysis (Malvern, Salsbury, UK), and revealed an average vesicle size distribution at 
117nm (Figure 5-2, A) for multiple exosome preparations. We quantified the levels of 
CD81 expression in both populations (Figure 5-2, B) and found that individuals with DS 
have a 39% higher average level (1433 ± 87 pg/ml) of this exosomal normalization marker 
relative to controls (1027 ± 87pg/ml), and a student’s t-test revealed the difference was 
significant (p = 0.002). We further divided the control and DS groups into two age 
categories, below 35 and above 35 years old (Figure 5-2, C). A two-way ANOVA 
(Karyotype x Age) revealed that only having DS was the primary driver of CD81 levels 
with no significant effects found for age. Tukey’s posthoc adjusted comparisons revealed 
significantly increased CD81 levels for individuals with DS, for both in the young (p = 
0.05) and older DS groups (p = 0.04) compared to age-matched controls. These findings 
demonstrated that neuron-derived exosomes are more abundant in blood samples acquired 
from those with DS. This result is interesting, as similar observations have been made in 
vitro with DS cell cultures (Skogberg, Lundberg et al. 2014) and in vivo with the Ts2Cje 
mouse models of DS (Perez-Gonzalez and Levy 2016).  
 





Figure 5-2. CD81 exosome marker levels are elevated in people with DS. (A) Our 
neuronal exosome isolation technology captures L1CAM+ exosomes that have an 
average size diameter of 117nm.  Grey shading represents ± SEM from several exosome 
isolations. (B) CD81 quantification reveals that the DS cohort has over 39% more 
circulating neuronal exosomes than age-matched controls. (C) Two-way ANOVA of 
younger (<35) and older (>35) revealed that only having DS had significant effect on 
neuronal exosome secretion levels, and no age effects were observed. Error bars 
represent an average ± SEM. 
 




5.3.2 Effects of DS and Age on AD Biomarkers 
Three neuronal exosome biomarkers, Aβ42, P-T181-Tau, and P-S396-Tau, were 
significantly elevated in the DS population relative to the control population (Figure 5-3, 
A-C); Student’s t-test, p < 0.0001 for each biomarker; n = 37 for control non-DS, and n= 
47 for DS participants).  
 
Figure 5-3. Overall neuronal exosome AD biomarkers in control and DS 
populations. (A) Aβ42: participants with DS exhibited significantly elevated levels (p 
< 0.0001) compared to age-matched control participants. (B) P-T181-Tau: participants 
with DS exhibited significantly elevated levels (p < 0.0001) compared to age-matched 
controls. (C) P-S396-Tau: participants with DS exhibited significantly elevated levels 
(p < 0.0001) compared to age-matched controls. Error bars represent ± SEM. N = 37 
for non-DS control participants, and N=47 for participants with DS. 
 




I further divided the control and DS groups into two age categories, below 35 and 
above 35 years old (high AD incidence), and performed a two-way ANOVA to test for 
interaction. For all three neuronal exosome biomarkers, there was a highly significant 
effect of having DS, no age effect and no significant interaction found. For Aβ42 levels 
(Figure 5-4, A; F1,78 = 44.46, p < 0.0001), Tukey’s post hoc analyses revealed significant 
elevations in young DS (p = 0.024) and older DS groups (p < 0.0001) compared to age-
matched controls. Analysis revealed that 29.5% of total variation was attributed to DS 
alone due to over 2.5-fold expression differences. For P-T181-Tau levels (Figure 5-4, B; 
F1,80 = 64.53, p < 0.0001), Tukey’s post hoc analyses revealed significant elevations in 
young and older DS groups (both p < 0.0001) compared to age-matched controls Analysis 
revealed that 36.4% of total variation was attributed to DS alone due to greater than 2-fold 
expression differences. For P-S396-Tau levels (Figure 5-4, C; F1,78 = 50.76, p < 0.0001), 
Tukey’s post hoc analyses revealed significant elevations in both young (p = 0.002) and 
older DS groups (p < 0.0001), compared to age-matched controls. Analysis revealed that 
33.7% of total variation was attributed to DS alone due to over 2-fold expression 
differences. These findings demonstrated that these neuronal exosome markers were all 
significantly elevated in those with DS compared to age-matched controls regardless of 
age category.  
 
A linear regression analysis of each neuronal exosome biomarker across age was 
performed to determine whether there were significant age-related trends in the DS group 
or the age-matched control group (Figure 5-5). 
 





Figure 5-4. Group differences in AD biomarkers in neuronal exosomes isolated 
from blood of individuals with and without DS of different ages. Age was divided 
into those below 35 years of age vs. those above 35 years of age. Note that both young 
and older individuals with DS exhibited significantly increased levels of all three AD 
biomarkers, compared to age-matched controls. (A) Aβ42: younger participants with 
DS exhibited significantly elevated levels (p = 0.024) compared to age-matched 
controls. Older participants with DS exhibited significantly elevated levels compared 
to age-matched controls (p < 0.0001). (B) P-T181-Tau: younger participants with DS 
exhibited significantly elevated levels (p = 0.001) compared to age-matched controls. 
Older participants with DS exhibited significantly elevated levels compared to age-
matched controls (p < 0.0001). (C) P-S396-Tau: younger participants with DS 
exhibited significantly elevated levels (p = 0.002) compared to age-matched controls. 
Older participants with DS exhibited significantly elevated levels compared to age-
matched controls (p < 0.0001). Error bars represent ± SEM. 
 





Aβ24 levels were 210% greater (Figure 5-5, A; F1,79 = 67.71, p < 0.0001) in the DS (mean: 
6.74 ± 1.71) compared to the control (mean: 2.17 ± 0.61) group. However, there was no 
association between age and Aβ42 levels for the non-DS control group (p = 0.729) or the 
DS group (p = 0.454), indicating no significant age effects on Aβ42 levels, even when all 
Figure 5-5. Effects of age on AD biomarkers in neuronal exosomes isolated from 
blood samples of individuals with and without DS. No age effects were observed for 
either Aβ42, P-T181-Tau or P-S396-Tau. (A) Aβ42: There was no significant effect of 
age on Aβ42 levels in the DS group. The y-intercepts for DS group and non-DS control 
group were significantly different (p < 0.0001). Age-matched control participants did 
not exhibit any main effects of age. (B-C) P-T181-Tau and P-S396-Tau: No age effects 
were observed for either P-T181-Tau or P-S396-Tau. However, the y-intercepts for both 
P-T181-Tau and P-S396-Tau were significantly different (p < 0.0001) between the DS 
group and age-matched control group. Dotted lines represent the 95% confidence band 
of the best fit line. 
 




DS groups were included in the analysis. I observed a significant doubling of P-T181-Tau 
levels (Figure 5-5, B; F1,81 = 98.16, p < 0.0001) for DS (mean: 146.3 ± 27.73) relative to 
the non-DS control group (mean: 71.92 ± 13.40). The slope of P-T181-Tau levels was also 
not significantly different from zero for either group: non-DS control (p = 0.861) and DS 
(p = 0.076). Similarly, the levels of P-S396-Tau were 76% greater (Figure 5-5, C; F1,79 = 
69.61, p < 0.0001) for the DS group (mean: 22.87 ± 4.09) relative to the non-DS control 
group (mean: 12.95 ± 1.68). Similarly, the slope of P-S396-Tau was not significantly 
different from zero for either group: non-DS control (p = 0.069) and DS (p = 0.962). All 
three neuronal exosome biomarker had at least a 2-fold elevation in levels for participants 
with DS regardless of age or dementia diagnosis. 
 
Pearson correlation analyses revealed that Aβ42 levels were significantly correlated 
with P-S396-Tau (r = 0.438, p = 0.008) and a trend for P-T181-Tau and P-S396-Tau (r = 
0.316, p = 0.059) in the non-DS control group. Based on this analysis, Aβ42 significantly 
correlated with P-T181-Tau (r = 0.261, p = 0.022) and P-T181-Tau significantly correlated 
with P-S396-Tau (r = 0.32, p = 0.029) in the DS group Figure 5-6. 
 
Figure 5-6. Pearson correlations of AD biomarkers in neuronal exosomes and Age.  
 




5.3.3 Gender Effects on AD Biomarkers 
Student’s t tests revealed no significant difference (p > 0.10) between male and 
female participants for the Aβ42 or the P-S396-Tau levels, but showed a significant gender 
effect for the P-T181-Tau levels only in the older controls (p = 0.05) and the older DS 
group (p = 0.02) (Figure 5-7). Since there was no gender effect on P-T181-Tau levels for 
any young groups, I excluded gender from further analyses and focused on dementia-
related effects within the DS participants. 
 
5.3.4 Effects of Dementia Status in Aged DS Subjects 
I further divided the adult DS group into two categories: 1) those with NCI and 2) 
those with early or fully symptomatic dementia indicative of DS-AD Figure 5-8. Aβ42 
levels were significantly decreased (p = 0.048) in adults with DS and dementia symptoms, 
relative to those with no apparent dementia (Figure 5-8, A). P-T181-Tau levels were not 
significantly different between the two groups (Figure 5-8, B). By contrast, P-S396-Tau 
levels were significantly elevated (Student’s t-test, p = 0.008) in participants with early or 
fully symptomatic dementia compared to those with DS and no dementia (Figure 5-8, C). 
Figure 5-7. Student’s t tests of AD biomarkers in neuronal exosomes by Gender.  
 




Altogether, these data suggest that neuronal exosome levels of Aβ42 and P-Tau follow 
different trajectories in adults with DS who exhibit symptoms of dementia. 
 
Figure 5-8. Neuronal exosome levels by clinical diagnosis (A) Aβ42: Student’s t test 
revealed a significant decrease in Aβ42 levels for adults with early symptomatic or fully 
symptomatic dementia compared to no apparent dementia subgroup (p = 0.048). (B) P-
T181-Tau: There was no significant overall effect between the two groups. (C) P-S396-
Tau: Student’s t test revealed a significant increase for DS adults diagnosed with early 
or fully symptomatic dementia relative to DS adults with no apparent dementia. Error 
bars represent ± SEM. 
 




5.3.5 Serum BDNF Levels in DS Subjects 
I further assessed serum BDNF levels from the three adult DS groups: 1) those not 
cognitively impaired, NCI 2) those with early symptomatic dementia, MCI and 3) those 
with fully symptomatic dementia, DS-AD and from a control population without DS or 
cognitive impairments (Figure 5-9, B). I performed a one-way ANOVA to test whether 
there are significant changes between the groups and found that both DS-NCI and DS-AD 
have significant elevations of serum BDNF relative to a control population based on 
Tukey’s post hoc multiplicity adjusted values (p = 0.003 and p = 0.001) respectively. All 
DS groups had 30% or greater average serum BDNF levels relative to the control 
population. Counterintuitively, cognitive impairment seems to further elevate BDNF 
measures (DS-NCI: 30% increase, DS-MCI: 35% increase, DS-AD 65% increase) 
although this effect may be related to age given the relationship of BDNF and AD. 
 
5.3.6 Correlation of BDNF Levels to Neuron-derived Exosome Biomarkers in DS  
Within the two biomarkers studies, there were a total of 31 patient samples with DS 
that were commonly analyzed. I perform a linear regression analysis of each neuronal 
exosome biomarker plotted against corresponding BDNF level (in x-axis) to determine 
whether there were significant trends in the DS group. The was no correlation between 
neuronal exosome levels of Aβ42 or P-Tau and circulating BDNF levels  
 






In this Chapter, I reported Aβ42 and P-Tau levels from neuronal exosomes isolated 
from blood samples in individuals with DS, as a function of age and dementia status. The 
manuscript was published in 2016 (Hamlett et al., 2016), and I was the first author. The 
findings show a marked increase in AD biomarker levels in individuals with DS as early 
as 8 years of age. Extrapolation of the linear regressions suggests that these abnormal 
neuronal exosome biomarker levels may be elevated already at birth in DS, but further 
Figure 5-9. Serum BDNF levels in the DS population. (A) Circulating BDNF levels 
show a positive increase of age until around 20 years, then decreased steadily well into 
60 years of age. The slopes and y-intercepts for both periods were significantly different 
(p < 0.0001) between the younger and older DS group. Dotted lines represent the 95% 
confidence band of the best fit line. (B) Although those with DS show a trend to have 
more circulating BDNF in serum, one way ANOVA revealed that there are no 
significant differences between the groups. Error bars represent an average ± SEM.  
 




studies are needed to confirm this hypothesis. DS adults diagnosed with dementia exhibited 
lower Aβ42, and higher P-S396-Tau levels compared to non-cognitively impaired adults 
with DS. This reveals that different AD biomarkers follow different trajectories in 
exosomes as a consequence of the AD process. I found that circulating BDNF levels 
increase steadily in the DS population until the age of 20 and then begin to decrease. There 
was no significant difference in circulating BDNF levels between controls or individuals 
with DS regardless of cognitive status, but I did see strong correlations with neuronal 
exosome P-Tau levels, where increases in BDNF resulted in a decrease in total P-Tau. 
  
It is not surprising that Aβ42 levels were elevated early in DS because the APP gene 
is located on chromosome 21 (Hartley, Handen et al. 2014, Wiseman, Al-Janabi et al. 
2015), and previous studies have shown elevations of toxic amyloid peptides in the plasma 
of young adults with DS (Hoyo, Xicota et al. 2015). A recent positron emission tomography 
(PET) imaging study, using the beta-amyloid, plaque-specific Pittsburgh compound-B 
(PIB), showed an accumulation of Aβ in DS, but only in those >35 years of age (Annus, 
Wilson et al. 2015). In contrast, others have shown that levels of Aβ42 in plasma were 
lower in individuals with DS diagnosed with dementia compared to subjects with DS but 
no dementia (Schupf, Zigman et al. 2010). Diffuse amyloid plaques have been described 
as early as age 15 in postmortem brain samples from people with DS (Mann, Yates et al. 
1984, Lemere, Grenfell et al. 1999). Increased levels of Aβ42 have also been reported in 
the CSF of adults with DS (Wisniewski, Wisniewski et al. 1985, Hartley, Blumenthal et al. 
2014, Mondragon-Rodriguez, Perry et al. 2014) and in children with DS (Englund, 
 




Anneren et al. 2007). Interestingly, findings from the Dominantly Inherited Alzheimer 
Network (DIAN), an international registry of individuals at risk for developing autosomal 
dominant AD, suggest that early biomarkers predict onset and trajectory of dementia in 
vulnerable populations (Moulder, Snider et al. 2013). The DIAN studies showed early high 
levels of AD biomarkers in the CSF, followed by reduced Aβ levels in CSF, demonstrating 
that early blood or CSF biomarkers can be used to mark the onset of AD, where PET 
imaging might only capture changes in the brain after pathological processes have already 
been activated. The sensitivity discrepancy between PET imaging versus plasma and CSF 
studies may reflect PIB binding affinity preferences to protein-lipid components (Matveev, 
Spielmann et al. 2014) or PIB tracer signal strength.  
 
Since the Tau gene is not known to be affected by the trisomy, it is more surprising 
that the P-Tau levels, including both phosphorylation loci studied here, are elevated early 
in DS. Phosphorylation of Tau protein at the carboxyl terminus has been shown to be one 
of the earliest pathological events in both AD and in DS-AD (Mondragon-Rodriguez, Perry 
et al. 2014), and may occur prior to accumulation of brain fibrillary P-Tau. Here, I found 
that neuronal exosome levels of both P-T181-Tau and P-S396-Tau were significantly 
increased in younger individuals with DS compared to age-matched controls and that this 
hyperphosphorylation profile persisted into late adulthood when DS co-occurred with AD 
dementia. The highest levels of exosomal P-S396-Tau were found in cases diagnosed with 
dementia, suggesting that P-Tau continues to accumulate in exosomes as AD pathology 
progresses. The data here support previous P-Tau observations regarding AD-related 
 




progression in adults with DS but also suggest that significant elevations occur, at least in 
neuronal exosomes, as early as 8 years of age in children with DS. In view of our novel P-
Tau findings, future studies targeting earlier age ranges in DS should be undertaken to gain 
insight into the early neuropathological processes associated with DS. The data reported 
here may also bolster new in vivo imaging studies, using novel P-Tau radioligands (Dani, 
Edison et al. 2016). The biological mechanisms driving the elevated P-Tau levels early in 
those with DS remain unknown. 
 
Alternative mechanisms for Tau dysregulation can be found in several genes involved 
in the trisomy. For example, SOD1 is located on the triplicated segment of Chr. 21, and is 
involved in oxidative stress which exacerbates AD pathology in the DS brain (Schupf, Lee 
et al. 2015). In addition, hyperphosphorylation of Tau can be influenced by dysregulation 
of alternative splicing of Tau reported in DS as well as in AD (Ginsberg, Che et al. 2006) 
and may underlie the abnormal hyperphosphorylation of Tau (Iqbal, Gong et al. 2013). 
Furthermore, two genes located on Chromosome 21, the Dual-specificity tyrosine 
phosphorylation-regulated kinase 1A (DYRK1A) gene, and regulator of calcineurin 1 
(RCAN1), are highly expressed in the DS brain (Ferrer, Barrachina et al. 2005, Harris, 
Ermak et al. 2007, Kimura, Kamino et al. 2007), and have been implicated in the 
dysregulation of Tau phosphorylation associated with early onset AD in DS. Interestingly, 
Dyrk1A-mediated phosphorylation of RCAN1 induces a targeted phosphorylation cascade 
that leads to Tau phosphorylation (Jung, Park et al. 2011). Taken together, dysregulation 
of these genes suggests a novel set of molecular mechanisms underlying the increase in 
 




Aβ42, P-S396-Tau, and P-T181-Tau that I observed in neuronal exosomes isolated from 
children with DS which will be further explored in continued studies.  
 
Here I discovered that serum BDNF levels in the DS population follow a unique 
trajectory over age when compared to the biomarkers found in neuronal exosomes. Higher 
serum BDNF levels may protect against the future occurrence of dementia and AD so as 
BDNF levels drop (after the age of 20) those with DS may lose these protective properties. 
Previous findings suggest a role for BDNF in the biology and possibly in the prevention of 
dementia and AD (Weinstein, Beiser et al. 2014). I observed a strong correlation between 
serum BDNF and only P-Tau cargos in neuronal exosomes and a manner that higher BDNF 
levels significantly decreased P-Tau. While the exact interface behind this mechanism is 
unknown, BDNF is known to induce a rapid dephosphorylation of tau protein through a 
PI-3Kinase signaling mechanism (Elliott, Atlas et al. 2005) which speaks to the 
connections of BDNF and tauopathy. These findings may suggest that BDNF may protect 
against the inappropriate spread of P-Tau species in neuronal exosomes, which could be a 
therapeutic target. Given that increases in toxic Aβ42 peptides impairs vesicular sorting 
and increase exosome biogenesis (Almeida, Takahashi et al. 2006), BDNF levels may 
afford more protection to with DS. I did notice a slight trend for BDNF increases in those 
with DS, with slightly higher BDNF in DS patients that have suffered cognitive decline. 








I reason that neuronal exosome isolated from blood may provide a unique insight into 
BDNF biology as assessed from only brain origins. Further work is needed to test whether 
circulating serum BDNF is equivalent to neuronal exosome BDNF for those with or 
without DS. It is also possible that the isoform of BDNF that I measured using a selective 
commercial ELISA kit represents mostly pro-BDNF and not the mature form (mBDNF). 
Studies in individuals with AD have shown a significant increase in pro-BDNF and a 
reduction in mBDNF (Neto, Borges et al. 2011). Decreased levels of the mature form of 
BDNF in aging has been associated with decreased hippocampal synaptic plasticity, 
neurogenesis, and cognitive ability (Erickson, Miller et al. 2012) and may be reflective of 
the age-related cognitive impairment observed in both NS and TS mice. Further studies are 
also needed to reveal which specific forms of BDNF are present in neuron-derived 
exosomes versus in serum itself. These studies can lead to significant increase in 
knowledge regarding different biological mechanisms involved in DS-AD vs. AD in the 
general population.  
 
In sum, the capacity to quantify Aβ42 and P-Tau in neuronal exosomes from easily 
acquirable blood samples has permitted us to show significant abnormalities in these 
proteins at an early age in individuals with DS. As expected, due to the increase in APP 
gene dosage, Aβ42 levels were increased throughout the lifespan in participants with DS, 
but paradoxically were significantly reduced in those with a clinical diagnosis of dementia. 
Amyloid levels are also reduced in CSF in patients with DS-AD, as well as AD in the 
general population (Blennow 2004, Dekker, Fortea et al. 2017). It is plausible that Aβ42 is 
 




sequestered in the brain with the onset of dementia, as also suggested by previous blood 
levels of this AD biomarker in the DS population. On the other hand, P-S396-Tau and P-
T181-Tau levels were increased early in life, and P-S396-Tau showed a significant further 
increase in dementia suggesting that Tau phosphorylation plays a role in dementia onset 
and progression in DS.  
 
The repeatability of my data suggests that this neuronal exosome approach offers 
several benefits for interrogation of early events in AD pathogenesis in DS. Exosomal 
screening allows insight into the profile of proteins secreted from neurons. This is 
particularly useful when working in the DS community where confounds of intellectual 
disability and functionality make a diagnosis of dementia more difficult. Another 
significant benefit is that outcome measures can be reliably obtained either from serum or 
plasma samples from a consortium of biobanks since data are normalized against the same 
neuronal exosomal marker. Finally, a neuronal exosome approach may prove useful in 
evaluating potential drug targets for early intervention of AD, while enabling reliable 
measures of therapeutic efficacy. Future studies will include comparison studies between 
whole plasma and neuronal exosome amyloid levels, as well as an expanded search for 
other biomarkers in neuronal exosomes that may predict dementia and/or other conditions 










  The work described in Chapter 5 involved an international project exploring novel 
biomarker methods in individuals with Down syndrome across their life span. This 
collaboration, which was coordinated by Dr. Granholm and myself, included investigators 
from Hospital of Sant Pau in Barcelona (Spain), the University of California at Irvine 
(UCI), Barrow Neurological Institute (Arizona), the Linnaeus University in Sweden, and 
Medical University of South Carolina (MUSC). The overall aims were to examine 
alterations in levels of neuron-derived exosome biomarkers in children, young adults, and 
older adults with DS in comparison to age-matched non-DS controls, and also whether AD 
biomarkers were altered in individuals with DS with a dementia diagnosis. I coordinated 
the collaboration, collected and banked all blood samples, wrote the manuscript and 
performed all statistical work in this project. Therefore, I am also the first author of this 
manuscript, which was recently published in Alzheimer & Dementia (Hamlett et al., 2016; 
Impact Factor 17). Further, I spent time at the NIH laboratory conducting the first set of 
experiments (Dr. Ed Goetzl) and learned firsthand how to perform the exosomes 
purification work upon which Chapter 5 is based. Quantification of BDNF with ELISA 
was performed by Dr. Aurélie Ledreux and to some extent, Laura Colombo. This work was 
supported by various sources: Alzheimer’s Association (ACG), Lejeune Foundation USA 
(ACG), the BAND2 Program (EJG), and an unrestricted grant from Nanosomix, Inc. for 
methodological development (EJG), AG14449, and Barrow Neurological Institute Barrow 
and Beyond (EJM). This work was partially supported by research grants from the Carlos 
III Institute of Health, Spain (grants PI11/02425 and PI14/01126 to JuanFortea) and the 
 




CIBERNED program, jointly funded by FondoEuropeo de Desarrollo Regional (FEDER), 
Unión Europea, “Una manera de hacer Europa.” This work has also been partially 
supported by a “Marató TV3” grant (20141210 to Juan Fortea), a grant from the Griffols 
Foundation and by the Fundació Catalana de Síndrome de Down. The US National 
Institutes of Health supported this study through the following grants: R01AG 21912 (E.D., 
I.T.L.); R01HD065160 (E.D., I.T.L) UL1 TR00414 (I.T.L.). The National Center for 
Research Resources and the National Center for Advancing Translational Sciences 
supported this study through Grant UL1 TR000153. 
  
 




Chapter 6: Discussion 
 
6.1 Brief Overview 
The primary goal of my studies was to examine biological mechanisms for 
neuropathology in Down syndrome. LC-NE activity, BDNF, and inflammation are three 
facets of DS-AD that are modulated by highly coordinated processes and upon individual 
failure creates disruption in the whole. This interplay underlies why DS-AD reflects an 
emergent spectrum of neuronal disorders that occur together. In Chapter 3, the first aim 
of my dissertation studies was to understand the mechanisms by which the LC-NE may 
alter memory performance and neuroinflammation in Ts65Dn mice. I employed two study 
paradigms: 1) LC inhibition at four months when LC morphology appears intact and 2) LC 
stimulation at 14 months when the LC has suffered neurodegeneration. The first series of 
experiments were designed to assess whether stimulation of the LC-NE after degeneration 
is evident, would rescue memory deficits neuroinflammation. The second series of 
experiments were designed to assess whether inhibition of the LC-NE before degeneration 
is evident, would enhance memory deficits and exacerbate neuroinflammation. Having 
determined that inflammation may be rapidly modulated by LC-NE activity, Chapter 4 
assessed the efficacy of activating the resolution system via a proresolution mediator SPM 
therapeutic approach. The first series of experiments were designed to test the efficacy of 
administering a purified resolution mediator, RvE1, to rescue memory deficits, chronic 
neuroinflammation and a peripheral component of inflammation in Ts65Dn mice. In 
Chapter 5, I utilized a novel method for purifying neuronal exosomes from blood and 
 




examined three circulating neuronal exosome biomarkers, Aβ42, P-T181-Tau and P-S396-
Tau along with serum BDNF levels over broad cross sections of age with the hypothesis 
that exosome markers and circulating BDNF levels would define a preclinical period for 
DS-AD. One potential therapeutic option to prevent neuroinflammation, as observed in 
Ts65Dn mice, may be to artificially enhance proresolution mediators. In summary, my 
dissertation work demonstrated that the LC-NE modulates memory performance and 
neuroinflammation with great precision in mice. Behavioral modulation was directly 
affected within 10 minutes while molecular markers of neuroinflammation were affected 
in only 9 days of LC inhibition. Finally, initiation of proresolution therapy or other 
inflammation-targeted interventions for DS-AD may need to occur long before cognitive 
scores begin to decline in the DS population as novel blood biomarkers reveal 2-3 times 
higher AD biomarkers already in childhood in the DS population.  
 
6.2 In-depth Discussion of the Findings from the DREADD studies (Chapter 3)  
Ts65Dn mice exhibit declarative memory deficits, especially in spatial and working 
memory (Holtzman, Santucci et al. 1996, Hunter 2004), and this memory loss coincides 
with degeneration of cholinergic neurons (Granholm 2000, Hunter, Bachman et al. 2004), 
hippocampal and LC-NE neurons (Lockrow, Fortress et al. 2012, Fortress, Hamlett et al. 
2015) in the brain. Our recent evidence linked neuroinflammation as a general contributor 
to the multifaceted neurodegeneration in Ts65Dn mice (Hunter 2004, Lockrow J 2011). I 
will first discuss the LC influence on neuroinflammation from the perspective of 
adrenoreceptor functions with a novel insight gleaned from the DREADD studies. Then I 
 




will discuss specific NE effects on memory indices observed at pre-degenerative and post-
degenerative intervals of LC decline. 
 
6.2.1 DREADD and Adrenergic Crosstalk: A GPCR Mystery at the Synapse 
In Chapter 3, I used DREADD receptors to specifically control LC-NE neurons in 
mice during cognitive tasks. Although these designer receptors have been designed to 
respond only to CNO, they still maintained signaling through Gq or Gi and β-arrestin 
signaling pathways, which was presumed to be identical to normal M3 and M4 receptors. 
Similarly, the adrenoreceptors also signal through Gs or Gi and β-arrestin signaling adapter 
molecules. In our experimental paradigm, the neurons of the LC express both DREADDs 
and adrenoreceptors, but the physiological consequences of Hsa21 trisomy on the 
architecture of GPCRs are not fully explored. In Figure 3-10, I observed significant 
elevations of β1-AR expression in Ts65Dn relative to NS mice already at four months of 
age. The near 30% increase was found in both hippocampus and frontal cortex, both areas 
that are extensively innervated by the LC. I assumed that adrenoreceptor elevation might 
be in part due to a compensatory response to physiological changes in LC-NE function 
which may reduce NE release in terminal fields, already at four months of age. Likewise, 
I hypothesized that hM4D-mediated inhibition of the LC-NE firing rate would potentially 
exacerbate the β1-AR phenotype in both karyotypes. Surprisingly, hM4D inhibition of the 
LC normalized Ts65Dn brain β1-AR levels to that observed in NS mice without any 
observable effects on β1-AR levels in NS mice. Degeneration of LC-NE neurons occurs 
both in DS-AD and in AD and is an early event in the degenerative process (Braak and Del 
 




Tredici, 2012). LC-NE degeneration exacerbates other AD pathology (Kalinin, Gavrilyuk 
et al. 2007, Heneka, Nadrigny et al. 2010) but changes in adrenoreceptors in the AD brain 
could also lead to a protracted response to NE. Both α1-AR and α2-AR have been shown 
to be decreased in AD, while I demonstrate changes in β1-AR in Ts65Dn mice.  
 
DREADD hM4D inhibition of the LC resulted in an unanticipated normalization 
of β1-AR density which could be explained by several potential mechanisms. 
Norepinephrine activates nine different adrenergic receptors with different functional 
outcomes, depending on the expression pattern of these receptors and G protein affinities. 
Most adrenergic receptors are expressed in LC neurons and are anterogradely transported 
to the terminals, with ɑ1 (Gq-coupled), ɑ-2 (Gi-coupled), and β1-3 (Gs-coupled) all present 
at the presynaptic and postsynaptic terminals. Since these receptors are present on both 
sides of the synapse, it is difficult to know by which receptor subtypes and at which 
locations intervention mediate effects. When presynaptic, adrenoreceptors, like the 
α2 receptors, can function as autoreceptors to inhibit further release of NE by negative 
feedback. If LC-NE activity is suppressed in Ts65Dn mice, one may expect compensatory 
elevations in all adrenoreceptors. In support of this expectation, a recent study observed 
significant elevations in the β2 adrenoreceptor in presynaptic terminals of Ts65Dn mice 
(Dang, Medina et al. 2014). If compensatory elevations of the ɑ2 (Gi-coupled) 
adrenoreceptors occur within presynaptic terminals of the LC, the interference could 
manifest dysfunction in NE release, resulting in NE deficiency from a morphologically 
normal LC. Post-synaptic ɑ2 adrenoreceptors may yield a blunted response to NE by 
 




decreasing of intracellular cAMP production. Another explanation could be involved with 
G-protein cross talk between hM4D and β1-AR in the presynaptic terminals of the LC, a 
biological phenomena also known as functional agonism. In line with this, adrenoreceptors 
likely form homodimers and heterodimers, that result in more complex receptor functions.  
 
Studies have revealed a similar biological mechanism where selective agonists of 
M2 mAChR potentiate β2-AR-signaling (Fernandes, Fryer et al. 1992, Pera and Penn 
2014). Although these studies were conducted in smooth muscle, I believe that the 
activation of the Gi-coupled hM4D used in this study was equivalent to M4 or M2 Gi-
coupled receptors, possibly leading to similar Gi cross-talk to β1-AR. This may produce 
the acute effects in memory that I observed while having long term consequence of NE 
release from the LC presynaptic terminal. Functional agonism has been documented in 
several other GPCR systems where Ca2+ signaling by one type of GPCR can be enhanced 
or inhibited by stimulation of a different type of GPCR (Werry, Wilkinson et al. 2003), 
which bolsters the idea of crosstalk as a potential mechanism in this unusual β1-AR 
observation. Finally, it is also possible that chronic inhibition of the LC-NE neuron firing 
rate in Ts65Dn mice (with an already compromised NE transmitter system) gives rise to 
degeneration of postsynaptic terminals, which could account for the loss of β1 receptors in 
Ts65Dn mice after chronic hM4D stimulation. This notion will be followed up with 








Given this interesting GPCR effect in β1-ARs, I postulate that NE signaling could 
be dysfunctional even if the LC is morphologically normal and releasing NE to terminal 
fields. All β-adrenoreceptors are Gs-coupled and upon activation render adenylate cyclase 
activated, which hydrolyzes adenosine triphosphate (ATP) into cyclic adenosine 
monophosphate (cAMP). If adrenoreceptors are desensitized or not properly incorporated 
into a correct signaling architecture at the pre- or postsynaptic terminals, one would 
hypothesize a blunted neuronal cAMP response to NE release. In line with this hypothesis, 
basal production of cAMP was significantly reduced in the hippocampus and cerebral 
cortex of Ts65Dn compared to NS mice, but whether this results in an adrenoreceptor 
deficiency in signaling is unknown. Although not specific, cAMP has been used as a 
measure of NE signaling in mouse models of neurodegeneration (Dierssen, Vallina et al. 
1997, Heneka, Nadrigny et al. 2010, Baamonde, Martinez-Cue et al. 2011).  
 
It would be interesting to explore this GPCR effect with selective agonist and 
antagonists of adrenoreceptors in electrophysiological experiments to further test receptor 
elevations or cAMP deficiencies seen in Ts65Dn mice. Although this is an interesting 
continuation of my studies, it was not possible to conduct these studies within the frame of 
my dissertation. Regarding cAMP reason, human studies of cardiac tissue revealed that 
metoprolol agonism of β1-AR restores ion channel functions by an unknown mechanism. 
In another study, formoterol, a long-acting β2 adrenergic agonist, improved cognitive 
function promotes dendritic complexity in Ts65Dn mice, but the mechanism remains 
unknown (Dang V 2014). In contrast, Prazosin is an α1-AR antagonist that reduces Aβ 
 




generation in neuronal cultures and improves behavioral and inflammatory outcome 
measures in a mouse model for AD (Katsouri, Vizcaychipi et al. 2013). Whether these 
kinds of pharmacological treatment would be beneficial in normalizing basal cAMP 
deficits in Ts65Dn mice remains a mystery. Clinically, patients with hypertension who took 
beta blockers had decreased dementia incidence and cognitive decline rate (Khachaturian, 
Zandi et al. 2006, Rosenberg, Mielke et al. 2008), but the mechanism behind this 
correlation remains unknown. GPCRs can also be impaired by designer peptides that could 
be potentially employed in similar studies (Gilchrist, Mazzoni et al. 1998). Lastly, 
immunoprecipitation methods of adrenoreceptors that target bound-factors should also be 
explored since deficiencies or interference in docking and adapter proteins could 
undermine GPCR architecture. How the balance of adrenoreceptors orchestrate adequate 
responses to NE in Ts65Dn mice is still an open question, and our observations suggest 
further studies aimed at answering this question would be valuable. 
 
6.2.2 LC-NE modulation of inflammation had temporal precision  
In regards to neuroinflammation, the interface of noradrenergic tone has significant 
effects on microglia. In particular, agonism of β-adrenoceptors, either by norepinephrine 
or alternatively by dobutamine, depresses brain inflammation and is neuroprotective across 
various paradigms that activate microglia (Mori, Ozaki et al. 2002, Dello Russo, Boullerne 
et al. 2004, Kong, Ruan et al. 2010, Markus, Hansson et al. 2010). Forskolin, a 
phosphodiesterase inhibitor, also elevates cAMP and thus mimics some of the anti-
inflammatory effects of β-adrenergic agonists on microglia (Prinz, Hausler et al. 2001). 
 




Recent studies in the Granholm lab revealed that microglial morphological changes were 
present at low levels as early as four months of age in Ts65Dn mice and that microglial 
activation increased throughout aging (Lockrow, Boger et al. 2011). In Chapter 3, I 
recapitulated this previous finding by showing that CD45 staining was significantly 
elevated in Ts65Dn mice relative to normosomic controls. Specifically, DREADD hM4D 
inhibition of the LC during the behavioral task period (9 days in total) significantly elevated 
CD45 expression by as much as 40% in both NS and Ts65Dn mice (Figure 3-11). Whether 
there is an increase in microglial cell number or merely an increase in Cd45 expression 
levels in existing microglial cells is yet to be explored. However, I cannot conclude that 
this measure is exclusively from existing microglial cells as new evidence in the field 
suggests that CD45-positive microglia in the brain can be derived from peripheral 
monocyte extravasation from the blood through the BBB during pro-inflammatory status 
such as stroke or injury (Mandrekar-Colucci and Landreth 2010). Altogether, these data 
reflected a robust inflammatory response that was increased following selective NE 
inhibition, but future studies are utilizing multiplexed immunofluorescence, or perhaps 
inducible genetic tagging methods would be needed to tease apart distinct cellular 
contributions of this phenotype in the brain. 
 
Whether changes in the NE are a late manifestation of Ts65Dn pathology or an 
early contributor to inflammatory and neurodegenerative changes remains a central 
question in vivo. I have observed that the apparent gross structure and cell density of the 
LC seem to be equivalent between NS and Ts65Dn mice at 4 months of age (Hamlett, 
 




Boger et al. 2015) (Figure 3-2). Yet, given the remarkable time precision of LC influence 
on CD45 expression, I hypothesize that an unknown LC dysfunction could underlie the 
elevated CD45 expression I observed in Ts65Dn mice. This hypothesis was tested 
previously by assessing the effects of DSP-4 neurotoxic depletion of LC neurons on 
inflammatory morphology, in which the Granholm lab discovered that inflammation in 
Ts65Dn mouse was exacerbated by LC lesions using the specific DSP-4 NE neurotoxin 
(Lockrow, Boger et al. 2011). Our findings are consistent with work in other mouse models 
of AD (Heneka, Ramanathan et al. 2006, Pugh, Vidgeon-Hart et al. 2007) also was 
demonstrated in a standard C57BL/6J mice at 2 months of age (Yao, Wu et al. 2015). 
Furthermore, stimulating microglia with L-DOPS supplementation led to reduced 
microglial activation under naïve conditions in Ts65Dn while NE supplementation 
increased microglial phagocytosis of Aβ (Heneka, Nadrigny et al. 2010, Kalinin, Polak et 
al. 2012, Fortress, Hamlett et al. 2015). Altogether, neuroinflammation is modulated with 
high precision very early in life and has implications in the appropriate recycling of Aβ. It 
seems that any disruption of adrenergic control can lead to abnormal inflammation in very 
short time periods. Thus chronic disruption would set the stage for the inflammatory 
phenotype seen in the brain of Ts65Dn mice.  
 
Current literature on inflammation and neurodegeneration suggests that although 
immune dysfunction was initially thought to be a secondary effect of amyloid accumulation 
in AD, it is now considered an early event that exacerbates and potentially precedes AD 
pathological cascades (Lucin and Wyss-Coray 2009, Heneka, Carson et al. 2015). 
 




Specifically, the presence of Aβ in the brain has been shown to prime microglia and elicit 
the production of immune mediators. In the context of chronic activation, glia and 
astrocytes undergo morphological changes that can result in dysregulation of immune 
feedback loops and reduced levels of critical trophic factors (Heppner, Ransohoff et al. 
2015). These dynamic alterations may aggravate Tau propagation and ultimately lead to 
neuronal death. Characteristics of DS biology is not only the increased expression of 
amyloid precursor protein, but also the upregulation of neuroinflammatory astrocyte-
induced proteins (e.g. S100), excess production of inflammatory cytokines (e.g. IL-1α 
and ), increased interferon (INF) and JAK/STAT signaling, and chronic microglial 
activation (Donato, Cannon et al. 2013). Moreover, overexpression of Hsa21 products 
leads to increased activation of the p38-MAPK inflammatory pathways, which promote 
hyperphosphorylation of Tau and neurofibrillary tangle formation (Sheng, Jones et al. 
2001). The net result of these understudied cascades is a chronic, pro-inflammatory 
environment poised to promote AD pathology. Given that nearly all adults with DS display 
neuropathological evidence of AD by the age of 40, they represent the largest and most 
understudied early onset Alzheimer’s disease group (Wilcock 2012). As such, I believe 
that adults with DS represent a critical cornerstone to our understanding of 
neuroimmunological changes underlying late onset and early onset AD biology while also 
offering a window into modifiable inflammatory risk factors. 
 
Individuals with DS have pervading inflammatory issues already early in life that 
may underlie the high prevalence of AD. Blood levels of inflammatory markers are 
 




increased early in those with DS (Rodrigues, Debom et al. 2014), and the inflammatory 
markers correlate with AD biomarkers in adults (Naude, Dekker et al. 2015). When 
measuring serum levels of inflammatory biomarkers in a mouse model of DS, the Ts65Dn 
mice, I found significant elevations in several pro-inflammatory cytokines (IL-1β, TNFα, 
IL-6) as well as increased levels of both Granulocyte-colony stimulating factor (G-CSF), 
which is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem 
cells and release them into the bloodstream, and Granulocyte-macrophage colony-
stimulating factor (GM-CSF), which is a glycoprotein secreted by macrophages that 
function as a signaling cytokine, see Figure 4-12. These data demonstrate that this DS 
mouse model exhibits inflammatory traits similar to those observed in humans with DS 
and can be used to model the role of peripheral inflammatory processes for development 
of DS-AD. 
 
6.2.3 LC-NE Activity is Necessary for Specific Memory Indices 
NS mice were not impaired in the NORT task at any age assessed, and the control-
GFP cohorts were not affected by treatment with CNO. This suggests that our surgical 
procedure, viral manipulations, and aging itself had no overall effect on this measure. 
Similarly, a DSP-4 lesion does not seem to affect intact and/or young animals to the same 
extent as aged or diseased (Lockrow, Boger et al. 2011). Ts65Dn mice consistently showed 
a severe NORT deficit that was approximately 75-85% reduction in discrimination index 
across all ages assessed. I found that LC-NE modulation of this activity to be essential for 
hM4D-mediated inhibition of the LC significantly impaired NORT performance in NS 
 




mice to a level that is similar to naïve (not treated with CNO) Ts65Dn performance levels 
at 4 months of age. The effects were both rapid (only 10 mins) and persistent in both short-
term (90 min) and long-term (24hr) intervals when CNOA was given daily. Together with 
proven targeting success, I feel that these data fully support the role of the LC-NE in rodent 
object memory. Remarkably, the Ts65Dn performance levels at 4 months of age were not 
significantly different from NORT impairments observed at 14 months of age. I previously 
assumed that degeneration of LC-NE neurons, which is overtly apparent at 12 months of 
age, was responsible for a noradrenergic deficiency that was responsible for deficient 
NORT performance. The deficient NORT performance observed in 4 month old Ts65Dn 
mice suggests that physiological dysfunction of the LC-NE neurotransmitter system may 
exist at very early ages in Ts65Dn mice long before the apparent loss of neurons. Of 
interest, Ts65Dn mice do occasionally show a slight yet significant perseverance to the 
familiar object rather than the normal drive to investigate the novel object with higher 
frequency. This tendency for perseveration fits well with previous studies in Ts65Dn mice 
(Hyde, Frisone et al. 2001, Driscoll, Carroll et al. 2004) and may affect performance in this 
task, following a delayed inter-trial interval. 
 
DREADD hM4D-mediated inhibition of the LC-NE had minimal impact on spatial 
reference memory in 4month old Ts65Dn mice. As seen in the meta-analysis in Figure 1-
10, Ts65Dn mice make over 100% more errors in the final trails of the WRAM task 
compared to NS mice while NS mice retain similar performance across all ages studied. 
This suggests that aging itself (at least up to 10 months of age) is less correlated to a 
 




WRAM performance than aneuploidy. In our study, Ts65Dn mice consistently showed a 
severe spatial memory deficit with approximately 100% more errors mid-way through the 
task and over 200% more errors than age-matched NS mice by the final trails. Interestingly, 
I found that hM4D inhibition of the LC had little impact in this task overall but did observe 
a significant deficiency effect during the very last trials (Figure 3-8). Expanding the “win-
stay” WRAM task to 4-5 days may be valuable for future Ts65Dn studies. After a brief 
rest, the mice were subjected to a WRAM-based cognitive flexibility task by switching the 
platform to a new location. Although Ts65Dn mice make more errors, they do demonstrate 
perseverance to the platform arm by the trial end (Figure 3-9, A) suggesting that an 
understanding of the task objective was achieved. Interestingly, Ts65Dn mice failed to lose 
this perseverance phenotype even after being introduced to a new platform location eight 
times, and this effect is exacerbated by hM4D inhibition of the LC. Furthermore, The NS 
mice gained a perseverance phenotype with hM4D inhibition of the LC. When analyzed 
by total errors in this new condition, I observed that NS mice quickly learned the new 
platform location but seemed to make more errors with LC inhibition. This LC inhibition 
effect was significant with Ts65Dn mice (p = 0.02) further suggesting that the LC 
modulates cognitive flexibility which is already deficient in Ts65Dn mice. NS mice 
typically improve performance in the WRAM task by as much as 20% as they performed 
one trial block to the next and this improvement is steady across days, and all trial blocks. 
The Ts65Dn mice made similar gains over the trials initially but lost this ability in final 
trial blocks suggesting a deficiency in their ability to perfect the task.  
 
 




In this task, I assumed that the drive to escape the water is equivalent between NS 
and Ts65Dn mice, but the LC is known to modulate motivation (Aston-Jones, Rajkowski 
et al. 2000), which may bias escape drive. The concept of motivation is captured in the 
Yerkes-Dodson relationship between LC activity, arousal, and performance on the task 
(Aston-Jones and Cohen 2005). The importance of arousal relates to attention and 
motivation. Dampened arousal can lead to inattentive behavior and drowsiness while 
heightened arousal (by enriched environmental events that strongly motivate memory) can 
facilitate behavior performance. The LC-NE activity is known to mediate the balance 
between arousal and inattentiveness by the frequencies and timings of tonic and phasic 
burst activation. Normally, LC neurons exhibit a tonic activity mode, which is associated 
with task disengagement. Environmental enrichments that drive increased need for task-
related decision processes (such as swimming in the WRAM) cause a shift to punctuated 
phasic LC activation which is proposed to optimize task performance. LC-NE dysfunctions 
in Ts65Dn mice could manifest decreased tonic LC activity and/or deficits on burst mode 
phasic LC-NE activations. Our data supports this theory since hM3D stimulation of the 
LC-NE significantly increased performance in the NORT task (Figure 3-5). 
 
The mechanisms behind NE influence on hyperactivity in Ts65Dn and other 
rodents models is intriguing. In the Colobomo mouse model, hyperactivity is thought to 
result from of a 50% reduction in the synaptosomal associated protein-25 kD protein 
(SNAP-25), a presynaptic protein that regulates vesicle release by exocytosis. In this 
model, depletion of NE by DSP-4 significantly reduced the locomotor activity which 
 




broadly suggests that NE regulation is linked to hyperactivity. Interestingly, in this mouse 
model, interventions with an antagonist of ɑ2 adrenoreceptors (yohimbine, clonidine, or 
guanfacine) ameliorated hyperactivity (Hess, Jinnah et al. 1992) which suggested a role for 
adrenoreceptors. In Humans, polymorphisms in three adrenergic receptor gene regions 
(ADRA2A, ADRA2C, and ADRA1C ) have been associated with hyperactivity associated 
with Attention Deficit Disorder (ADHD), which further suggests the involvement of the 
noradrenergic functions in hyperactivity. Interestingly, polymorphisms in the 
norepinephrine transporter (NET) are also associated with ADHD. A study examining the 
relationship between NET and ADHD found that drugs that act as blockers of NET are also 
efficacious in treating ADHD (Biederman and Spencer 2000). LC-enhancing medications, 
such as Atomoxetine or L-DOPS (Asherson, Stes et al. 2015) have been utilized for 
individuals with ADHD and could be considered in future clinical treatment paradigms for 
DS-AD patients since attentional deficits and executive dysfunction are both common in 
DS (Lanfranchi, Jerman et al. 2010). In Chapter 3, I found that hM3D stimulation of the 
LC-NE decreased hyperactivity and perseverance. In stark contrast, hM4D inhibition of 
the LC-NE had no effects on hyperactivity in either NS or Ts65Dn mice. This fidning 
suggest other transmitter systems may be involved. For instance, dopamine is also known 
to affect locomotor activity in rodents (Viggiano, Ruocco et al. 2004) and the balance of 
dopaminergic and noradrenergic in the prefrontal cortex are likely influencing the 
contrasting outcomes. Altogether, these observations clinically relate to short-term 
attentional deficits in people with DS (Mauerberg-deCastro, Cozzani et al. 2009, 
Lanfranchi, Jerman et al. 2010) which imply potential LC dysfunctions in the DS 
 




population that may be remedied by pharmacological treatments. Declining LC function is 
also hypothesized to underlie sleep disturbance (Vazey and Aston-Jones 2014). 
Interestingly, when sleep rhythm disturbance in several animal models, including Ts65Dn 
mice, is correlated with declarative memory deficits (Ruby, Fernandez et al. 2013, 
Takeuchi, Duszkiewicz et al. 2016). Over 50% of children with DS experience sleep 
problems (Fernandez, Nyhuis et al. 2017) and this may be related to LC function. 
 
6.3 In-depth Discussion of the Findings from the Resolution studies in Chapter 4 
I explored a proresolution mediator approach with the primary focus of limiting the 
inflammatory phenotype in the Ts65Dn mouse. Since RvE1 has shown great efficacy in 
other inflammatory modulation approaches, I hypothesized that a chronic 1 month would 
provide protection to 8-month-old Ts65Dn. Remarkably, our RvE1 treatment normalized 
all memory indices and cognitive flexibility deficits measured in Ts65Dn mice without 
effects on NS mice. This profound result prompted a deeper investigation into the receptors 
and signaling outcomes of the treatment. I first discuss the proresolution outcomes of RvE1 
therapy from the perspective of neuroinflammation and peripheral cytokine measures. 
Then I discuss specific RvE1-mediated molecular changes and how these may underlie the 
profound improvements in all memory indices performed by Ts65Dn mice. 
 
6.3.1 RvE1 mediates activation of ERK1/2 signaling 
RvE1 is known to bind ChemR23 and BLT1, both Gαi-coupled protein receptors 
but how chronic binding affects these receptors is unknown. Under our treatment paradigm, 
 




I observed significant decreases in both receptors of about 30-40% regardless of brain 
region assessed (Figure 4-8). These results indicate that at least two different RvE1 
receptors mediate resolution signaling. The changes observed in both receptors could be a 
compensatory modulation to the therapy, but the mechanism of this response is unknown. 
Importantly I did not observe this compensatory effect in the closely related ALX-FPL2 
receptor, which does not bind ChemR23, which suggests a response outcome specific to 
the RvE1 ligand. I anticipated that activation of these receptors would increase the ratio of 
phosphorylated ERK to total ERK, suggesting increased activation, and observed 10-20 
increases in this p-ERK ratio primarily in the frontal cortex and the hippocampus, with 
little change in the parietal cortex for both NS and Ts65Dn mice. ERK activation seems to 
have pleiotropic effects that are relevant to neurodegeneration. For instance, sustained 
activation of ERK has been observed from neurotoxic lesion with 6-OHDA (Kulich and 
Chu 2001) suggesting that ERK activation plays a direct mechanistic role in toxicity. 
Abnormal ERK activation has also been observed in the prefrontal cortex of a mouse model 
of Autism (Faridar, Jones-Davis et al. 2014). I observed that Ts65Dn mice trend to 
preexisting elevations of this p-ERK ratio especially in the frontal cortex when compared 
to NS mice (Figure 4-8). This correlation speaks to the fact that individuals with DS have 
high rates of autistic behavior (Naerland, Bakke et al. 2017).  
 
In contrast, increased ERK activation also mediates neuroprotective effects. For 
example, neuroprotection by BDNF against cell death is mediated by ERK and other 
pathways that involved downstream changes in DNA promoter binding and mRNA 
 




translation (Nguyen, Yao et al. 2005). How ERK signaling can have a multifaceted effect 
is partly due to compartmentalization within each cell of the brain. Distinct protein 
scaffolding molecules are required for ERK activation at the plasma membrane, 
endosomes, and the Golgi apparatus (Omerovic and Prior 2009). ERK-activation is able to 
target both cytoplasmic and nuclear molecules depending on the site of phosphorylation. 
ERK activation at the Golgi apparatus is sequestered in the cytoplasm and targets 
cytoplasmic molecules. To that point, recent evidence revealed that ERK activation also 
had cross-reactivity with other protein kinases, particularly p38 protein. Most of the 
proinflammatory cytokines are regulated by NF-κB, which is itself regulated by p38 
MAPK (Carter, Knudtson et al. 1999). In vitro assays demonstrated that ERK was able to 
phosphorylate PPARγ (Adams, Reginato et al. 1997) which has implications for its role in 
inflammatory regulation. Currently, the downstream targeting bias of ERK activation by 
proresolution receptors is a central question that remains unanswered. Also, the specific 
activation status and localization of PPARγ remains to be elucidated. 
 
Clearly, ERK is a complex signaling effector that has both negative and positive 
outcomes. In Chapter 5, I did not determine if ERK-related scaffolding molecules and 
cytoplasmic or nuclear fractions had biased signaling outcomes under the proresolution 
intervention. Future experiments could be employed to more closely follow the 
phosphorylation cascade in a time course upon RvE1 treatment. This kind of study may 
best be applied in a cell culture in vitro model ideally from human IPS cells that have been 
differentiated to form microglia or neurons but could also be performed in a typical 
 




fibroblast or neuroblastoma lineage. Such experiments could define a time course in which 
to further explore the same signaling dynamics in the Ts65Dn mouse were sample are more 
limited to exploratory work. 
 
6.3.2 Chronic RvE1 therapy normalized the Ts65Dn inflammatory phenotype 
My work also supported the hypothesis that neuroinflammation affects Calbindin-
D28k (Cal 28k) morphology in the hippocampus. Extending the work of Hunter et al 
(2004), I showed that early alterations were present in Cal 28k-positive CA1 pyramidal 
neurons at an age prior to BFCN atrophy (Figure 3-2). This finding is consistent with 
human aging, as Cal 28k expression is reduced during normal aging, and precedes 
cholinergic dysfunction during AD (Mufson, Ginsberg et al. 2003). Morphology changes 
in Cal 28k are not only early, but are progressive as well, and there is a near complete loss 
of Cal 28k expression in the CA1 hippocampus of 18-month-old Ts65Dn mice (Figure 3-
2). In these studies, I additionally determined that Cal 28k reductions are partially 
connected to inflammation, as neuroinflammatory increases brought on by NE depletion 
contributed to Cal 28k loss (Figure 3-10). Interestingly, similar losses to Cal 28k have 
been noted in the human CA1 during AD (Sutherland, Wong et al. 1993). Combined with 
my findings, this may suggest that modulation of inflammation can be more powerful than 









In the context of longevity, this type of inflammatory effect may offer a new 
therapeutic window to stop AD progression in the DS community. The profound effects I 
observed in Ts65Dn memory performance after RvE1 administration could have been at 
least partially driven by modulation of the hematopoietic system and/or reprogramming of 
white blood cells. Mechanisms behind how the immune system signals to the brain in 
response to systemic inflammation are not fully understood. Inflammation can initiate 
signaling from the hematopoietic system to various organs including the brain. The 
traditional view of this communication has been that individual factors, such as 
inflammatory cytokines, are released by immune cells that in turn bind to specific targets 
cells (neurons, glia, or oligodendrocytes) in the brain where they exert their effects. But 
our recent studies in Chapter 5 prove that extracellular vesicles are readily found in the 
blood. As an alternative approach to resolution signaling it may be gainful to isolate 
exosomes from mice (or rats to increase the blood draw volume) at both pre- and post-
RvE1 intervention and perform proteomic studies on the cargo contained within. One might 
hypothesize that the beneficial effects were also vectorized in these vesicle systems. 
 
6.4 In-depth Discussion of Findings from the Biomarker Studies in Chapter 5 
I implemented a novel technology that enables explorations of the cargo found in 
neuronal exosomes. The biomarkers in this specialized cargo revealed a unique phenotype 
in those with DS that has profound implications on why, how and when AD begins in this 
population. Our BDNF studies over broad cross sections of age revealed interesting trends 
with the highest clarity seen in the field so far. Altogether, these studies inform the clinical 
 




mindset on when therapeutic interventions may be needed for those with DS. 
 
6.4.2 Neuronal Exosomes offer a Snapshot of Brain Health 
The cargo inside neuronal exosomes provides a specific proteomic niche in which 
to explore novel biological aspects of brain health. No other method allows such a snapshot 
of neuronal activity with minimal invasiveness, a feature that makes our methodology 
highly relevant to the clinic. Alarmingly high levels of all three AD biomarkers were found 
to occur across all ages, even as early as 8 years of age. An interesting question lies in how 
children with DS are able to escape the pathological events that may be correlated with the 
high exosomal transfer of expelled proteins? The protective mechanism could be related to 
LC modulation of inflammation, active resolution processes, and even neurotrophic 
support, with the latter being discussed in the next section. As seen in studies of CSF, 
neuronal exosomes also recapitulate decreases in Aβ42 in those with DS that have suffered 
abnormal cognitive impairments. The correlations of these biomarkers to the current 
knowledge of AD are profound. Clinical trials focused on AD would likely benefit by using 
this type of biomarker as a novel, and sensitive way to assess the efficacy of an intervention. 
I presume that any intervention that can help neurons better deal with the burden of amyloid 
plaques and hyperphosphorylated Tau would likely reduce the need to expel these proteins 









6.4.2 Serum BDNF and the Neuronal Exosome P-Tau connection 
Decreased levels of the mature form of BDNF in aging have been associated with 
decreased hippocampal synaptic plasticity, neurogenesis, and cognitive ability (Erickson, 
Miller et al. 2012) and may also be reflective of the age-related cognitive impairment 
observed in both NS and TS mice (Bimonte-Nelson, Hunter et al. 2003). BDNF clearly 
follows a downward trajectory in the DS population that initiates at about the age 
of twenty. Given that mature BDNF signaling, via tyrosine receptor kinase B (TrkB) 
receptors, is capable of decreasing Tau phosphorylation, it is not surprising that I 
found significant correlations between BDNF and two types of dementia -related P-
Tau species. A disconnect lies in how circulating BDNF, which comes from many 
sources, may influence the cargo of neuronal exosomes. One explanation could be 
that the majority of circulating BDNF actually comes from brain sources which had 
direct interface with the exosome cargo. Alternatively, circulating BDNF from all 
sources may cross the blood brain barrier and find an interface in the brain by other 
means. Further studies are needed to reveal which specific forms of BDNF are present in 
neuron-derived exosomes versus in serum itself. These studies can lead to a significant 
increase in knowledge regarding different biological mechanisms involved in DS-AD vs. 










6.5 Trisomy 21 in Society 
 Identifying the factors that contribute to or reduce healthy aging can lead to 
improved precision medicine that could prevent the onset of aging-related diseases like 
AD. Although genetics may account for some portion of longevity, general stability of gene 
expression is also a primary driver for healthy aging. The studies conducted in this 
dissertation were conducted for the benefit of those with Trisomy 21 and on mouse models 
that recapitulate the syndrome of this aneuploidy. To fully understand how this work 
affects society, one must consider the reality of Trisomy 21 as a spectrum. Down syndrome 
may best describe those who have an absolute or high penetrance of Trisomy 21 in their 
body structure. On the other end of the spectrum, all individuals have some level of 
Trisomy 21 in their cells, which may be highly variable depending on the tissue or cellular 
level examined. A big question that remains to be answered is “What is the nature of 
aneuploidy in society.” The pursuit of this question could reveal a biological fact of nature 
that could have unforeseen influence at all levels, from individuals to nations. 
  
6.6 Future Directions 
In sum, the experiments that I conducted for this dissertation have led to many 
significant observations in LC-NE modulation, novel therapeutic leads from Ω3 lipid 
biology, and in biomarkers for AD. One important lesson I have learned during my tenure 
in the Granholm lab is on the importance of working together and with others to find 
solutions to emerging scientific questions. Collaboration with clinical professionals, and 
other institutions were fundamental to the success of the exosome biomarkers studies. 
 




Furthermore, I found the biological insight gained from many collaborative experts during 
the manuscript writing process to be extremely helpful for proper interpretation of the 
findings. I had the opportunity to get training directly from Dr. Goetzl, who is the leading 
expert in neuronal exosome isolation and characterization. This experience will 
undoubtedly enhance my future investigations and empower my career as I progress toward 
being a postdoctoral researcher. It is with hope that my work will yield positive outcomes 
for individuals that have Trisomy 21 and also bring positive educational gains for “you” 
the current reader. There was no better joy than that felt when a bulk of my research effort 
featured in this dissertation was débuted at an international conference focused on Trisomy 
21. How better to end a graduate experience that was a long time coming.  
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